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Signal transduction and protein-protein interactions 
Cells in multicellular organisms constantly receive and react to external stimuli. 
Signals from outside the cell initiate signal transduction cascades within the cell, 
and in this way diverse external signals are detected, amplified and integrated to 
generate cellular responses such as changes in enzyme activity, gene expression or 
ion-channel activity. An appropriate response to external signals is necessary for 
the proper functioning of individual cells and for multicellular life to be possible. A 
central feature of signal transduction and many biological processes is the ability of 
proteins to bind each other in a highly specific manner. Studying protein complex 
formation in detail and understanding the forces that drive the interaction is 
therefore of great interest.  
Protein complexes vary greatly in their properties, with equilibrium dissociation 
constants (Kd) spanning many orders of magnitude. Some proteins form stable 
complexes, interacting for a long time, whereas others interact only briefly. The 
properties of protein complexes are related to their biological functions. Antibody-
antigen complexes or enzyme-inhibitor complexes require tight binding and high 
specificity, to ensure a proper immune response or strict control of enzyme activity. 
In contrast, proteins involved in signal transduction cascades or in electron transfer 
often need to interact with multiple partners and maintain a high turnover. 
Consequently, these protein complexes tend to be more transient and to display a 
lower binding affinity. 
In our current understanding of protein complex formation at least two steps are 
involved, with the first step being the formation of an encounter complex. This 
involves the proteins coming together, mainly with the help of long-range 
electrostatic forces, to form a loosely-bound intermediate state. From the encounter 
complex the proteins can either dissociate or proceed to form a final complex 
involving short-range interactions such as hydrogen bonding, van der Waals forces 
General introduction 
11 
and the hydrophobic effect. The role of the encounter complex is to accelerate the 
rate of specific complex formation, by reducing the dimensionality in the 
diffusional search process and increasing the lifetime of macromolecular collisions 
[1]. 
The equilibrium between the encounter complex and the productive complex varies 
between protein complexes. Some protein complexes exist mainly as a specific, 
well-defined complex, whereas in other protein-protein interactions the encounter 
complex is populated for a significant part of the time. Some electron transfer 
complexes can even exist purely as an encounter complex, never proceeding to 
form a specific complex [2]. 
 
Phosphotyrosine signalling and modular proteins 
In order for multicellular life to be possible cell proliferation, differentiation, 
adhesion and motility need to be strictly controlled. Many of these processes are 
regulated by tyrosine phosphorylation, which is believed to have been necessary 
for the transition from single-cell to multicellular organisms [3-5]. Tyrosine 
phosphorylation, the covalent addition of a phosphate group to the hydroxide group 
in the side chain of a tyrosine residue in a protein, is regulated by two groups of 
enzymes: protein tyrosine kinases and protein tyrosine phosphatases. Protein 
tyrosine kinases catalyze the transfer of a phosphate group from ATP to a tyrosine 
residue, and this action is opposed by protein tyrosine phosphatases that catalyze 
the reaction of phosphate removal. Addition of a phosphate group to a tyrosine 
residue creates a high-affinity binding site for Src homology 2 (SH2) domains. 
This leads to the formation of new protein complexes, and thereby, to the 
transmission of the signal. Tyrosine phosphorylation signalling can therefore be 
considered to consist of three components: A „writer‟ (the kinase), a „reader‟ (the 
SH2 domain) and an „eraser‟ (the phosphatase), which can be combined to generate 
Chapter 1 
12 
remarkably diverse signalling responses [6], including  hormone-, growth factor-, 
immune-, and adhesion-based signalling [7-10]. Because of their involvement in so 
many signalling pathways and regulatory events protein tyrosine kinases are 
important drug targets. Many human diseases are recognized to be associated with 
abnormal phosphorylation of cellular proteins resulting from disregulation of 
kinase activity [11]. 
Despite its importance, tyrosine phosphorylation is still a relatively rare event in 
cells compared to the more common serine/threonine phosphorylation, and it was 
discovered only in 1979 [12]. Like many important scientific discoveries the 
finding of protein tyrosine phosphorylation was a serendipitous event. In the 
processes of determining whether a protein was phosphorylated on serine or 
threonine residues, Tony Hunter used an old buffer in which the pH had changed to 
a point that allowed phosphotyrosine to be separated from phosphothreonine [13]. 
The main sites of tyrosine phosphorylation in the cell are focal adhesions, the sites 
of attachment of the cell to the extracellular matrix (ECM). At focal adhesions 
integrin receptors link ECM proteins to the actin cytoskeleton involving a 
multitude of signalling and adaptor proteins (Fig. 1.1). Focal adhesions perform at 
least two important functions in the cell, they transmit force or tension at adhesion 
sites in order to maintain strong attachments to the ECM, and they are of central 
importance in many signalling pathways that regulate cell growth, survival and 
gene expression [14]. 
Many eukaryotic signalling proteins are modular proteins, containing several 
individually folded domains connected by linker regions. These domains can be 
protein-interaction domains or domains with a catalytic function. Common for 
these signalling proteins is that their activity is tightly regulated. The activity is 
normally low under basal conditions, but the proteins can be activated by specific 
ligands binding to the protein-interaction domains. This way the activity is 
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intrinsically coupled to protein localization. Recognition of short peptide sequences 
by modular interaction domains plays a central role in regulating cellular 
behaviour, since it is via these protein-protein interactions that the assembly of 
signalling protein complexes and larger protein networks can occur [15;16]. 
 
Figure 1.1. Focal adhesions. At focal adhesions integrin receptors bind to extracellular matrix 
proteins. A number of proteins, including talin, paxillin, vinculin and -actinin, bind to the 
cytoplasmic tails of integrins, linking the integrins to the actin cytoskeleton. The large protein 
complexes also contain signalling proteins such as FAK and Src that promote focal adhesion turnover 
and cell motility. 
Two proteins with a central role at focal adhesions are the non-receptor protein 
tyrosine kinases focal adhesion kinase (FAK) and Src kinase. FAK and Src are 
involved in a number of processes such as cell proliferation, survival and migration 
[17;18]. Increased activity and expression of Src and FAK has been demonstrated 
in many human cancers and is implicated in increased metastatic potential and 







In 1911, Peyton Rous discovered that a cell-free filtrate of a chicken tumour was 
able to induce the formation of tumours in other chickens. Rous concluded that the 
tumour was caused by a „filterable agent‟, as viruses were known at the time [29]. 
The idea that the virus, later called Rous sarcoma virus, could cause cancer was at 
first controversial, but it was later proven that the cancer-causing ability of the 
virus could be attributed to a viral gene, v-src [30]. A cellular counterpart of v-Src, 
Src, was subsequently discovered and found to be conserved in the vertebrate 
genome, indicating that the v-src gene had been incorporated into the viral genome 
through recombination. V-Src differs from Src in deletions at the C-terminal and in 
point mutations throughout the gene [31]. Unlike v-Src, Src is not constitutively 
active and is poorly transforming under normal conditions, but can act as an 
oncogene when activated [32;33]. This makes Src a proto-oncogene, the first of 
many to be discovered [34]. 
Src has a molecular weight of 60 kDa. It is expressed ubiquitously, but with the 
highest levels in the brain, osteoclasts and platelets [35]. It is a member of the Src 
family of protein tyrosine kinases that also includes Fyn, Yes, Lck, Hck, Blk, Fgr, 
Lyn, Yrk, Brk and Srm [36]. The members of the Src family share a conserved 
domain structure consisting of an N-terminal myristoylated SH4-domain followed 
by a region unique to each family member, an SH3 domain, an SH2 domain, a 
kinase domain and a C-terminal regulatory region [37]. The myristoylation 
facilitates attachment of Src to membranes. The SH3 domain and the SH2 domain 
are involved in protein-protein recognition, and facilitate the interaction of Src with 
its substrates. 
The Src SH3 domain is about 60 amino acid residues in size. It has a β-barrel 
structure consisting of five antiparallel β-strands and two loops, known as the RT 
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and n-Src loops [38] (Fig. 1.2). SH3 domains bind to sequences that can adopt a 
left-handed helical conformation. These sequences often contain a characteristic 
proline-rich motif, PxxP. Src SH3 target sequences can be divided into two classes, 
which bind in opposite orientations to the SH3 domain. The binding orientation is 
largely determined by the position of an arginine residue close to the proline-rich 
core motif [39]. 
 
Figure 1.2. Solution structure of the Src SH3 domain (PDB entry 1SRL [40]). 
The SH2 domain of Src contains about 100 aminoacids. It recognises and binds to 
sequences containing a phosphorylated tyrosine residue. The structure consists of a 
central β-sheet flanked by two α-helices, with connecting loops in-between [41] 
(Fig. 1.3). The preferred sequence for Src SH2 domain-binding is pYEEI [42], and 
the binding has been described by the „two-pronged plug two-holed socket‟ model, 
where the phosphotyrosine is inserted into a pocket containing a conserved 
arginine residue, and the isoleucine at position pY+3 binds to a hydrophobic 
pocket [43]. 
The Src kinase domain consists of a small amino-terminal lobe, with a 
predominantly antiparallel -sheet structure, and a larger carboxyl-terminal lobe 





Figure 1.3. Solution structure of the Src SH2 domain (PDB entry 1HCS [45]). 
 
Activation and regulation of Src 
Src is an important component in many signalling pathways, and can be activated 
in different ways, including activation by receptor tyrosine kinases [46]. Several 
mechanisms of activation and regulation of Src have been proposed [47]. 
The C-terminal part of Src contains a regulatory tyrosine residue, Y529 (if not 
stated otherwise mouse Src numbering is used throughout this work), which can be 
phosphorylated by the tyrosine kinase c-Src terminal kinase (Csk). When Y529 is 
phosphorylated the SH2 domain binds to this region, while at the same time the 
SH3 domain binds to the linker region between the SH2 domain and the kinase 
domain. Together these intramolecular interactions cause the protein to assume a 
closed, inactive conformation [48;49]. When the C-terminal phosphate is removed, 
Src assumes an open, active form (Fig. 1.4). In contrast to Src, v-Src lacks the 
negative-regulatory element, and is constitutively active. Full activation of Src also 
requires the phosphorylation of a tyrosine residue in the kinase domain, Y418, 




Figure 1.4. Activation of Src. Phosphorylation of Y529 in the C-terminal tail of Src by Csk causes 
the tail to bind to the SH2 domain. Together with interactions between the SH3 domain and the SH2-
kinase linker, this locks the protein into an inactive conformation. Removal of the phosphate group by 
cellular phosphatases and interactions of the SH3 and SH2 domains with external ligands opens the 
protein up into an active conformation. Phosphorylation of Y418 in the kinase domain stabilizes the 
active conformation and is required for full activation of Src. Figure adapted from [51]. 
A likely mechanism for activation of Src is the removal of the C-terminal 
phosphate group by protein tyrosine phosphatases. Elevated levels of the protein 
tyrosine phosphatase PTP1B, which is able to dephosphorylate Src, has been found 
in breast cancer cell lines [52]. 
Competition between the low-affinity intramolecular binding sites for the SH2 and 
SH3 domains and high affinity binding sites in other proteins is another possible 
mechanism of activation. Upon binding of a ligand by the SH2 or SH3 domain, the 
closed, inactive conformation of Src would be disrupted and the protein would 
assume an open, active form instead. The use of domains for autoinhibition 
enhances the specificity – since the SH2 and SH3 domains already have 
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intramolecular binding sites, only specific binding sites of higher affinity can bind 
to the domains and activate the protein [53]. 
 
Focal adhesion kinase 
FAK, initially identified in 1992 [54;55], is the only member in the FAK family of 
nonreceptor tyrosine kinases apart from PYK2. FAK can be found in the majority 
of tissues and cell types, and is evolutionary conserved in mammals and lower 
eukaryotic organisms [56]. 
FAK contains a FERM (band 4.1, ezrin, radixin, moesin homology) domain, a 
tyrosine-kinase domain and a focal adhesion targeting (FAT) domain. The crystal 
structure of the kinase domain has been determined and displays the typical protein 
kinase bilobal architecture; with the smaller N-terminal lobe containing a five-
stranded antiparallel β-sheet and a single α-helix, and the larger C-terminal lobe 
being mostly α-helical [57] (Fig. 1.5). 
The FAT domain is a four-helix bundle required for localization of FAK to focal 
adhesions via binding to paxillin [58;59]. The FERM domain is a three-lobed 
domain thought to mediate protein-protein interactions by binding to cytoplasmic 
domains of transmembrane receptors, such as the cytoplasmic region of β-integrin 
subunits [60-62]. 
The linker region connecting the FERM and the catalytic domain contains a 
proline-rich site which forms a binding-motif for Src family SH3 domains [63;64]. 
In the same linker the major autophosphorylation site in FAK, Y397, is situated. 
When phosphorylated, it forms a high-affinity binding site for the SH2 domains of 
Src family kinases, the p85 subunit of phosphatidylinositol 3-kinase (PI3K) and 




Figure 1.5. Crystal structure of the FAK kinase domain (PDB entry 1MP8 [70]). 
 
Regulation of FAK and interaction with Src 
Evidence is mounting that the FERM domain of FAK can interact with the 
catalytic domain, acting as an autoinhibitor of FAK activity [71-74]. A crystal 
structure of FAK including the FERM domain, linker region and catalytic domain 
shows FAK in an autoinhibited state [75]. In this structure the FERM domain binds 
the kinase domain, blocking access to the active site and to the kinase activation 
loop, as well as sequestering the Y397 phosphorylation site. This gives rise to a 
model of FAK activation where the FERM domain is displaced by competitive 
binding of an activating protein, such as the cytoplasmic regions of β-integrins or 
growth factor receptors. After FERM domain displacement Y397 is rapidly 
autophosphorylated and the PxxP sequence in the same linker region is exposed, 
enabling binding of the SH2 and SH3 domains of Src (Fig. 1.6). The interaction of 
Src and FAK leads to phosphorylation of other tyrosine residues in FAK and full 
activation of both proteins. The FAK-Src complex further phosphorylates various 
adaptor proteins, affecting a number of downstream signalling cascades [76]. 
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Phosphatidylinositol 3-kinase (PI3K) 
Phosphatidylinositol 3-kinases, also known as phosphoinositide 3-kinases, are a 
family of enzymes that phosphorylate inositol lipids at the 3' position of the inositol 
ring to generate the 3-phosphoinositides PI(3)P, PI(3,4) P2 and PI(3,4,5) P3 [77]. 
The resulting phosphoinositides act as second messengers in signal transduction 
cascades controlling cellular activities such as proliferation, differentiation, 
chemotaxis, survival, trafficking, and glucose homeostasis. PI3Ks therefore play a 
central role in many processes in the cell, and deregulated PI3K signalling is 
implicated in diseases such as cancer and diabetes [78]. 
 
Figure 1.6. Model of activation of FAK and interaction with Src. In the inactive state the FERM 
domain blocks the access to the kinase domain active site, while sequestering the PxxP and Y397 
regions in the FERM-kinase linker. In this model binding of a partner protein to the FERM domain is 
proposed to be the first step in FAK activation, freeing the kinase domain to autophosphorylate Y397 
in cis or in trans. Src recruitment occurs via binding of the SH2 domain to the phosphorylated Y397 
and binding of the SH3 domain to the proline-rich region. Phosphorylation of tyrosines Y576 and 
Y577 in the FAK activation loop by Src leads to full activation of FAK and prevents inhibition by the 
FERM domain. From Ref. [79] copyright (2007), with permission from Elsevier. 
 
PI3Ks can be divided into different classes depending on their structure and 
substrate specificity. Class IA PI3Ks are heterodimers consisting of a catalytic 
domain with a molecular weight of around 110 kDa (the p110 subunit) and an 
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adaptor/regulatory subunit known as the p85 subunit, which contains two SH2 
domains and one SH3 domain [80]. The SH2 domains bind to phosphotyrosine 
residues generated by tyrosine kinases, allowing for translocation of PI3K to the 
membranes where its lipid substrates can be found. 
Compared to the SH3 domain of Src, the PI3K p85 subunit SH3 domain contains a 
15 aminoacid insertion, and the sequence identity of the two domains is only 21%. 
Despite these differences, the protein structures are remarkably similar [81;82]. 
Screening of a combinatorial peptide library for binding to the PI3K p85 SH3 
domain lead to the identification of the consensus sequence RXLPPRP [83]. Like 
the Src SH3 domain the PI3K SH3 domain binds peptides in a left-handed type II 
polyproline helical conformation [84]. 
 
Methods used to study protein complexes 
NMR chemical shift perturbation mapping 
NMR is a powerful technique for mapping the binding site of a protein upon 
complex formation with another protein or a ligand [85;86]. In chemical shift 





spectrum is normally recorded of the free protein, which needs to be 
15
N-labelled. 
In the spectrum each peak corresponds to an amide group in the protein, such as the 
protein backbone amides for all amino acid residues except prolines. N-H groups in 
sidechains of asparagine, glutamine, histidine and tryptophan residues may also 
give rise to crosspeaks. After addition of an unlabelled binding partner to the 
15
N-
labelled protein another NMR spectrum is recorded. Nuclei situated at the binding 
interface may experience a change in their chemical environment upon binding. 
The chemical shifts in both the nitrogen and proton dimensions are sensitive to this 
change and the position of the resonance in the spectrum will change. The average 
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chemical shift perturbation in the nitrogen and proton dimensions can be calculated 




binding are the chemical shift 









                (1) 
By mapping the chemical shift changes onto the protein structure information can 
be obtained about the binding interface. If the binding induces structural or 
conformational changes in the protein, chemical shift perturbations can also be 
seen for residues situated away from the binding site. 
In order to determine the binding constant the unlabelled binding partner is titrated 
into the 
15
N-labelled protein and a 2D NMR spectrum is recorded at each titration 
point. The chemical shift perturbations caused by binding can be followed if the 
chemical exchange rate is large compared to the chemical shift difference between 
the free and bound forms, measured in radians per second. From the chemical shift 
perturbations during the titration the binding constant can be determined. The use 
of deuterated 
15
N-labelled protein together with TROSY experiments extends the 
limit of the method to protein complexes of a molecular weight above 100 kDa 
[87]. 
 
Paramagnetic relaxation enhancement NMR 
Paramagnetic relaxation enhancement (PRE) NMR is a technique that can be used 
to determine the structure and dynamics of protein complexes. It is based on the 
fact that magnetic dipolar interactions between the spins of a nucleus and the 
unpaired electrons of a paramagnetic centre lead to an increase in the relaxation 





r is the distance between the unpaired electron and the nucleus. Some 
metalloproteins contain intrinsic paramagnetic centres, to other proteins a 
paramagnetic probe can be attached through site-specific labelling. The relaxation 
rates of the nuclei in the other protein are then measured, and an increase in the 
relaxation rate indicates that the nucleus has been in the vicinity of the probe. The 
larger the relaxation effect, the closer that part of the unlabelled protein came to the 
probe on the other protein. The paramagnetic contribution to the transverse 
relaxation rate, R2,para, can be determined for the amide proton of each aminoacid 
residue in the protein. This can subsequently be converted into a distance between 
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where r is the distance between the paramagnetic centre and a given amide proton, 
τc is the correlation time of the dipolar interaction of the electron and the nucleus, 
ωh is the proton Larmor frequency, γ is the proton gyromagnetic ratio, g is the 
electronic g-factor and β is the Bohr magneton. Because of the large magnetic 
moment of the unpaired electron the PRE effects are large and can provide long-
range distance restraints of up to 35 Å [89]. The distance restraints can be used in 
docking calculations to determine the relative orientation of the macromolecules in 
the complex. The strong distance-dependence of the PRE enables the detection of 
protein complex orientations that are populated only a small fraction of the time. 
This has been exploited to study encounter complexes involved in protein-nucleic 






Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is a method that is suitable for studying both 
low-affinity and high-affinity macromolecular interactions. In an ITC experiment a 
macromolecule is placed in a sample cell, a ligand is injected in a programmed 
sequence of steps, and the tiny amounts of heat associated with the non-covalent 
interactions involved in binding are measured. From this, the affinity, the change in 
enthalpy and the stoichiometry of binding can be estimated and the change in 
entropy can be calculated, providing a complete thermodynamic characterization of 
the interaction [95;96]. 
 
Scope and outline of thesis 
In order to learn more about how protein tyrosine kinases function, it is important 
not to focus on the kinase domain alone, but also on the interaction with other 
domains. The main topic of this thesis is the interaction of Src and FAK, mediated 
via the SH2 and SH3 domains of Src, and the goal is to outline the details of this 
interaction. To this end, a number of model systems of the FAK-Src interaction are 
studied, ranging from peptide-protein interaction studies to binding studies 
involving isolated protein domains. In addition, the interaction of a PI3K SH3 
domain with a photocleavable peptide is investigated. 
In chapter 2, the interaction of peptides derived from the SH3 domain binding site 
in FAK with the Src SH3 domain is studied, using paramagnetic relaxation 
enhancement nuclear magnetic resonance spectroscopy (PRE NMR) together with 
chemical shift perturbation analysis. In chapter 3, the binding of peptides from the 
SH2 domain binding site of FAK to the Src SH2 domain are studied using (PRE) 
NMR and isothermal titration calorimetry (ITC). Chapter 4 contains a study of 
peptides containing both SH2 domain- and SH3 domain-binding sites interacting 
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with a Src SH3-SH2 domain fragment, and the effect of decreasing the distance 
between the binding sites in the peptide is investigated using NMR and ITC. In 
chapter 5, the expression of the catalytic domain of FAK in insect cells is 
described, together with the purification and characterization of the protein. In 
chapter 6, an NMR binding study of the FAK catalytic domain with the Src SH2 
domain is presented. In chapter 7, the construction of GFP-labelled SH3 or SH2 
domain-containing phosphotyrosine reporter constructs is described, and the 
behaviour of the constructs in mammalian cells is characterized. In chapter 8, the 
interaction of the SH3 domain of the p85 subunit of PI3K with a photocleavable 
peptide is studied, investigating what effect modifying the peptide has on the 
interaction. Finally, chapter 9 contains a general discussion of the results presented 








Mobility of TOAC spin-labelled peptides 






Paramagnetic relaxation enhancement provides a tool for studying the dynamics as 
well as the structure of macromolecular complexes. The application of side-chain 
coupled spin-labels is limited by the mobility of the free radical. The cyclic, rigid 
amino acid spin-label TOAC (2,2,6,6-Tetramethylpiperidine-1-oxyl-4-amino-4-
carboxylic acid), which can be incorporated straightforwardly by peptide synthesis, 
provides an attractive alternative. In this study, TOAC was incorporated into a 
peptide derived from focal adhesion kinase (FAK), and the interaction of the 
peptide with the Src homology 3 (SH3) domain of Src kinase was studied, using 
paramagnetic NMR. Placing TOAC within the binding motif of the peptide has a 
considerable effect on the peptide-protein binding, lowering the affinity 
substantially. When the TOAC is positioned just outside the binding motif the 
binding constant remains nearly unaffected. Although the SH3 domain binds 
weakly and transiently to proline-rich peptides from FAK, the interaction is not 
very dynamic and the relative position of the spin-label to the protein is well-
defined. It is concluded that TOAC can be used to generate reliable paramagnetic 
NMR restraints. 
 
This chapter is based on: 
Lindfors, H.E., de Koning, P.E., Drijfhout, J.W., Venezia, B. and Ubbink, M. 
(2008). Mobility of TOAC spin-labelled peptides binding to the Src SH3 domain 
studied by paramagnetic NMR. J. Biomol. NMR 41, 157-167. 
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Introduction 
In recent years, paramagnetic relaxation enhancement (PRE) NMR spectroscopy 
has become a useful tool for studying the structure and dynamics of 
macromolecular complexes [97-110]. PREs are caused by the magnetic dipolar 
interaction of a nucleus with the unpaired electron in a paramagnetic centre, 
leading to an increased relaxation of the nuclear magnetization and a decreased 
intensity of the corresponding NMR peak. The magnitude of the PRE depends on 
the distance between the observed nucleus and the paramagnetic centre. Thus, 
PREs can provide information about the distance between the amino acid residues 
in one protein and a paramagnetic group in another protein, which can be used to 
determine the structure of the complex. The non-linear distance dependence of the 
PREs also makes it possible to detect the presence of alternative protein 
conformations, even if the proteins only spend a small fraction of the time in the 
minor state [90;100;111]. 
A common approach in paramagnetic NMR is to use site-directed spin labelling, in 
which a spin label is attached to a cysteine residue engineered onto the protein 
surface. Commonly used spin labels include nitroxide spin labels [100;112-116] or 
metal-chelating spin labels [117;118]. A disadvantage of these spin labels is their 
high mobility due to the conformational freedom of the cysteine side chain and the 
linker of the spin label. This causes the position of the spin label to be ill-defined 
and leads to averaging of paramagnetic effects. The mobility of the spin-label can 
be limited by attaching it to the protein via two arms, making it possible to model 
the position of the paramagnetic centre relative to the protein within a few Å 
[119;120]. 
For the study of peptide-protein interactions, labelling with 2,2,6,6-
tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid (TOAC, Fig. 2.1) provides 
an alternative. TOAC is an amino acid with a stable nitroxide radical and a reduced 
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mobility, due to its rigid structure. It can be incorporated directly into peptides via 
solid-phase synthesis [121-123] and recent advances in chemical protein synthesis 
[124] may also enable the incorporation of TOAC into proteins for paramagnetic 
NMR protein interaction studies. TOAC-containing peptides have been used 
extensively for EPR studies [125-138]. Despite the wide-spread use of TOAC for 
EPR, to our knowledge it has not been employed for structural studies using 
paramagnetic NMR. Here, we use PRE NMR spectroscopy to study the structure 
and dynamics of TOAC-labelled peptides binding to the Src homology 3 (SH3) 
domain of Src kinase. SH3 domains are ubiquitous interaction domains involved in 
a vast number of signal transduction pathways. These modular domains generally 
recognize and bind to proline-rich regions that can form polyproline type II helices, 
with a core motif of the form PxxP [15]. The Src SH3 domain has been shown to 
bind to peptides derived from a region in focal adhesion kinase (FAK) with a 
sequence RALPSIPKL [139]. Using TOAC-labelled peptides derived from this 
region of FAK, we find that although the peptide-protein interaction is of a weak 




Cloning and protein expression 
A DNA fragment coding for the mouse Src SH3 domain, residues 85-142, was 
amplified by PCR from the full-length Src plasmid pUSE Src wt (kindly provided 
by Prof. B. van de Water), and ligated into pET28a, using the NcoI and XhoI 
restriction sites. The resulting construct was verified by DNA sequencing. The 
15
N-
labelled, His-tagged SH3 domain was produced in Escherichia coli BL21 
incubated in M9 minimal medium with 
15
NH4Cl as the sole nitrogen source. A 
freshly transformed E.coli BL21 colony was used to inoculate 10 ml 
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LB/kanamycin (50 g/L) and incubated overnight at 37 °C and 250 rpm. The 
preculture was diluted 1:100 into the 
15
N-minimal medium and incubated to an 
OD600 of 0.6, at which point gene expression was induced by the addition of 0.5 
mM isopropyl β-D-1-thiogalactopyranoside. After 4 h the cells were harvested by 
centrifugation. 
 
Figure 2.1. Structure of the nitroxide radical-containing amino acid 2,2,6,6-Tetramethylpiperidine-1-
oxyl-4-amino-4-carboxylic acid (TOAC). 
 
Protein purification and NMR sample preparation 
The cell pellet was resuspended in lysis buffer (20 mM Tris-HCl, pH 8, 0.5 M 
NaCl, 10 mM imidazole and 1 mM phenylmethanesulfonyl fluoride) and cells were 
lysed by two passages through a French pressure cell. The cell lysate was 
centrifuged at 40000 rpm for 30 minutes, the supernatant was loaded onto an 
affinity column (HisTrap HP, GE Healthcare) and protein was eluted with a 
gradient of 10-300 mM imidazole. Pure fractions, as judged by SDS-PAGE, were 
pooled, concentrated and exchanged into NMR buffer (20 mM KPi, pH 6.5, 100 
mM NaCl). All NMR experiments were performed in this buffer. The purity of the 
protein was estimated to be above 95 %. The protein concentration was determined 








Peptide synthesis and preparation 
Synthetic peptides were prepared by normal Fmoc-chemistry using preloaded 
Tentagel resins, PyBop/NMM for in situ activation and 20% piperidine in NMP for 
Fmoc removal [141]. Couplings were performed for 75 min. The amino acid N-
terminally of TOAC was coupled overnight at 37°C using HATU/NMM activation. 
After final Fmoc removal peptides were cleaved with TFA/H2O 19/1 containing 
additional scavengers when a cysteine or a tryptophan was present in the peptide 
sequence and isolated by ether/pentane precipitation. The peptides were treated 3 h 
with 10% ammonia, lyophilized and stored at −20°C until use. Peptides were 
checked on purity using rpHPLC and on integrity using MALDI-TOF mass 
spectrometry. Fmoc-TOAC-OH was prepared as has been described before [121]. 
Peptides were kindly provided by Dr. Jan Wouter Drijfhout. 
Before the NMR titrations peptides were dissolved in NMR buffer and the pH was 
adjusted to 6.5 with small aliquots of 0.1-0.5 M solutions of NaOH or HCl. The 
fraction of paramagnetic peptide was checked by EPR and found to be 53% for 
peptide P3Tm and 30% for peptide P3Te. Francesco Scarpelli is gratefully 
acknowledged for help with EPR measurements. 
 
NMR experiments 
All NMR experiments were recorded at 303 K on a Bruker DMX600 spectrometer 
equipped with a TCI-Z-GRAD cryoprobe (Bruker, Karlsruhe, Germany). 
The data were processed with Azara (ftp://www.bio.cam.ac.uk/pub/azara/) and 
analyzed using Ansig For Windows [142;143]. For amide backbone resonance 
assignments 3D NOESY-HSQC and 3D TOCSY-HSQC spectra were recorded on 
a 1 mM 
15
N SH3 sample containing 6% D2O. The protein was assigned with the 
help of assignments for chicken Src SH3-SH2 domains [144].  
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Titrations were performed by adding microliter aliquots of concentrated peptide 
stock solution to 500 l of 
15





H HSQC spectra were recorded before addition of peptide and at 
each titration point. The chemical shift perturbations for the amide 
15
N nuclei were 
plotted against the molar ratio of peptide to protein. The data were analysed using a 
non-linear least squares fit to a one-site binding model (Equation 1) [145] with the 
programme Origin (OriginLab corporation, Northampton, MA). 
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In Eq.1, R is the molar ratio of peptide to protein, Δδbinding is the chemical shift 
perturbation at a given ratio of peptide to protein, Δδ∞ is the chemical shift 
perturbation at 100% bound protein, L is the initial concentration of 
15
N-labelled 
protein, U is the concentration of the peptide stock solution, Ka is the association 
constant of the complex and C is a parameter introduced to correct for any error in 
R, e.g. caused by the use of a theoretical extinction coefficient for the protein. R 
and Δδbinding are the independent and dependent variables, respectively, and Δδ∞, C 
and Ka are the fitted parameters. 















binding are the chemical shift perturbations of the amide 




After activation of the nitroxide spin label, peptides were titrated into 
15
N-labelled 
Src SH3 domain, and HSQC spectra were recorded with peptide P3 as a 
diamagnetic control to obtain experimental distance restraints for subsequent 
docking calculations [114]. To correct for any differences in concentration between 
the paramagnetic and control samples, the peak intensities of all residues were 
normalized internally against a residue unaffected by peptide binding. For all 
residues, the ratio between paramagnetic peak intensity (Ipara) and diamagnetic peak 
intensity (Idia), measured by the peak heights, was calculated. The residues were 
divided into three classes: residues that disappeared in the paramagnetic spectrum, 
visible residues with an intensity ratio of less than 0.85 and residues with an 
intensity ratio above 0.90. R2,dia, the transverse relaxation rate of a resonance in the 
diamagnetic sample, was determined from the peaks after processing with a 2 Hz 
line-broadening exponential window function. The linewidth at half maximum, 
υ1/2, was extracted from a Lorentzian peak fit using the software MestRe-C [146]. 
After correction for the artificial line-broadening the R2,dia was obtained according 
to Eq. 3: 
2/1,2 diaR                   (3) 
The paramagnetic contribution to the transverse relaxation rate, R2,para, was 
calculated from Eq. 4 [114], where Ipara and Idia is the peak intensity in the 
paramagnetic and diamagnetic experiment, respectively, and t is the total INEPT 













                  (4) 
The R2,para values were converted into distances between the amide and the spin 
label, using Eq. 5: 































               (5) 
where r is the distance between the unpaired electron of TOAC and a given amide 
proton of SH3, τc is the correlation time of the dipolar interaction of the electron 
and the nucleus, ωh is the proton Larmor frequency, γ is the proton gyromagnetic 
ratio, g is the electronic g-factor and β is the Bohr magneton, fp is the fraction of 
peptide that was paramagnetic and fb is the fraction of protein that was bound to 
peptide in the experiment. The fraction of protein bound was determined using the 
titration data, for P3Te it was estimated to 80% and for P3Tm to 44% at the 
concentrations used. Assuming no internal mobility of the spin label, the 






, where τr is the rotational correlation 
time of the protein-peptide complex and τs is the effective electron relaxation time. 
In the case of organic nitroxide radicals the electronic relaxation times are long and 
the correlation time is therefore dominated by the rotational correlation. The 
rotational correlation time of the protein-peptide complex was estimated to 5 ns, 
using the software hydroNMR [147] and a structure of chicken Src SH3 bound to a 
similar peptide, PDB Entry 1RLQ [39]. 
For residues broadened beyond detection in the paramagnetic spectrum the 
maximum intensity ratio was estimated from the noise level and converted into an 
upper distance restraint (class 1). Residues with an intensity ratio between 0 and 
0.85 were given both upper and lower distance restraints (class 2). For residues 
with an intensity ratio above 0.9, a common lower distance restraint was estimated, 
using a R2,dia value representative of the spectrum and an intensity ratio set to 0.90 
(class 3). The calculated distances using this R2,dia will differ slightly from the 
distance calculated using an individual R2,dia value for each residue, but the 
differences are within the margins used in the docking calculations and it is 
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therefore not necessary to use a separate R2,dia for each residue in this class. 
Intensity ratios between 0.85 and 0.90 were not used to generate restraints. 
 
Docking calculations 
The PDB file 1RLQ [39], containing a structure of chicken Src SH3 bound to a 
proline-rich peptide, was modified by mutating residue T125 (chicken Src 
numbering, corresponding to residue 127 in mouse Src) to S in silico, in 
accordance with the mouse Src SH3 sequence. Random starting positions were 
generated for the TOAC oxygen atom, and rigid-body docking calculations were 
performed in Xplor-NIH [148]. Only one energy term, corresponding to the 
distance restraints, was used. Restraint files can be found in Appendix A. 
For the solutions obtained in the docking calculations, Q-factors [97;149] were 















                (6) 
where robserved,i is the distance from the TOAC oxygen atom to the amide proton of 
residue i derived from the PRE NMR data, and rcalculated,i is the spin-label to amide 
distance for residue i in the docked structure. 
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Results and discussion 
To study the interaction of the Src SH3 domain with FAK peptides, three peptides 
were synthesized: one unlabelled control peptide, P3, with the sequence 
RALPSIPKL, and two peptides containing a TOAC residue either at one end of the 
sequence or within the binding motif. The peptide with TOAC within the core 
binding motif has the sequence RALP-TOAC-IPKL and is referred to as P3Tm, the 
peptide with TOAC at the end is referred to as P3Te, with the sequence TOAC-
RALPSIPKL. All peptides contained acetylated and amidated N- and C-termini, 
respectively. 
Titrations with non-paramagnetic peptides 
Upon titration of peptide P3 into 
15
N-labelled Src SH3 domain, chemical shift 
perturbations were observed for some backbone amides. Broadening of NMR 
peaks for residues with large shift changes indicated that the resonances of free and 
bound SH3 were in intermediate to fast exchange on the NMR timescale. From the 
binding curves (Fig. 2.2) a Kd of 56 ± 11 μM was determined. 
 
Figure 2.2. 15N Chemical shift perturbations of SH3 resonances upon titration with peptide P3. The 
curves represent the best global fit to a 1:1 binding model with a Kd of 56 ± 11 μM. 
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Titration of non-activated peptide P3Te produced very similar chemical shift 
perturbations (Fig. 2.3) and a Kd of 95 ± 15 μM. This indicates that placing TOAC 
at the end of the peptide influences the binding of the peptide to the SH3 domain to 
some extent, although the effect is limited. For peptide P3Tm, which contains a 
TOAC residue within the binding motif, the observed chemical shift changes are 
much smaller than for peptides P3 and P3Te at the same ratio of peptide to protein 
(Fig. 2.3). Fitting of the data to a 1:1 binding model yields a dissociation constant 
of 0.9 ± 0.1 mM, a 16-fold weaker binding. 
 
Figure 2.3. Comparison of 15N chemical shift perturbations of two SH3 resonances upon peptide 
titration. Filled symbols: Residue E16. Open symbols: Residue T33. Squares: Peptide P3, Triangles: 
Peptide P3Te, Circles: Peptide P3Tm. 
The TOAC in P3Tm is within the binding motif, but in a position where it is 
expected to point outward and not directly make contact with the protein. Pairs of 
TOAC residues have been shown to promote helical content in short peptides 
[151], however, no direct spectroscopic evidence exists that a single TOAC residue 
causes any changes in secondary structure of peptides [134]. For comparison, the 
average chemical shift perturbations were calculated and extrapolated to 100% 
bound protein for all three peptides (Fig. 2.4). The binding maps show very similar 
patterns (Fig. 2.5), indicating that the peptides bind in a similar conformation. 
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Figure 2.4. Extrapolation of 15N Chemical shift perturbations to infinite peptide:protein ratio for SH3 
resonances in the complex of SH3 with peptides P3, P3Te and P3Tm, respectively. Missing 
resonances in SH3-P3Tm were exchange-broadened beyond detection at the point of extrapolation. 
 
Paramagnetic peptide experiments and docking calculations 
After deprotonation of the TOAC nitroxide, peptides were added to 
15
N-labelled 
Src SH3 domain, causing a decrease in intensity for some residues (Fig. 2.6). 
Distance restraints were calculated from the NMR data and used in docking 
calculations. For peptide P3Tm multiple rigid-body docking runs with random 
starting positions for the TOAC nitroxide oxygen atom consistently produced a 
single low-energy solution (Fig. 2.7A). Analysis of the solution shows that 
virtually all restraints are satisfied and that the position of the spin-label is well-
defined (Fig. 2.7B). Any violations observed can be explained by small movements 
of residues situated in more flexible regions of the protein. To measure the 
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agreement between the observed and calculated distances a Q-factor was calculated 
for the double-bounded restraints (see Experimental Procedures). For peptide 
P3Tm the Q-factor was 0.08 with a correlation coefficient of 0.96 (Fig. 2.7C). The 
calculated position of the spin-label is reasonable as judged from comparison with 
a structure of chicken Src SH3 domain in complex with a similar peptide (Fig. 
2.7D). It should be noted that the introduction of the TOAC can have distorted the 
peptide, given the large reduction in the affinity.  
Although the error margins used for the distance restraints are very narrow (Fig 
2.7B), almost all restraints are satisfied. To investigate what effect random error in 
the observed intensity ratios has on the calculations, the observed ratios for P3Tm 
were randomly varied between −20% and +20% for all residues with both upper 
and lower distance restraints (class 2). In this way 30 datasets were generated. For 
two residues the intensity ratios sometimes exceeded 0.9, in those cases the ratio 
was set to 0.9. New R2,para values were calculated for the 30 data sets, generating 
new distance restraints. Docking calculations were performed for each set of 
randomized distance restraints, yielding a cluster of solutions (Fig. 2.8A). Analysis 
of the solutions shows that the variation in target distance and calculated position 
due to variation in intensity ratios is small (Fig. 2.8B). An average root mean 
square deviation (RMSD) from the mean position of 0.7 Å was calculated, with a 
standard deviation of 0.3 Å, suggesting that any error contributions caused by 
uncertainty in the determined intensity ratios are likely to be small. Other 
contributions to the error come from the use of an overall correlation time for all 
residues, as well as any errors in the estimated fraction bound protein and fraction 
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Figure 2.5. Chemical shift perturbations upon 
titration with peptides P3 (A), P3Tm (B) and 
P3Te (C), mapped onto the surface of Src SH3 
domain (PDB entry 1RLQ [39]). Shift changes 
were extrapolated to 100% bound protein and 
SH3 residues were coloured according to the 
size of the average chemical shift perturbation, 
Δδavg. Red: Δδavg≥0.3 ppm; orange: 
0.3>Δδavg≥0.1 ppm; yellow: 0.1>Δδavg≥0.04 
ppm; blue: Δδavg<0.04 ppm. Shown in grey are 
residues that could not be assigned (proline 
residues or residues that were exchange-




Figure 2.6. A) and C): Intensity 
ratios of backbone amide SH3 
resonances in complex with 
paramagnetic peptide P3Tm (A) / 
P3Te (C) and control peptide P3. 
The dashed horizontal line 
represents an intensity ratio of 
0.85, residues with intensity ratios 
below this are considered to be 
affected by TOAC. The asterisks 
indicate residues for which no 
intensity ratio data were available. 
B) and D): Detail from the 
spectrum of SH3 in complex with 
peptide P3Tm (B) / P3Te (D) in 
red, overlaid with the spectrum of 




Figure 2.7. A) Calculated position of TOAC oxygen atom, shown as pink sphere, in complex 
between peptide P3Tm and SH3 (shown in green). B) Violations analysis of calculated position of 
TOAC in P3Tm in complex with SH3. Dotted line: PRE-derived distance; white circles: distance in 
calculated structure; shaded area: error margins used in calculations. For class 1 residues (upper 
bound only) the error margin was +2Å, for class 3 residues (lower bound only) a −2Å error margin 
was used, and for class 2 residues (both upper and lower distance restraints) the error margins were 
±1 Å. C) Distance from TOAC oxygen atom to backbone amide proton for class 2 residues: distance 
obtained in rigid-body docking calculations versus PRE-derived distance. D) Same as a), overlaid 
with structure of SH3 in complex with peptide RALPPLPRY, shown in yellow (PDB entry 1RLQ 
[39]). In purple is shown the residue in peptide RALPPLPRY that corresponds most closely to the 
position of TOAC in peptide P3Tm. 
A consideration for single time-point measurements is that the magnetization 
recovery levels will differ between the paramagnetic samples and the diamagnetic 
control, owing to the PRE on the longitudinal relaxation rate [152]. The higher 
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recovery levels for the paramagnetic sample can lead to a systematic 
underestimation of the PRE effects, resulting in overestimated distances from the 
spin-label to the protein. This effect does not seem to be very pronounced in our 
system, given that the calculated position for the TOAC nitroxide is already close 
to the protein surface. 
 
Figure 2.8. A) Influence of variation in intensity ratio on calculated spin-label position. Shown as 
pink spheres are the resulting TOAC oxygen atom positions for 30 data sets, for which Ipara/Idia for the 
class 2 residues has been randomly varied by 20%. The calculated TOAC positions have an average 
RMSD from the mean of 0.7 Å, with a standard deviation of 0.3 Å. B) combined violation analysis of 
the 30 “randomized” datasets. Dotted line: mean of the PRE derived distance for the 30 data sets. 
White circles: Mean of calculated distance from TOAC oxygen atom to backbone amide proton for 
the 30 data sets, error bars: ± one standard deviation. Shaded area: For class 1 and class 3 residues: 
error margins used in the calculations, +2Å and −2Å, respectively. For class 2 residues: ± one 
standard deviation from the PRE derived distance. 
Rigid-body docking calculations for the position of TOAC in the complex of SH3 
and peptide P3Te also yields a single, reproducible solution (Fig. 2.9A). Analysis 
of the solution, however, shows violations for several residues (Fig. 2.9B). A Q-
factor of 0.17 was calculated together with a correlation coefficient of merely 0.62 
(Fig. 2.9C). Closer inspection of the data shows that the poor fit is largely due to 
one residue, D10 (corresponding to residue D93 in full-length mouse Src). This 
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residue has an intensity ratio of 0.70, but is located far from the rest of the residues 
that exhibit an effect from the spin-label, and pulls the calculated final position of 
the spin-label away from the other residues. Excluding this outlier from the 
docking calculations changes the final position of the TOAC oxygen atom, the 
TOAC is now positioned further away from the centre of the peptide in a more 
realistic position (Fig. 2.10A). This improves the fit, with a new Q-factor of 0.13 
and a correlation coefficient of 0.81 (Fig. 2.10B, C). There are still regions where 
the observed PRE effect is slightly larger than expected from the calculated 
structure. This is typically seen in systems where dynamics is present [100] and can 
be accounted for by small movements of the spin-label placed at one end of the 
peptide, where the flexibility is higher. The effect felt by residue D10 cannot be 
explained by small peptide movements around the binding site. It is, however, 




By using TOAC it was demonstrated that the interaction between the Src SH3 
domain and a proline-rich peptide derived from FAK is not very dynamic, and the 
position of the peptide relative to the protein is remarkably well-defined, despite 
the weak and transient binding. For studies of peptide-protein interactions, 
paramagnetic NMR with TOAC spin-labelled peptides provides a way to gain 
information about  
the dynamics as well as the structure of the complex. The rigid structure of TOAC 
makes it an attractive alternative to spin-labelling via cysteine residues, although 
the introduction of a TOAC residue in a peptide may have a large influence on the 
binding affinity when introduced in the core of the recognition motif. With the 
advancements in chemical synthesis of partial or even entire proteins, the 
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application of TOAC in studies of interactions of proteins with small molecules, 
nucleic acids or other proteins will be feasible. 
 
Figure 2.9. A) Calculated position of TOAC 
oxygen atom, shown as pink sphere, in 
complex between peptide P3Te and SH3 (in 
green, residue D10 is shown in purple). 
Overlaid with structure of SH3 in complex 
with peptide RALPPLPRY, shown in 
yellow. (PDB entry 1RLQ [39]). The N-
terminus of the peptide, coloured blue, 
corresponds to the place of attachment of the 
TOAC amino acid in peptide P3Te. B) 
Violations analysis of calculated position of 
TOAC in P3Te in complex with SH3. Dotted 
line: PRE-derived distance; white circles: 
distance in calculated structure; shaded area: 
error margins used in calculations. For class 
1 residues (upper bound only) the error 
margin was +2Å, for class 3 residues (lower 
bound only) a −2Å error margin was used, 
and for class 2 residues (both upper and 
lower distance restraints) the error margins 
were ±1 Å. C) Distance from TOAC oxygen 
atom to backbone amide proton for residues 
with both upper and lower distance restraints 
(class 2): distance obtained in rigid-body 






Figure 2.10. A) Calculated position of 
TOAC oxygen atom, shown as pink sphere, 
in complex between peptide P3Te and SH3 
(in green, residue D10 is shown in purple), 
after excluding residue D10 from the 
calculations. Overlaid with structure of SH3 
in complex with peptide RALPPLPRY, 
shown in yellow (PDB entry 1RLQ [39]). 
The N-terminus of the peptide, coloured 
blue, corresponds to the place of attachment 
of the TOAC amino acid in peptide P3Te. B) 
Violations analysis of calculated position of 
TOAC in P3Te in complex with SH3, after 
excluding residue D10 from the calculations. 
Dotted line: PRE-derived distance; white 
circles: distance in calculated structure; 
shaded area: error margins used in 
calculations. For class 1 residues (upper 
bound only) the error margin was +2Å, for 
class 3 residues (lower bound only) a −2Å 
error margin was used, and for class 2 
residues (both upper and lower distance 
restraints) the error margins were ±1 Å. C) 
Distance from TOAC oxygen atom to 
backbone amide proton for residues with 
both upper and lower distance restraints 
(class 2), after exclusion of residue D10 
from calculations: distance obtained in rigid-











The interaction between the tyrosine kinases Src and focal adhesion kinase (FAK) 
is a key step in signalling processes from focal adhesions. The phosphorylated 
tyrosine residue 397 in FAK is able to bind the Src SH2 domain. To establish the 
extent of the FAK binding motif, the binding affinity of the SH2 domain for 
phosphorylated and unphosphorylated FAK-derived peptides of increasing length 
was determined and compared with that of the internal Src SH2 binding site. It is 
shown that the FAK peptides have higher affinity than the internal binding site, and 
that seven negative residues adjacent to the core SH2 binding motif increase the 
binding constant 30-fold. A rigid spin-label incorporated in the FAK peptides was 
used to establish on the basis of paramagnetic relaxation enhancement whether the 
peptide-protein complex is well-defined. The peptide-protein complex exhibits 
dynamics, despite the high affinity of the peptide. These findings are interpreted in 
the context of the two step model for complex formation, involving the encounter 
state as an intermediate in which the proteins form a loose, dynamic complex. The 
strong electrostatic interaction between the positive side of the SH2 domain and the 
negative peptide results in a high affinity but may also favour the dynamic 
encounter state explaining the spread of the paramagnetic effects over the SH2 
domain.  
This chapter will be published as:  
Lindfors, H.E., Drijfhout, J.W., Arendsen, Y. and Ubbink, M (2010). Dynamics in 
a high-affinity peptide-SH2 domain complex. Submitted. 
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Introduction 
Focal adhesion kinase (FAK) and Src kinase are non-receptor protein tyrosine 
kinases involved in processes such as cell proliferation, cell survival and cell 
motility. Like many signal transduction proteins FAK and Src are examples of 
modular proteins, consisting of individually folded protein interaction or catalytic 
domains separated by linker regions. FAK contains a FERM (erythrocyte band 4.1 
ezrin, radixin, moesin homology) domain, a tyrosine kinase domain and a focal 
adhesion targeting (FAT) domain [153]. whereas Src contains an N-terminal 
myristoylated membrane targeting region followed by a unique domain, a Src 
homology 3 (SH3) domain, a Src homology 2 (SH2) domain, a tyrosine kinase 
domain and a C-terminal regulatory region [154]. 
SH2 domains, found in many proteins involved in tyrosine kinase signalling, are 
~100-amino-acid protein modules that recognize and bind to phosphorylated 
tyrosine sequences in specific target proteins [155]. Phosphopeptide library studies 
have shown that the specificity of SH2 domain interactions mainly depends on the 
three to five residues following the phosphorylated tyrosine [156]. For Src family 
kinases the SH2 domain consensus sequence is pYEEI [157], of which the 
phosphotyrosine and the isoleucine are inserted into two binding pockets in the 
SH2 domain [158]. The Src SH2 domain plays an important role in the regulation 
of Src activity by binding to a phosphorylated tyrosine, Y527, in the C-terminal tail 
of Src. Together with interactions between the SH3 domain and the linker 
connecting the SH2 domain to the kinase domain, this locks the protein into a 
closed, inactive form [159]. Upon recruitment of FAK by integrins, Y397 in the 
linker connecting the FERM domain to the kinase domain becomes phosphorylated 
[160]. The amino acid sequence of this site, YAEI, is close to the Src family SH2 
consensus binding motif, and phosphorylation of the tyrosine creates a high-
affinity binding site for the Src SH2 domain [139;161-163]. 
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Macromolecular complexes differ not only in binding affinity but also in dynamics, 
here defined as the motion of one binding partner relative to the other in the 
complex [100;164-167]. In the two-step model of macromolecular complex 
formation macromolecules first associate to form a loosely-bound intermediate 
state known as the encounter state [168] before proceeding to the formation of a 
well-defined complex. In this model, long-range electrostatic forces serve to bring 
two randomly diffusing proteins together and help orient them relative to each 
other [169;170]. This promotes complex formation by a reduced-dimensionality 
search, where the macromolecules first bind non-specifically and then diffuse 
along each other [171]. The equilibrium between the encounter state and the well-
defined state differs between complexes, some non-physiological electron transfer 
protein complexes have even been shown to exist mainly as an encounter complex 
[172]. Dynamics in macromolecular complexes can be studied using paramagnetic 
relaxation enhancement (PRE) NMR, which has become increasingly popular in 
recent years [97;100;173]. The strong and highly localized nature of PRE makes it 
possible to detect lowly populated states in which nuclei in one of the molecules 
approach the spin-label attached to the other molecule. The spin-labelled amino 
acid TOAC (2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid) can 
be incorporated into peptides via solid-phase synthesis [121;122]. Averaging of the 
paramagnetic effects caused by motion of the spin-label relative to the peptide can 
be avoided with TOAC because of its rigid structure. This makes TOAC a useful 
tool for studying peptide-protein interactions with PRE NMR. Recent PRE NMR 
studies of the complex of the Src SH3 domain with a TOAC-labelled peptide 
derived from FAK showed that although the peptide-protein complex is weak, the 
position of the spin-label relative to the SH3 domain is remarkably well-defined 
(chapter 2). This indicates that the peptide binds the SH3 domain in a specific 
manner, rather than the displaying the dynamics that might be expected based on 
the low-affinity character of the complex. This poses the question whether it is 
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possible to relate the degree of dynamics in a peptide-protein complex to the 
binding affinity of the complex. 
Here, we have studied the interaction of the Src SH2 domain with phosphorylated 
and unphosphorylated peptides derived from the C-terminal tail of Src and the 
Y397 SH2 binding site in FAK, using chemical shift perturbation analysis NMR, 
PRE NMR and microcalorimetry. First, we established that charged residues 
outside the SH2 core binding motif have a large influence on the binding affinity. 
Subsequently, we introduced TOAC in these extended, high affinity peptides and 
observed that the interaction with the SH2 domain is surprisingly dynamic. These 





Peptides were synthesized using the method described in chapter 2 and were kindly 
provided by Dr. Jan Wouter Drijfhout. 
Cloning and protein expression 
A DNA fragment encoding the mouse Src SH2 domain, residues 147-250, was 
generated by PCR and restricted with NcoI and XhoI for insertion into the 
expression vector pET28a. For protein production Escherichia coli BL21 cells 
were transformed with SH2-pET28 and incubated overnight in LB medium 
supplemented with 50 mg/L kanamycin at 37°C while shaking at 250 rpm. The 
preculture was diluted 1:100 into fresh medium, using LB medium with 50 mg/L 
kanamycin for production of unlabelled protein, and M9 minimal medium with 50 
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mg/L kanamycin using 
15
NH4Cl as the sole nitrogen source for 
15
N-labelled 
protein. Cultures were incubated at 37°C and 250 rpm until an OD600 of 0.6, protein 
production was induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside and 
cells were harvested via centrifugation 3-5 h later.  
Protein purification 
Cells were resuspended in lysis buffer (20 mM Tris-HCl pH 8, 0.5 M NaCl, 10 mM 
imidazole, 1 mM phenylmethanesulfonyl fluoride and 50 µg/mL DNAse) and lysed 
by two passages through a French pressure cell. The lysate was cleared by 
centrifugation at 40,000 rpm for 30 minutes and the supernatant containing the His-
tagged SH2 domain was loaded onto an affinity column (HisTrap HP, GE 
Healthcare). After washing with 20 mM Tris-HCl pH 8, 0.5 M NaCl and 60 mM 
imidazole the protein was eluted with the same buffer containg 300 mM imidazole. 
The eluted protein was diluted 10-fold with 20 mM HEPES pH 6.8, loaded onto an 
ion-exchange column (HiTrap SP, GE Healthcare) and eluted with a 50-500 mM 
NaCl gradient. Fractions were checked by SDS-PAGE and the purity of the protein 
was estimated to be above 95%. The protein concentration was determined using a 






NMR experiments were recorded at 303 K on a Bruker DMX600 spectrometer 
equipped either with a TXI-Z-GRAD probe or a TCI-Z-GRAD cryoprobe (Bruker, 
Karlsruhe, Germany). The data were processed with Azara 
(http://www.bio.cam.ac.uk/azara/) and analyzed using Ansig For Windows [142]. 









H] TOCSY-HSQC spectra were recorded on a 4 mM 
15
N-SH2 sample in 20 
mM KPi pH 6.5, containing 6% D2O for lock. The resonances were assigned with 
the help of assignments for the human SH2 domain [174]. 
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For peptide titrations, stock solutions of 4-20 mM peptide were prepared by 
dissolving peptides in 20 mM KPi, pH 6.5, 0.1 M NaCl and adjusting the pH to 6.5 
with small aliquots of 0.1–0.5 M solutions of NaOH or HCl. Titrations with 
unlabelled peptides were performed by the addition of microliter aliquots of 
peptide to samples containing 0.20-0.26 mM 
15
N SH2 in 20 mM KPi pH 6.5, 0.1 M 




H] HSQC spectra were recorded at the start of the 
titration and after each addition of peptide. Spin-labelled peptides were added to 
similar samples without DTT. Diamagnetic control experiments were carried out 
after reduction of the paramagnetic peptides by ascorbate. 
Chemical shift perturbation analysis 
For titrations with unlabelled peptides the chemical shift perturbations for the 
amide 
15
N nuclei were plotted against the molar ratio of peptide to protein. The 
data were analysed using a non-linear least squares fit to a one-site binding model 









 /1  
In Eq.1, R is the molar ratio of peptide to protein, Δδbinding is the chemical shift 
perturbation at a given ratio of peptide to protein, Δδ∞ is the chemical shift 
perturbation at 100% bound protein, L is the initial concentration of 
15
N-labelled 
protein, U is the concentration of the peptide stock solution, Ka is the association 
constant of the complex and C is a parameter introduced to correct for any error in 
peptide concentration, e.g. caused by the hygroscopicity of the peptides or the 
uncertainty in connection to the weighing out of milligram amounts of peptide. A 
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value of C greater than one means that the actual peptide concentration was lower 
than expected. R and Δδbinding are the independent and dependent variables, 
respectively, and Δδ∞, C and Ka are the fitted parameters. 















binding are the chemical shift perturbations of the amide 
nitrogen and amide proton, respectively, extrapolated to 100% bound protein. 
Distance restraints and docking calculations 
To correct for any differences in concentration between the paramagnetic and 
diamagnetic samples, the peak intensities of all residues were normalized internally 
against a residue unaffected by the peptide binding. The ratio between the 
paramagnetic and the diamagnetic peak intensities (measured by the peak heights) 
was calculated for all residues. The residues were subsequently divided into three 
classes: residues that disappeared in the paramagnetic spectrum (class 1), residues 
with an intensity ratio equal to or greater than 0.90 (class 2) and visible residues 
with an intensity ratio of less than 0.85 (class 3). Intensity ratios between 0.85 and 
0.90 were not used for generating restraints. The average intensity ratio for class 2 
residues was calculated (0.97 for peptide ETDDpYAEIIDEED and 1.11 for peptide 
ETDDYAEIIDEED) and in order to adjust the average to exactly 1 all intensity 
ratios in the experiment were divided by this factor and the classes were adjusted 
according to the scaled intensity ratios. 
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The paramagnetic contribution to the transverse relaxation rate, R2,para, was 
determined as described in chapter 2 and converted into distances between the 






























                (3) 
where r is the distance between the unpaired electron of TOAC and a given amide 
proton of SH2, τc is the correlation time of the dipolar interaction of the electron 
and the nucleus, ωh is the proton Larmor frequency, γ is the proton gyromagnetic 
ratio, g is the electronic g-factor, β is the Bohr magneton, fp is the fraction of 
peptide that was paramagnetic and fb is the fraction of protein that was bound to 
peptide in the experiment. The fraction of bound protein, fb, was estimated from 
NMR titration data (74% for ETDDpYAEI-Toac-DEED and 31% for ETDDYAEI-
Toac-DEED), and the fraction of paramagnetic peptide, fp, was determined using 
EPR (59% for peptide ETDDpYAEI-Toac-DEED and 49% for peptide 
ETDDYAEI-Toac-DEED). The total correlation time of the protein-peptide 
complex was estimated to 8 ns, using the software hydroNMR [147] and a structure 
of human Src SH2 bound to a phosphorylated peptide, PDB Entry 1HCS [175]. 
Francesco Scarpelli is gratefully acknowledged for help with EPR measurements. 
For class 2 residues, with an intensity ratio equal to or above 0.9, a common lower 
distance restraint was estimated using a R2,dia value representative of the spectrum 
and an intensity ratio set to 0.90. The calculated distances using this R2,dia will 
differ slightly from the distance calculated using an individual R2,dia value for each 
residue, but the differences are within the margins used for this class in the docking 
calculations. Class 3 residues, with an intensity ratio between 0 and 0.85, were 
given both upper and lower distance restraints. Individual error margins were 
calculated for class 3 residues by determining the standard deviation of the noise in 
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the spectra and calculating a maximum and a minimum intensity ratio for each 




















min         (4a, b) 
where SDpara and SDdia are the standard deviations of the noise in the paramagnetic 
and diamagnetic spectra. The maximum and minimum intensity ratios were 
subsequently used to calculate minimum and maximum R2,para values and converted 
into upper and lower distance restraints according to Eq. (3) (for R2,para values see 
Appendix B). For class 1 residues, broadened beyond detection in the paramagnetic 
spectrum, the maximum intensity ratio was estimated from the noise level and 
converted into an individual upper distance restraint for each residue. In the 
docking procedure the SH2 domain was kept fixed and only the TOAC oxygen 
atom, taken to represent the paramagnetic centre, was free to move. Rigid-body 
docking calculations were performed in Xplor-NIH [148]. Ten runs were carried 
out in which random starting positions were generated for the TOAC oxygen atom, 
and energy minimization was performed until convergence was reached with a 
maximum of 100 steps. Only one energy term, corresponding to the distance 
restraints, was used, with the energy term being zero if the calculated distance 
between the amide proton and the TOAC oxygen atom matches the target distance 
within the restraint boundaries calculated above. For distances outside the allowed 
margins a square well energy function was used. 
Due to uncertainties in determining the fraction of bound protein and the fraction 
of paramagnetic peptide, the fp and fb values were varied and additional 
calculations performed. The effect on the calculated TOAC position was marginal 
and the conclusion that a single position for the spin-label relative to the protein 
cannot account for the observed PREs remains the same. 
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Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) experiments were carried out at 303 K on a 
Microcal (Northampton, MA) VP-ITC microcalorimeter. Unlabelled protein and 
peptide solutions were dialyzed exhaustively against the same buffer (50 mM 
HEPES pH 6.8, 0.1 M NaCl, 1 mM TCEP), centrifuged and degassed before 
experiments. A 25 μM SH2 solution was placed in a sample cell with a volume of 
1.4 mL and binding isotherms were recorded following the injection of peptide 
(stock concentration 250 μM), while continuously stirring at 307 rpm. An initial 4 
μL-injection was followed by 27 injections of 10 μL each, with 4-minute intervals 
between injections. Experiments were performed in triplicate and the standard 
deviations of the measured values are reported as the error margin. The error in 
TS was calculated using standard error propagation. Dilution heats were 
determined by titration of peptide into buffer and subtracted from the peptide into 
protein titration data. Using the Origin software supplied by Microcal, data were 
analyzed with a non-linear least squares fit to a one site binding model after 
deletion of the first titration point. In the fits, uncertainty in the peptide stock 
solution concentration caused the stoichiometry parameter, n, to differ from 1, with 
an average value of N=1.58 for the three measurements. The original peptide 
concentration 250 μM was therefore divided by this value (new concentration 158 
μM), and the fits were repeated. The reported parameters are the result of these fits. 




The peptide-binding face of the Src SH2 domain is predominantly positively 
charged. Inspection of the sequence surrounding the Y397 SH2 domain binding 
Chapter 3 
58 
site in FAK reveals that the flanking residues are mostly negatively charged. To 
investigate the influence of the surrounding residues on the interaction with the 
SH2 domain peptides derived from the FAK Y397 site were synthesized in 
phosphorylated and unphosphorylated forms, either comprising only the SH2 core 
binding motif or including the surrounding residues as well. Phosphorylated and 
unphosphorylated peptides from the C-terminal autoinhibitory region of Src were 
synthesized in addition (Table 1). 
Titration with the unphosphorylated Src C-terminal peptide YQPG did not produce 
any significant chemical shift perturbations of backbone amide resonances of the 
SH2 domain, indicating no detectable binding of the SH2 domain to this peptide. 
The phosphorylated version of the same peptide, pYQPG, caused large chemical 
shift perturbations for some backbone amides. From the binding curves (Fig. 3.1A) 
an equilibrium dissociation constant Kd of 63 ± 20 μM was determined. Peptide 
YAEI, representing the core binding site on FAK, bound extremely weakly to the 
SH2 domain, with a Kd of at least 10 mM (Fig. 3.1B). For the phosphorylated 
version of the same peptide, pYAEI, a Kd of 3 ± 2 μM was found (Fig. 3.1C). The 
unphosphorylated peptide also containing the residues surrounding the core SH2 
binding motif, ETDDYAEIIDEED, demonstrated a much higher binding affinity 
for the SH2 domain compared to the shorter unphosphorylated peptide, yielding a 
Kd of 0.34 ± 0.16 mM (Fig. 3.1D). 
Titration with the long, phosphorylated peptide ETDDpYAEIIDEED also gave rise 
to large chemical shift perturbations of some amide resonances, but the binding of 
this peptide to the SH2 domain proved to be too tight to obtain a value of the 
equilibrium dissociation constant using NMR spectroscopy. In the titrations the 
resonances of free and bound SH2 domain range from being in fast exchange on 
the NMR time-scale for peptides YAEI and ETDDYAEIIDEED, via fast-to-
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intermediate exchange for peptide pYQPG and intermediate-to-slow exchange for 
peptide pYAEI, to slow exchange for peptide ETDDpYAEIIDEED (Fig. 3.2). 
Table 1. SH2-peptide binding assays. pY=phosphotyrosine. All peptides were acetylated and 
amidated on the N-, and C-termini, respectively. C is a parameter introduced to correct for any error 
in peptide concentration (see experimental procedures). 
Peptide sequence Derived from Kd C Method 





pYQPG Src C-terminal 
region 
63 ± 20 μM 1.56 NMR 
YAEI FAK Y397 ≥10 mM 1 NMR 
pYAEI FAK Y397 3 ± 2 μM 1.28 NMR 
ETDDYAEIIDEED FAK Y397 0.34 ± 0.16 mM 0.67 NMR 
ETDDpYAEIIDEED FAK Y397 73 ± 12 nM 1.58 ITC 
ETDDYAEI-Toac-DEED FAK Y397 0.75 ± 0.40 mM 1.89 NMR 
ETDDpYAEI-Toac-
DEED 
FAK Y397  1 μM 1 NMR 
 
Using ITC, a Kd of 73 ± 12 nM was determined for the interaction of peptide 
ETDDpYAEIIDEED with the SH2 domain. The binding is driven by an enthalpic 
change (H) of -10.6±0.1 kcal/mol, with the entropic term (TS) being -0.7±0.2 
kcal/mol (Fig. 3.3 and Table 2). A comparison of enthalpy and entropy changes of 
binding of peptides ETDDpYAEIIDEED and PQpYAEIPI [176] under similar 
conditions with the Src SH2 domain shows a somewhat larger favourable enthalpic 
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 contribution for the former (Table 2). The shorter peptide exhibits a favourable 
entropic contribution, whereas peptide ETDDpYAEIIDEED displays an 
unfavourable entropy term. 
 
Figure 3.1. 15N chemical shift perturbations of SH2 resonances upon titration with peptides. The 
curves represent the best global fit to a 1:1 binding model (Eq. 1). A) peptide pYQPG B) peptide 
YAEI C) peptide pYAEI D) peptide ETDDYAEIIDEED. 
 
To compare the effect the different peptides have on the SH2 domain average 
chemical shift perturbations were extrapolated to 100% bound protein for all 
assigned residues in the SH2 domain (Fig. 3.4). Peptide pYQPG affects a rather 
limited set of residues in the SH2 domain, mainly around the phosphotyrosine 
binding pocket (Fig. 3.4B), whereas peptides derived from FAK affect a larger 
number of residues, especially the longer peptides (Fig. 3.4C-F). The 
Dynamics in a high-affinity peptide-SH2 domain complex 
61 
unphosphorylated and phosphorylated peptides cause quite similar chemical shift 
perturbations in the SH2 domain, indicating that they bind in similar ways (Fig. 
3.4C and D, E and F). 
 
Figure 3.2. Detail from HSQC spectra of SH2 domain in titrations with peptides YQPG (A), YAEI 
(B), ETDDYAEIIDEED (C), pYQPG (D), pYAEI (E) and ETDDpYAEIIDEED (F). Spectra from a 
few titration points are shown overlaid, with starting points (free protein) in black and titration end 












) G (kcal/mol) H (kcal/mol) TS 
(kcal/mol) 
ETDDpYAEIIDEED
a 1.4 (±0.2) x 
10
7 
-9.9  ± 0.1 -10.6  ± 0.1 -0.7 ± 0.2 
PQpYAEIPI
b 2.9 (±0.4) x 
10
6 
-8.7  ± 0.1 -7.7  ± 0.2 1.0  ± 0.2 
a
 Binding isotherms recorded in 50 mM HEPES, pH 6.8, 1mM TCEP and 100 mM NaClat 
303 K. 
b
 Values taken from [177], (20 mM HEPES, pH 7.5, and 100 mM NaCl at 298 K).  
 
Dynamics of peptide binding 
In order to investigate the dynamics of the interaction between the SH2 domain and 
the longer peptides derived from FAK, peptides containing the spin-labelled amino 
acid TOAC were synthesized (Table 1). The paramagnetic TOAC was introduced 
to determine whether the bound peptide assumes a single, well-defined orientation 
or samples several orientations. The strong distance dependence of the PRE and the 
rigidity of the spin-label relative to the peptide should result in highly localized 
PREs if the peptide orientation is well-defined. To assess the influence of TOAC 
on the peptide-protein interaction first, NMR titrations were performed with 
TOAC-labelled peptides in the reduced, non-paramagnetic form. For both the 
unphosphorylated peptide ETDDYAEI-Toac- DEED and the phosphorylated 
peptide ETDDpYAEI-Toac-DEED the binding affinity was somewhat reduced 
compared to the unlabelled peptides, with a Kd of 0.75 ± 0.40 mM for the 
unphosphorylated TOAC peptide. The exchange between free and peptide-bound 
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SH2 forms is faster for ETDDpYAEI-Toac-DEED compared to 
ETDDpYAEIIDEED, suggesting somewhat lower affinity for the former. The 
binding is, however, still too tight to be determined by NMR.  
 
Figure 3.3. Representative isothermal titration calorimetry curves for the binding of Src SH2 to 
peptide ETDDpYAEIIDEED. A) raw data after baseline correction, B) integrated data corrected for 




Figure 3.4. Chemical shift perturbations upon titration with peptides A) YQPG, B) pYQPG, C) 
YAEI, D) pYAEI, E) ETDDYAEIIDEED, F) ETDDpYAEIIDEED, G) ETDDYAEI-Toac-DEED 
(reduced state) H) and ETDDpYAEI-Toac-DEED (reduced state) mapped onto the surface of the SH2 
domain. Shift changes were extrapolated to SH2 fully bound to peptide and residues were coloured 
according to the size of the average chemical shift perturbation, Δδavg. Red: Δδavg≥0.3 ppm; orange: 
0.3>Δδavg≥0.1 ppm; yellow: 0.1>Δδavg≥0.04 ppm; blue: Δδavg<0.04 ppm. Non-assigned residues are 
shown in grey. 
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From the titration it can only be estimated that the phosphorylated TOAC-peptide 
binds with a Kd of less than a 1 µM. Due to the limited amount of material no ITC 
experiments could be carried out to precisely determine the binding constant. 
Extrapolation of the average chemical shift perturbations to 100% bound protein 
shows that despite the small changes in affinity, the unphosphorylated peptides 
ETDDYAEIIDEED and ETDDYAEI-Toac-DEED bind in a similar way (Fig 3.4E 
and F), as do the phosphorylated peptides ETDDpYAEIIDEED and ETDDpYAEI-
Toac-DEED (Fig 3.4G and H). 




N-HSQC spectra of the SH2 domain complexed to the 
paramagnetic TOAC-peptides were recorded, and from a comparison of the peak 
intensities in the paramagnetic and diamagnetic control samples the PRE (R2,para) 
was derived (see Experimental Procedures), at peptide-to-protein ratios of 2:1 and 
2.6:1 for the phosphorylated and unphosphorylated peptide, respectively. Mapping 
of the experimentally determined R2,para-values onto the SH2 domain shows that the 
observed effects are spread over a large part of the protein for both peptides (Fig 
3.5A, B) contrary to the expectation for a well-defined orientation. 
To establish whether the PREs agree with a single position of the spin label relative 
to the protein, distance restraints were derived from the R2,para-values and the 
position of a pseudoatom representing the spin-label was obtained by energy 
minimization using the restraints as the sole energy term. The calculations 
converged to a single position for the TOAC nitroxide. However, it differs by 
approximately 9.5 Å from a prediction based on comparison with the structure of 
Src SH2 in complex with another phosphopeptide [178] (Fig. 3.6). Furthermore, 
analysis of the restraint violations shows that many of the amide-spin label 
distances in the calculated structure fall outside the range set by the paramagnetic 
effects (Figs. 3.7 and 3.8). This demonstrates that the single calculated position of 
the spin-label is not sufficient to explain all paramagnetic effects observed. 
Violations plots based on the R2,para-values instead of the distances are shown in 
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Figs. 3.9 and 3.10. These results provide a clear indication that the TOAC-based 
spin-label samples a significant part of the SH2 surface. 
 
 
Figure 3.5. R2,para values derived from NMR data of SH2 domain in complex with ETDDYAEI-Toac-
DEED (A) and ETDDpYAEI-Toac-DEED (B) mapped onto the SH2 domain surface. For comparison 
R2,para values from NMR data of Src SH3 in complex with the spin-labelled peptides Toac-
RALPSIPKL (C) and RALP-Toac-IPKL (D) (chapter 2) are shown. The fraction of paramagnetically 
labelled peptide (fp) and the fraction of protein bound to peptide (fb) are not identical for all four 
experiments, R2para values have been normalized against the lowest fp*fb value. For A) fp*fb=0.15, B) 
0.44, C) 0.24 and D) 0.23, meaning that R2para values for the phosphorylated peptide (B) have all been 
divided by 2.9 (=0.44/0.15), and similarly for SH3 R2para values. Purple: residues broadened beyond 
detection, red: R2para ≥50 s
−1, orange: 50 s−1>R2para≥24 s
−1, yellow: 24 s−1>R2para≥3.12 s
−1, blue: 
R2para<3.12 s
−1. In grey are shown residues not included in docking calculations (non-assigned 
residues or residues with an intensity ratio greater or equal to 0.85 and less than 0.9). 
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Figure 3.6. Calculated position of TOAC oxygen atom on the basis of PRE data (pink sphere) in 
complex between peptide ETDDYAEI-Toac-DEED (A) or ETDDpYAEI-Toac-DEED (B) and the 
Src SH2 domain, overlaid with a structure of SH2 in complex with peptide pYEEIE, shown in green 
(PDB entry 1HCS [179]). In blue is shown the expected position of TOAC based on the 
corresponding residue in peptide pYEEIE. 
 
Discussion 
The NMR titrations show that the FAK residues flanking the core binding motif 
have a large impact on the interaction with the SH2 domain. Including these 
surrounding residues increases the binding affinity by around 30 fold for both the 
phosphorylated and unphosphorylated peptides, demonstrating that residues outside 
the consensus Src family SH2 binding motif can contribute to SH2-mediated 
protein interactions. Introducing TOAC in the peptides just outside the core SH2 
binding motif somewhat reduced the binding affinity for the SH2 domain. It has 
been shown that introduction of TOAC in a peptide sequence can lower peptide-
protein binding affinity if TOAC is placed within the binding motif, but not if 
placed outside the immediate protein recognition site (chapter 2). Here, we find a 
small decrease in the affinity when TOAC is placed at the Y+4 position. Based on 
a published structure of the SH2 domain in complex with a phosphopeptide of the 
sequence pYEEIE [180] the TOAC is expected to be pointing away from the 
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protein surface, and therefore interfere minimally with the binding. It is possible 
though that the rigid structure of the spin-label to some extent restrains the peptide 
flexibility. However, the similarity of the chemical shift perturbations caused by 
spin-labelled and unlabelled peptides (Fig. 3.4) suggests that in spite of the effect 
on the binding affinity the modes of binding are similar. 
 
 
Figure 3.7. Violations analysis of calculated position of TOAC nitroxide in the complex of peptide 
ETDDYAEI-Toac-DEED with Src SH2. Spin-label to amide distances derived from the NMR data 
are shown as white squares, with the allowed distance range (error margins used in calculations) 
shown as a shaded area. Distances in the converged structure are shown as black circles, black circles 
outside the shaded area signify violations of the distance restraints. For comparison predicted amide-
spin label distances based on a structure of peptide pYEEIE in complex with the SH2 domain (PDB 
entry 1HCS, from [181]) are shown as white circles connected by a dotted line. Predicted distances 
were obtained by placing the TOAC in the Y+4 position in this peptide, which corresponds to the 
position of TOAC in ETDDYAEI-Toac-DEED. 
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Figure 3.8. Violations analysis of calculated position of TOAC nitroxide in the complex of peptide 
ETDDpYAEI-Toac-DEED with Src SH2. Spin-label to amide distances derived from the NMR data 
are shown as white squares, with the allowed distance range (error margins used in calculations) 
shown as a shaded area. Distances in the converged structure are shown as black circles, black circles 
outside the shaded area signify violations of the distance restraints. For comparison predicted amide-
spin label distances based on a structure of peptide pYEEIE in complex with the SH2 domain (PDB 
entry 1HCS, from [182]) are shown as white circles connected by a dotted line. Predicted distances 
were obtained by placing the TOAC in the Y+4 position in this peptide, which corresponds to the 
position of TOAC in ETDDpYAEI-Toac-DEED. 
Analysis of the docking calculations shows that for neither the phosphorylated nor 
unphosphorylated peptides is a single position of the spin-label relative to the 
protein sufficient to account for the observed paramagnetic effects, indicating that 
the peptide samples the surface of the SH2 domain in a dynamic fashion, despite 
the very high affinity of the long phosphopeptide for the SH2 domain. A possible 
explanation for this is that peptide and protein are first attracted to each other based 
on their opposite charges, and that the peptide subsequently moves over the SH2 
surface in search of the specific binding position. This view is in line with the two-
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step model for protein complex formation [183]. The encounter complex is thought 
to be dominated by electrostatic interactions. The highly negative peptide is 
strongly attracted by the positive surface of the SH2 domain, enhancing the 
formation of the encounter complex and thus the affinity. It has been shown that 
electrostatic interactions stabilize the encounter complex more than the final 
complex [184] and, consequently, the introduction of the negative charges not only 
enhances the affinity of complex formation, but also shifts the equilibrium between 
encounter state and final complex towards the former (Fig. 3.11). The electrostatic 
interactions between the charged patches on the protein and the peptide result in an 
ensemble of rapidly exchanging orientations, making the encounter state dynamic 
and explaining the spread of the PREs over the SH2 domain. This is supported by  
 
Figure 3.9. Violations analysis of calculated position of TOAC in ETDDYAEI-Toac-DEED in 
complex with SH2. Stars: R2,para values derived from NMR data; open circles: R2,para values in 
calculated structure; shaded area: error margins used in calculations. Filled circles show the expected 
R2,para values based on the position of the residue in peptide pYEEIE [185] corresponding to TOAC in 
the above peptides. Values exceeding 100 s-1 are shown as 100 s-1. 
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the observation that many of the residues showing high R2,para values are either 
positively charged or close to residues with a positive charge, whereas the peptide 
is highly negatively charged. 
 
Figure 3.10. Violations analysis of calculated position of TOAC in ETDDpYAEI-Toac-DEED in 
complex with SH2. Stars: R2,para values derived from NMR data; open circles: R2,para values in 
calculated structure; shaded area: error margins used in calculations. Filled circles show the expected 
R2,para values based on the position of the residue in peptide pYEEIE [186] corresponding to TOAC in 
the above peptides. Values exceeding 100 s-1 are shown as 100 s-1. 
The advantage of PRE NMR over other methods for studying dynamics in protein 
complexes is the possibility to detect complex orientations that are only populated 
for a small fraction of the time. For example, it is not likely that any intermolecular 
NOEs could be observed for the encounter state, due to its dynamic nature. 
Previous studies of the Src SH3 domain in complex with spin-labelled peptides 
derived from FAK have shown that in interactions of weak binding affinity the 
position of the peptide relative to the protein can still be remarkably well-defined 
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(chapter 2) with the effects of the spin-label on the protein concentrated to 
relatively small, well-defined areas (Fig 3.5C, D). The results presented here show 
that high-affinity binding can be surprisingly dynamic, and that residues outside the 




The negatively charged residues surrounding the Y397 SH2 binding site in FAK 
increase the binding affinity for the SH2 domain to peptides derived from this site 
by more than an order of magnitude, demonstrating that residues outside the SH2 
core binding motif can have a large influence on SH2-mediated protein 
interactions. Despite the high binding affinity for the phosphorylated peptide to the 
SH2 domain, the interaction exhibits dynamics. Previous work has shown that a 
low binding affinity in itself does not imply mobility in a peptide-protein complex, 
whereas this study shows that a high binding affinity does not necessarily imply a 
static way of binding. The strong electrostatic interactions enhance the affinity, but 
simultaneously appear to favour a more dynamic interaction. 
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Figure 3.11. Energy diagram of two-step model of peptide-SH2 domain complex formation, with the 
encounter complex denoted by an asterisk. Electrostatic interactions promote encounter complex 
formation and stabilize the encounter complex relative to the final complex, thereby shifting the 










A dynamic intermediate state in peptide-






The interaction of peptides derived from FAK with the SH32 domain of Src has 
been studied using NMR and ITC. The SH3- and SH2-binding sites in FAK are 
separated by more amino acid residues than what is required to simply span the 
distance between the peptide-binding faces on the SH3 and SH2 domains. Here, the 
length of the linker separating the SH3- and SH2-binding sites in FAK peptides has 
been reduced and the effect on the interaction with the SH32 domains has been 
investigated. Peptides in which the distance between the SH2- and SH3-binding 
sites is not sufficient for simultaneous SH2 and SH3 domain-binding were 
expected to almost exclusively bind to the SH2 domain, due to the high-affinity 
nature of SH2 domain-mediated interactions compared to SH3-peptide interactions. 
Contrary to expectations, a significant fraction of the peptide was found to bind to 
the SH3 domain at low peptide-to-protein ratios. In order to explain these 
observations we propose a model for the peptide-SH32 interaction in which long-
range electrostatic interactions between charges in the peptide and the SH2 domain 
help recruit the peptide into a dynamic encounter complex, from which the peptide 
can either bind the SH3 or SH2 domain, thereby increasing the affinity for the SH3 
domain compared to peptide interactions involving the isolated domain. 
 
This chapter will be published as part of: 
Lindfors et al (2010). A dynamic intermediate state in peptide-binding to the 
combined Src SH3 and SH2 domains. Manuscript in preparation. 
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Introduction 
A general feature of most signalling proteins is their modular architecture, meaning 
that they are constructed from several individually folded domains. The domains 
can either have catalytic functions or be interaction domains, involved in binding to 
other proteins, lipids or nucleic acids. Recognition of short peptide sequences by 
protein interaction domains plays an important role in the regulation of cellular 
behaviour by facilitating the assembly of the signalling protein complexes and 
larger protein networks involved [15;187]. The protein interaction domains do not 
only function to recruit the catalytic domain to its appropriate substrates in the cell, 
but are often also involved in the regulation of protein activity via domain 
rearrangements [188]. 
The Src family kinases (SFKs) are prototypical modular signalling proteins. These 
non-receptor protein tyrosine kinases are involved in the regulation of a number of 
cellular processes, including cell survival, proliferation, differentiation and motility 
[189]. SFKs share a common domain structure with an N-terminal myristoylation 
site, followed by a region that is unique for each family member, a Src homology 3 
(SH3) domain, a Src homology 2 (SH2) domain, a tyrosine kinase domain and a C-
terminal region containing a negative-regulatory tyrosine residue (Y529 in Src, 
using mouse Src numbering) [190]. The SH3 and SH2 domains are protein-
interaction domains found in a large number of signalling proteins [191]. SH3 
domains, first discovered in 1988 [192], bind to proline-rich sequences that adopt a 
left-handed helical conformation [15], whereas SH2 domains recognize 
phosphorylated tyrosine residues. Since the original discovery in 1986 [193], SH2 
domains have been identified in over 100 different protein sequences in humans 
[155]. The SH3 and SH2 domains of SFKs are involved in the regulation of protein 
activity via intramolecular contacts. Phosphorylation of Y527 in the C-terminal 
region of the kinase leads to association of this region with the SH2 domain. 
Together with the interaction of the SH3 domain with residues in the linker 
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connecting the SH2 domain with the catalytic domain, this intramolecular binding 
promotes a conformation by which kinase activity is repressed [194-197]. The SH2 
and SH3 domains therefore play a direct role in regulating kinase activity, and 
competition for SH3 or SH2 domain binding by external ligands leads to kinase 
activation [198;199]. Fragments encompassing the SH3-SH2 domains (SH32) from 
several SFKs have been characterized biochemically, structurally and 
computationally [139;144;200-206], because of the importance of these domains 
for the functioning of SFKs. 
Focal adhesion kinase (FAK) can activate Src and Fyn via interactions with their 
SH2 and SH3 domains [139;207;208]. The linker region between the FERM and 
catalytic domains of FAK contains a tyrosine residue, Y397, which becomes 
phosphorylated in connection with FAK activation [209]. N-terminal to the 
tyrosine, the linker contains a proline-rich region of the sequence RALPSIPKL. 
These residues contain the SH3 domain binding motif PxxP [210], whereas the 
phosphotyrosine region with sequence pYAEI is close to the consensus sequence 
pYEEI for SH2 domain binding [211]. Peptides derived from FAK spanning both 
the proline-rich and phosphotyrosine sites have been shown to bind to SH32 
fragments of Src and Fyn in a bidentate manner with equilibrium dissociation 
constants of 20-30 nM, which is a higher affinity than those seen for peptides 
containing an SH3 or SH2 binding site alone [139;212]. It has been shown that the 
interaction between the FAK peptide and the Fyn SH32 domains is restricted to the 
canonical SH3 and SH2 binding sites and that the interaction does not affect the 
dynamic independence of the two domains [213]. 
The SH3- and SH2- domain binding motifs in the FAK fragment are separated by a 
„spacer‟ consisting of 22 aminoacids, which is approximately 10 residues more 
than what is necessary to span the distance between the peptide-binding faces on 
the SH3 and SH2 domains [214]. This allows for simultaneous association of the 
SH3- and SH2 domains with their respective binding sites in the peptide. If the 
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length of the spacer separating the two binding sites in the peptide is reduced, the 
peptide-protein interaction would be expected to remain unaffected as long as the 
peptide can span the distance between the two domains. Upon further reduction of 
the spacer, the peptide would be expected to predominantly bind to the SH2 
domain, due to the much higher affinity of the SH2 domain for the phosphotyrosine 
sequence compared to the SH3 domain binding to the proline-rich sequence 
(chapters 2 and 3). Only after saturation of the SH2 domain binding site, would 
binding to the SH3 domain be expected to occur. To test this hypothesis, we have 
performed NMR and ITC experiments on the Src SH32 domains interacting with 
peptides derived from FAK, in which the spacer has been gradually reduced in 
length. In contrast to the hypothesis, even for short spacers simultaneous binding of 
both domains is observed, indicative of a SH3-peptide interaction that must have 
significantly higher affinity than what is observed for the SH3 domain with 
proline-rich peptides. We propose a model for the interaction in which electrostatic 
interactions of the peptide with the SH2 domain increase the effective affinity of 




Cloning, protein expression and purification 
A DNA fragment encoding the mouse Src SH3 and SH2 domains (SH32), residues 
85-250, was amplified by PCR from the full-length Src plasmid pUSE Src wt 
(kindly provided by Prof. B. van de Water). The PCR product was inserted into the 
expression vector pET28a using the NcoI and XhoI restriction sites and the 
resulting construct was verified by DNA sequencing. For production of His-tagged 
SH32 Escherichia coli BL21 (DE3) cells, transformed with SH32-pET28, were 
incubated overnight at 37°C and 250 rpm in LB medium supplemented with 50 
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mg/L kanamycin. The preculture was diluted at a volume ratio of 1:100 into fresh 
LB medium with 50 mg/L kanamycin for production of unlabelled protein or into 
M9 minimal medium with 50mg/L kanamycin using 
15
NH4Cl as the only source of 
nitrogen for production of 
15
N-labelled protein. Cultures were incubated at 37°C 
and 250 rpm, and protein production was induced with 0.5 mM IPTG when an 
OD600 of 0.6 was reached. Cells were harvested via centrifugation after 3-5 h, 
resuspended in 20 mM Tris-HCl pH 8, 0.5 M NaCl and 10 mM imidazole and 
stored at -80°C until protein purification. Following the addition of 1 mM PMSF 
and 50 µg/mL DNAse, the thawed cells were lysed using a French pressure cell 
and the lysate was cleared by centrifugation at 40000 rpm for 30 minutes. The 
supernatant was loaded onto an immobilized metal affinity column (HisTrap HP, 
GE Healthcare) equilibrated with 20 mM Tris-HCl pH 8, 0.5 M NaCl and 10 mM 
imidazole. The column was washed with the same buffer containing 60 mM 
imidazole before elution with the same buffer containing 300 mM imidazole. The 
eluted protein was diluted at a volume ratio of 1:5 with 20 mM Tris-HCl pH 7.6, in 
order to lower the NaCl concentration to 0.1 M. Protein was loaded onto an ion-
exchange column (HiTrap Q, GE Healthcare) equilibrated with 20 mM Tris-HCl 
pH 7.6, 0.1 M NaCl, and eluted using a gradient of 0.1 – 0.8 M NaCl. Fractions 
were checked by SDS-PAGE, and pure fractions were pooled and concentrated. 
The purity of the protein was estimated to be above 95%. The buffer was 
exchanged to NMR buffer for the 
15
N-labelled protein (20 mM KPi pH 6.5, 100 
mM NaCl and 1 mM DTT) and to ITC buffer for the unlabelled protein (20 mM 
HEPES pH 6.8, 100 mM NaCl and 1 mM TCEP). The protein concentration was 







Peptides were synthesized as described in chapter 2 and were kindly provided by 
Dr. Jan Wouter Drijfhout. Peptide stock solutions were prepared by weighing out 
A dynamic intermediate state in peptide-binding to the combined Src SH3 and SH2 domains 
81 
peptide and dissolving in NMR or ITC buffer and adjusting the pH by the addition 
of small aliquots of NaOH or HCl. 
Nuclear magnetic resonance spectroscopy 
All NMR experiments were performed at 303 K on a Bruker DMX600 
spectrometer equipped with a TCI-Z-GRAD cryoprobe (Bruker, Karlsruhe, 
Germany). The data were processed with Azara (http://www.bio.cam.ac.uk/azara/) 
and analyzed using Ansig For Windows [142]. 
Backbone amide resonance assignments were performed analogous to what has 
been described for the Src SH3 domain (chapter 2). Peptide titrations were 
performed through the addition of microliter aliquots of peptide stock solution with 





were recorded at the start of the titration and at every step. Chemical shift 
perturbations were analyzed as has been described in chapter 3. 
Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) experiments were carried out at 303 K on a 
Microcal (Northampton, MA) VP-ITC microcalorimeter. Experiments were 
performed and data were analyzed as described in chapter 3. 
Molecular graphics were generated using PyMol [150]. 
 
Results and discussion 
NMR titrations were performed with peptides derived from the SH3- and SH2-
domain binding sites in FAK, with gradually shorter spacers between the binding 
sites (Table 1). Previous ITC and NMR binding experiments have shown that a 
peptide derived from the SH2 binding site in FAK, p2, binds to the SH2 domain 
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with an equilibrium dissociation constant (Kd) of 73 nM, and that the interaction is 
in the slow exchange regime on the NMR time scale (chapter 3). In contrast to this 
high-affinity interaction, a peptide derived from the SH3 binding site in FAK, p3, 
was found to bind to the SH3 domain with a Kd of 56 µM in the fast-to-
intermediate exchange regime (chapter 2). 
Table 1. Peptides derived from FAK (SH3- and SH2-binding sequences underlined) with the length 
of the spacer between the SH3 binding site (RALPSIP) and the SH2 binding site (pYAEI) decreasing. 
The peptides containing either the SH3 domain or SH2 domain binding site are also shown. pY 
denotes a phosphotyrosine residue. All peptides were acetylated and amidated on the N-, and C-
termini, respectively.  
Peptide Sequence Number of residues 
removed compared 
to FAK sequence 
p32 RALPSIPKLANSEKQGMRTHAVSVSETDDpYAEIIDEED 0 
p-3 RALPSIPKLANSEKQGMAVSVSETDDpYAEIIDEED 3 
p-7 RALPSIPKLANSEKQSVSETDDpYAEIIDEED 7 
p-11 RALPSIPKLANSESETDDpYAEIIDEED 11 
p-15 RALPSIPKLANTDDpYAEIIDEED 15 
p-16 RALPSIPKLANDDpYAEIIDEED 16 
p-17 RALPSIPKLADDpYAEIIDEED 17 
p-19 RALPSIPKDDpYAEIIDEED 19 
p2 ETDDpYAEIIDEED - 
p3 RALPSIPKL - 
 
Titrations of Src SH32 with peptide p32, which contains both the SH3- and SH2-
binding motifs separated by the full-length sequence as it is present in FAK, leads 
to chemical shift perturbations in the SH3 and SH2 domains that are similar to 
those caused by peptides p3 and p2 (Fig. 4.1), indicating that the peptide-protein 
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interaction is confined to the SH3 and SH2 peptide binding faces on the protein. 
The chemical exchange behaviour for SH3 amides in the titration with p32 differs 
from that observed in the titration with p3. When p32 binds to Src SH32 both the 
resonances in the SH2 and SH3 domain show slow-exchange behaviour, whereas 
for p3 fast-to-intermediate chemical exchange is seen for all SH3 resonances 
affected by binding. This observation is illustrated in Fig. 4.2 for residues T17. 
Residue G155 is part of the SH2 binding site. 
Peptides containing the SH2-binding region in FAK bind too tightly to the Src SH2 
domain for the binding affinity to be determined with NMR (see chapter 3) and, 
thus, ITC was used instead. Due to solubility problems for the longest peptides p32 
and p-3, no high-quality ITC data could be obtained for these peptides. For peptide 
p-7, which is still long enough to span the distance between the SH3 domain and 
SH2 domain peptide-binding faces, ITC data were fitted to a one-site binding 
model, yielding a Kd of 28 nM (Fig. 4.3). This agrees well with values determined 
with surface plasmon resonance and ITC by Thomas et al. [139] and Arold et al. 
[215], for the binding of the Src and Fyn SH32 domains to a FAK peptide 
containing both the SH3 and SH2 binding sites. Comparison with results from ITC 
experiments involving binding of p3 or p2 to SH32 shows that the free energy 
change upon binding the peptide containing both an SH3- and SH2-binding site is 
less than the sum of the free energy changes upon binding p2 and p3 (Table 2), 
indicating that the binding is anti-cooperative. This is in agreement with what has 
been shown for the SH32 domains of Fyn, for which it was proposed that 
restriction of the conformational freedom of the FAK peptide, together with 
possible binding-induced partial structure in the peptide, causes a small entropic 
penalty [216]. In the absence of favourable contributions from additional contacts 




Figure 4.1. Average chemical shift perturbations (Δδavg, Eq. 1, chapter 1) in Src SH32 caused by 
peptide titrations. A) Shifts caused by peptide p3 at a peptide-to-protein molar ratio of 10:1 B) shifts 
caused by peptide p2 at a ratio of 5:1 C) Shifts caused by peptide p32, ratio 1.5:1 D) Shifts caused by 
peptide p-19 at a peptide-to-protein ratio of 10:1. Chemical shift perturbations are coloured according 
to size and mapped onto the surface of SH32 taken from a structure of nearly full-length Src in the 
inactive state, PDB entry 1FMK [217]. Red: Δδavg≥0.3 ppm; orange: 0.3>Δδavg≥0.1 ppm; yellow: 
0.1>Δδavg≥0.04 ppm; blue: Δδavg<0.04 ppm. Non-assigned residues are shown in grey. 
 
 
Figure 4.2. Detail from HSQC spectra of Src SH32 in titrations with peptides A) p3, B) p2 and C) 
p32. Spectra from a few titration points are shown overlaid, with starting points (free protein) in black 
and titration end points shown in purple. 
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Table 2. Thermodynamic parameters for peptides binding to Src SH32. Uncertainties in K, H and 
G are the standard deviations of three experiments, the uncertainty in TS was calculated using 





















-14.0 ±0.7 -8.5±0.7 -5.6±0.1 One-site 




-9.4±0.3 0.1±0.4 -9.4±0.1 One-site 




-20.5±0.3 -10.1±0.3 -10.5±0.1 One-site 
p-19 2.4±0.1 x 
10
6 
-12.1±0.1 -3.2±0.1 -8.8±0.1 One-site 
 
ITC data for peptide p-19 interacting with SH32 was fitted to a one-site binding 




 (Table 2 and Fig. 4.3D). The 
determined equilibrium association constant is comparable to the affinity of the 
SH32 domains for peptide p2, containing only the SH2-binding site. In addition to 
the one-site binding model a two-site binding model was tried, but this did not 




Figure 4.3. Representative isothermal titration calorimetry curves for the binding of Src SH32 to 
peptides A) p3, B) p2, C) p-7 and D) p-19. Top panel: raw data after baseline correction. Bottom 
panel: integrated data corrected for the heat of dilution of the peptide. The solid line in the bottom 
panel represents the best fit to a one-site binding model. 
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Examination of the exchange characteristics of SH2 and SH3 resonances in NMR 
titrations with gradually shorter peptides into an SH32 sample shows that for all 
peptides containing the phosphotyrosine the SH2 domain resonances remain in 
slow exchange. For the longer peptides the SH3 resonances also show slow 
exchange between free and bound forms, but for peptides with more than 15 amino 
acid residues removed from the linker the exchange becomes faster. For peptide p-
16 slow-to-intermediate exchange was observed, for peptide p-17 the SH3 
resonances are in intermediate-to-fast exchange, and for the shortest peptide, p-19, 
fast exchange behaviour is observed for the SH3 resonances (Fig. 4.4). 
For the shorter peptides, such as p-19, the distance between the SH3- and SH2-
binding sites is too small for the peptide to bind to both domains simultaneously, 
causing the domains to compete for peptide binding. Positioning the SH3 domain 
and SH2 domain binding faces close enough together for simultaneous binding 
would require substantial domain rearrangements, which would be reflected by 
chemical shift perturbations of the linker residues. The chemical shift perturbations 
for these residues are all small, however, indicating that the relative orientation of 
the domains remains unchanged. In light of the large difference in binding affinity 
between the two domains (about 3 orders of magnitude), it would be expected that 
virtually all available peptide would bind the SH2 domain until the SH2 domain is 
saturated, and only then would the excess peptide bind to the SH3 domain. This 
would yield a sigmoidal binding curve for the SH3 domain. The chemical shift 
perturbations for a few SH3 resonances in the titration with p-19 are plotted against 




Figure 4.4. Detail from HSQC spectra of Src SH32 in titrations with peptides in which the distance 
separating the SH2- and SH3-binding sites has been gradually decreased from A) to H). For 
comparison the titration with peptide p3, containing only the SH3-binding site, is shown in I). Spectra 
from a few titration points are shown overlaid, with starting points (free protein) in black and titration 
end points shown in purple. 
In contrast to what was expected, the SH3 binding curve for peptide p-19 does not 
display a sigmoidal binding curve, but chemical shift perturbations are observed for 
SH3 resonances already at low concentrations. This means that a significant 
fraction of the peptide binds to the SH3 domain, to an extent that would indicate a 
considerably larger binding affinity than what has been determined for the proline-
rich sequence binding to the SH3 domain. In Fig. 4.5 a fit of the chemical shift 
perturbations to a 1:1 binding model is shown. It was assumed that the SH2 domain 
competes for the peptide with the SH3 domain, effectively decreasing the 
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concentration of the peptide available for binding the SH3 domain, at least at 
peptide-to-protein ratios smaller than 1. On the basis of this model, a correction 
factor for the peptide concentration was introduced as an additional parameter (for 
details see chapter 3). The best fit yields a correction factor of 3.6, with a binding 




 for the peptide interacting with the SH3 domain 
within SH32. This could suggest that about 30% of the peptide binds to the SH3 
domain and 70% to the SH2 domain, which would imply a remarkably high 
affinity of the p-19 peptide for the SH3 domain, only about 2.5-fold less than for 
the SH2 domain. 
 
Figure 4.5. Chemical shift perturbations for a few SH3 domain amides within the SH32 tandem upon 
titration with peptide p-19. The solid line represents a fit to a 1:1 binding model, yielding a correction 
factor for the peptide concentration of 3.6, Ka = 1.0 ± 0.4 x 10
5 M-1. For comparison the best fit 
without a correction factor is shown (dotted line), Ka = 1.3 x 10
3 M-1. 
The data suggest that the apparent affinity of the SH3 domain for its binding motif 
within the short peptide containing both an SH2- and SH3-binding site, p-19, is 
higher than the affinity of the SH3 domain for peptide p3, which contains only the 
SH3 binding site. Thus, the presence of the SH2 binding site in the peptide affects 
the binding of the SH3 motif to the SH3 domain within the context of the SH32 
protein. The increased affinity of peptide p-19 for the SH3 domain cannot be 
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explained by interactions of the SH3 domain with the SH2 binding site in the 
peptide because the NMR experiments showed that peptide p2, containing the SH2 
binding motif only, does not interact with the SH3 part of SH32. This conclusion is 
further supported by the fact that chemical shift perturbations in the SH3 domain 
caused by the interaction with peptide p-19 are very similar to those caused by 
binding of peptide p3, which does not contain the SH2-binding motif (Fig. 4.1). 
Binding of SH32 to short peptides with bindings sites for both domains can be 
described by a thermodynamic cycle for the free protein and peptide, two 1:1 
complexes and the 2:1 peptide-to-protein complex (Fig. 4.6A). Based on the 
experimental observations it can be concluded that the ratio of K1 and K3 is merely 
2.5. The values of K2 and K4 remain as yet undetermined.  
The data indicate a much tighter affinity for the SH3 domain for the peptide with 
the SH2 binding site than for p3. It is proposed that long-range electrostatic 
interactions between the negative charges surrounding the SH2 core binding motif 
and charges in the SH2 domain help recruit the peptide to the SH32. Such 
interactions have previously been shown to be important for SH2 domain-peptide 
interactions, increasing the affinity of the SH2 domain for the peptide more than 
30-fold and, at the same time, resulting in a dynamic mode of interaction in spite of 
the high affinity (see chapter 3). Recruitment of the peptide to the SH32 domains 
via long-range charge-charge interactions leads to a dynamic encounter state, from 
which the peptide may associate with either the SH2 or the SH3 domain (Fig. 
4.6B). Thus, SH3 binding profits from the formation of a relatively stable 
encounter complex, as has been observed for other complexes [100;218], 
increasing the affinity of the interaction. In this way the SH3 domain is able to 
compete effectively with the SH2 domain for peptide binding. The association 
constants for a second peptide will differ from the first one, because the positive 
charges on the SH2 domain will be shielded by negative charges on the peptide. 
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SH2 domains interact with their phosphotyrosine target sequences with a 
considerably higher binding affinity than SH3 domains interact with proline-rich 
sequences. For isolated domains the binding affinity of peptides for the SH3 
domain-interaction can be around a thousand-fold lower than for the SH2 domain 
(see chapters 2 and 3). In light of this large difference in binding affinity one might 
raise the question how much the SH3 domains contributes to the interaction of Src 
with target proteins. The results presented here show that via a dynamic encounter 
state, the SH3 domain affinity can be higher in the context of a multidomain 
protein than what is observed for individual domains. 
 
Figure 4.6. A) Model of interaction of Src SH32 with a peptide containing both SH2- and SH3-
binding sites in which the distance between the sites is too large for a single peptide to bind 
simultaneously to both domains. In this model, a peptide first binds the SH32 tandem either via the 
SH3or the SH2 domain, followed by a second peptide binding the other domain. An asterisk 
symbolizes the domain bound to peptide, and K1 to K4 denote the equilibrium association constants. 
B) Electrostatic interactions between positively charged residues in the SH2 domain and negatively 
charged residues at the SH2-binding site in the peptide help recruit the peptide into an encounter 
complex with the SH32 domains. From the encounter complex the peptide can either bind to the SH2 
or the SH3 domain, increasing K3 compared to peptide binding to an isolated SH3 domain. 
Conclusions 
Including both the SH3- and SH2- binding motifs in peptides derived from FAK 
increases the affinity for binding to Src SH32, compared to the individual domains 
interacting with their respective binding sites. If the distance between the SH3- and 
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SH2-binding motifs is decreased to a point that the length separating them is no 
longer sufficient for the peptide to interact simultaneously with the SH3 and SH2 
domains, the SH3 domain is still able to compete with the SH2 domain for peptide 
binding, in spite of the large difference in binding affinity for the isolated domains. 
We propose a model in which long-range electrostatic interactions between the 
negative residues surrounding the SH2-binding site and positive charges in the SH2 
domain help recruit the peptide into a dynamic encounter complex, from which the 
peptide can bind either the SH3 or SH2 domain, increasing the affinity of the SH3 
domain-peptide interaction. The distance between SH2- and SH3-binding motifs in 
Src target proteins differ, and, thus, such a dynamic intermediate may be a more 






Expression, purification and in vitro 






In this chapter a protocol for the expression of the FAK catalytic domain using a 
baculovirus expression vector system is presented, together with a protocol for 
purification and in vitro phosphorylation of the kinase domain. 
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Introduction 
For protein interaction studies or structural biology of proteins, relatively large 
amounts of pure protein are required. Eukaryotic kinases are notoriously difficult to 
express in Escherichia coli, often showing low expression levels or ending up as 
insoluble aggregates. In some cases, especially for small proteins, protocols for 
solubilization and folding can be successfully designed. For kinase domains, 
however, which in addition to being relatively large also possess catalytic activity, 
the recovery of properly folded and active protein from inclusion bodies is rarely 
successful. Recent strategies for improving expression of kinases in E .coli include 
coexpression of chaperones [219] to help with correct folding. In cases where the 
active kinase is toxic to cells or where the phosphorylated protein is metastable, 
coexpression of phosphatases can improve yield and solubility [220;221]. In many 
cases however, it is necessary to look for a more suitable expression system. For 
structural biology purposes, most tyrosine kinases have been expressed in 
baculovirus-infected insect cells [222]. 
The baculovirus expression vector system (BEVS) is widely used in academia and 
industry for the production of biologically active and functional recombinant 
proteins. Protein obtained from baculovirus-infected insect cells often shows 
proper post-translational modifications, such as disulfide-bond formation, 
glycosylation and acetylation. In general, proteins containing phosphorylation sites 
will be partially phosphorylated when produced in insect cells. 
To date there are no reports of successful large-scale expression of the FAK 
catalytic domain in bacteria, but both full-length FAK as well as the kinase domain 
isolated or in combination with the FERM domain have been expressed in insect 
cells [223-225]. 
Here, a protocol for expression, purification and in vitro phosphorylation of the 





A DNA fragment corresponding to amino acid residues 390-681 of mouse FAK, 
followed by 6 C-terminal histidine residues, was generated by PCR using a pET28 
vector containing this segment of FAK DNA as a template. The corresponding 
region of FAK includes the catalytic domain and an N-terminal peptide stretch 
containing part of the linker connecting the FERM and kinase domains. The PCR 
product was restricted with EcoRI and PstI and ligated into the vector pFastBac 
Dual, and the integrity of the resulting plasmid, pFastBac Dual-FAK2, was verified 
by sequencing. Competent E. coli DH10Bac cells (Invitrogen) were transformed 
with pFastBac Dual-FAK2 and plated on LB-agar containing 50 µg/mL 
kanamycin, 7 µg/mL gentamicin, 10 µg/mL tetracycline, 100 µg/mL X-gal and 40 
µg/mL IPTG. Colonies of clones in which successful transposition of FAK DNA 
into the bacmid had occurred were selected by blue/white screening and the 
presence of the insert was verified by PCR. The recombinant bacmid was isolated 
as described in [226] and the DNA concentration was determined via the 
absorbance at 260 nm. 
Insect cell culture and generation of viral stock 
Spodoptera frugiperda (Sf9) cells were kept as adherent cultures at 27°C in TNM-
FH medium containing 10% FBS (BD biosciences) supplemented with 50 U/mL 
penicillin and 50 µg/mL streptomycin. Cells were subcultured twice weekly by 1:5 
dilution in fresh medium. For recombinant baculovirus generation 2.3x10
6
 cells 
were seeded in 4 mL TNM-FH medium in a T25 flask. Cells were left to adhere for 
30-60 minutes at 27°C. For the transfection mixture 5.2 µg bacmid DNA and 15.6 
µL of the liposomal transfection reagent DOTAP were each separately diluted into 
300 µL TNM-FH medium without antibiotics, added together in a polystyrene tube 
and left at room temperature for 45 minutes, allowing nucleic acid/liposomal 
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complex formation to take place. The attached Sf9 cells were washed once with 2 
mL TNM-FH medium without antibiotics, 2.1 mL of the same medium were added 
to the bacmid/DOTAP mixture and the resulting 2.7 mL were added to the cells. 
Cells were incubated at 27°C and after 5 h the bacmid/dotap mixture was removed 
and replaced by 4 mL of normal TNM-FH medium containing antibiotics. Virus 
was harvested after 5 days, the medium containing the virus was centrifuged at 500 
g for 5 minutes, the supernatant was filtered through a 0.4 µm sterile filter and 2% 
NBS was added to the viral stock before storage at 4°C. For long-term storage an 
aliquot was kept at -80°C. To increase the titer of the virus the viral stock was 
amplified by 2-3 further rounds of infection at an estimated MOI of 0.01-0.1, 
harvesting at 2-4 dpi. 
Large scale protein expression 
Sf9 cells for protein expression were cultured at 27°C in Insect Xpress medium 
(BioWhittaker) supplemented with 50 U/mL penicillin and 50 µg/mL 
streptomycin. For culture scale-up, adherent cultures in T25 flasks were used to 
seed larger adherent cultures in T75 flasks. Subsequently, 2-3 full T75 flasks were 
used to start a 100 mL suspension culture in a 250 mL spinner flask, stirring at 55 
rpm. To keep cells in the logarithmic growth phase the cell density in suspension 




 cells/mL. For further scale-up of 
cultures, 2 spinner flasks were used to seed a 500-800 mL culture in a 2 l 
Erlenmeyer flask. The shaker flask culture was incubated at 27°C and 90 rpm. 
After sufficient increase in cell density, medium was added to a final volume of 
800 mL. At a cell density of 2x10
6
 cells/mL recombinant baculovirus was added to 
the culture at an estimated MOI of 1-10, together with 5 µM leupeptin (Tocris 
Bioscience) to reduce in-cellprotease activity. Cells were harvested at 5 dpi by 
centrifugation at 1000 rpm and 4°C for 30 minutes. Cell pellets were gently 
resuspended by swirling in 20 mM Tris pH8, 500 mM NaCl and 30 mM imidazole 
kept on ice, and the resuspended cells were stored at -80°C. 
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Expression and purification of YopH phosphatase 
Competent E. coli BL21 cells were transformed with the plasmid pCDFDuet 
containing the YopH tyrosine phosphatase from Yersinia [220;227]. The plasmid 
was generously provided by Dr. Markus Seeliger and Prof. John Kuriyan. Cultures 
were incubated overnight in LB medium supplemented with 50 µg/mL 
streptomycin at 37°C while shaking at 250 rpm. The preculture was diluted 1:100 
into fresh medium, grown to an OD600 of 0.6 and protein expression was induced 
by the addition of 1 mM IPTG. After 3 h cells were harvested by centrifugation and 
cell pellets were resuspended in 20 mM HEPES pH 6.8, 50 mM NaCl, 1 mM 
PMSF and 50 µg/mL DNAse. Cells were lysed by three passages through a French 
pressure cell and the lysate was cleared by ultracentrifugation (40 000 rpm for 30 
minutes at 4°C). The supernatant was loaded onto an ion-exchange column (HiTrap 
SP, GE Healthcare) equilibrated with 20 mM HEPES pH 6.8, 50 mM NaCl, and 
protein was eluted with a 50 – 500 mM NaCl gradient. Pure fractions (determined 
by SDS-PAGE) were pooled and the concentration was determined using a 




 [140]. Following 
the addition of 50% glycerol, the protein was stored at -20°C. 
Kinase purification and in vitro phosphorylation 
Unless stated otherwise, all purification steps were performed on ice or at 4°C. Cell 
suspensions were thawed and 1 mM PMSF, 20 µg/mL leupeptin and 50 µg/mL 
DNAse was added. Cells were lysed by the addition of 0.5% Triton X-100 and the 
lysate was cleared by ultracentrifugation at 40,000 rpm for 30 minutes. The 
supernatant was loaded onto an immobilized metal affinity chromatography 
column (1 mL HisTrap HP, GE Healthcare) using a peristaltic pump. After 
washing with 20 mM Tris pH8, 500 mM NaCl and 30 mM imidazole, the column 
was attached to a liquid chromatography system and protein was eluted with the 
same buffer containing 300 mM imidazole. Protein was dialysed against 50 mM 
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HEPES pH 7, 100 mM NaCl and 1 mM TCEP. Following dialysis, EDTA to a 
concentration of 1 mM was added and the protein was treated with YopH 
phosphatase at a molar ratio of 1:20 for 4 h at RT. Elution buffer containing 300 
mM imidazole was added to the phosphatase-treated protein at a volume ratio of 
1:15 for a final concentration of 20 mM imidazole, together with 2 mM MgCl2. To 
remove the phosphatase, protein was again loaded onto an immobilized-metal 
affinity chromatography column using a peristaltic pump, the column was washed 
and the protein eluted the same way as before. Protein was dialysed against 20 mM 
Tris pH 7.4, 150 mM NaCl, 4 mM MgCl2 and 1 mM TCEP for 3h. After dialysis 2 
mM ATP and 1 mM activated Na3VO4 [228] was added to the kinase domain, 
which was incubated at RT for 30-45 minutes to allow autophosphorylation of 
Y397 to take place. The kinase domain was placed at 4°C overnight. In order to 
separate phosphorylated from unphosphorylated protein, the protein was diluted 
2:3 with 20 mM Tris pH 7.6 containing 1 mM Na3VO4, bringing the NaCl 
concentration down to 100 mM, and the protein was loaded onto a 1 mL anion 
exchange column (1 mL HiTrap Q, GE Healthcare) equilibrated with 20 mM Tris 
pH 7.6, 100 mM NaCl and 1 mM Na3VO4, using a peristaltic pump. Following 
attachment to a liquid chromatography system the kinase domain was eluted using 
a gradient of 100-600 mM NaCl. 
Kinase domain phosphorylated at Y397 was dialysed against 20 mM HEPES pH 7, 
150 mM NaCl, 4 mM MgCl2, 1 mM TCEP and 0.1 mM Na3VO4. Protein was 
concentrated using Spectra/Gel Absorbent (Spectrum laboratories), the protein 





 [140] and the protein was stored at -80°C. The final yield of 
purified protein was around 2 mg per litre culture. For unphosphorylated kinase 
domain, protein was purified under the same conditions as described above, 





Proteins were transferred from SDS-polyacrylamide gels to PVDF membranes and 
membranes were blocked with 3% BSA in TBS for 1 h at RT. Blots were incubated 
at RT with primary antibody (1:1000 anti-FAK pY397 from Biosource or 1:2000 
anti-His4 from Qiagen) for 1 h, followed by incubation with horseradish 
peroxidase-conjugated secondary antibody for 1h. Protein signals were detected by 
ECL (GE Healthcare). 
 
Results 
The purification of the kinase domain and the phosphorylation state of Y397 were 
monitored by SDS-PAGE and Western blotting of samples taken at different stages 
of the purification (Fig. 5.1). The western blot against the phosphorylated form of 
Y397 shows that the kinase domain can become phosphorylated when expressed in 
Sf9 cells. Treating the protein with YopH phosphatase leads to the complete 
disappearance of the signal, while incubation with ATP lets the signal reappear. In 
lane 1-3 in Fig. 5.1, a band is visible below the kinase domain in the SDS-
polyacrylamide gel. This band is also visible when western blotting against the 
His-tag at the C-terminus of the protein, but not visible in the blot against pY397. 
Most likely this band is the product of proteolytic removal of the N-terminal Y397 
linker during protein expression and/or purification. This is further supported by 
the fact that this band is removed by anion-exchange chromatography, since the 
region around Y397 provides the dominant contribution to the net negative charge 
of the protein at the pH used and thus removing this region reduces the affinity of 
the protein for the anion-exchange column. 
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Figure 5.1. Purification and phosphorylation of FAK kinase domain. Top panel: SDS-PAGE, middle 
panel: western blot against His4, lower panel: western blot against pY397. Lanes: M: marker, 1: 
sample after first affinity column, 2: sample after YopH phosphatase treatment, 3: sample after 




The western blots show that, as expected, the protein is at least partly 
phosphorylated when expressed in insect cells. Under the conditions used, 
phosphatase treatment is very efficient and no phosphorylation of Y397 can be 
detected after incubation with YopH. The re-appearance of the pY397 signal shows 
that the purified kinase domain is active and that the chosen conditions are 
conducive to autophosphorylation of Y397. This phosphorylation state can be 
preserved through-out the purification. These results show in a qualitative way that 
in vitro phosphorylation can be achieved using this protocol. For a more 
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The catalytic domain of FAK including the linker containing the SH2 domain 
binding site Y397 can be expressed in insect cells infected with recombinant 
baculovirus, purified in an active form, and the phosphorylation state of the protein 






The interaction of Src SH2 with the focal 






The interaction of the Src SH2 domain with the catalytic domain of FAK, including 
the Y397 SH2 domain binding site, has been studied using NMR spectroscopy. 
Analysis of the chemical shift perturbations indicate that the Y397 site is not 
available for SH2 domain binding. The observed effects are spread over a 
relatively large area of the SH2 domain and the chemical shift perturbations are 
small, which is typical for dynamic complexes governed mainly by electrostatic 
interactions. Competitive binding experiments suggest that although the regular 
high-affinity SH2 domain binding site in FAK is not involved in the interaction, the 
binding affinity is still surprisingly high. 
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Introduction 
The interaction of FAK and Src plays a crucial role in a number of signalling 
pathways, regulating processes such as cell proliferation, survival and migration. 
The involvement of FAK and Src in many human diseases makes them important 
drug targets and has made Src and FAK the subject of many structural biology 
studies. For Src, crystal structures of isolated domains as well as of the full-length 
protein have been determined, elucidating the mechanism of Src activation [229-
233]. Crystal structures also exist of the isolated catalytic domain, FERM domain 
and FAT domain of FAK [234-237]. More recently, structures of a fragment of 
FAK comprising both the FERM and kinase domains have been published, 
suggesting a mechanism of FAK autoinhibition reminiscent of the one for Src 
[238]. In addition to the crystal structures, NMR structures of the Src SH2 and SH3 
domains exist, e.g. [39;239;240], as well as NMR structures of the FAT domain of 
FAK [241;242]. Examples of FAK and Src structures in the RCSB protein data 
bank can be found in Table 1. 
To date, no NMR studies involving the catalytic domain of FAK have been 
reported. In spite of the large body of structural biology research on FAK and Src, 
in vitro studies of the FAK-Src interaction are limited to the study of peptides 
derived from FAK binding to the SH3 and SH2 domains of Src [139], chapters 2-4 
this thesis. In these studies the SH2 and SH3 domains of Src bind to the peptide 
motifs present in the linker between the FERM and catalytic domains of FAK. 
In the regulation of Src and FAK activity intramolecular contacts between domains 
keep the proteins in an inactive state. In order to investigate whether any 
intermolecular contacts exist between Src and FAK outside the peptide binding 
motifs we have studied the interaction of the Src SH2 domain with the catalytic 
domain of FAK including the part of the FERM domain – kinase linker that 
contains the Y397 SH2 binding site (Fig. 6.1). Using NMR spectroscopy we find 
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that although the Y397 site seems unavailable for SH2 binding in the present FAK 
construct, the SH2 domain still binds the kinase domain, in a way typically seen for 
dynamic complexes governed mainly by electrostatics. 
Table 1. Examples of published structures of Src and FAK. 
Fragment Exp. method PDB  Reference 
Src kinase domain X-ray diffraction 1YOJ, 1YOL, 1YOM [243] 
Src SH3, SH2 and kinase 
domains 
X-ray diffraction 1Y57 [244] 
Src SH2 domain X-ray diffraction 1SPR, 1SPS [245] 
Src SH2, SH3, kinase 
domains and c-terminal tail 
X-ray diffraction 1FMK [246] 
Src SH2, SH3, kinase 
domains and c-terminal tail 
X-ray diffraction 2SRC [247] 
FAK FAT domain X-ray diffraction 1K04, 1K05 [248] 
FAK FAT domain X-ray diffraction 1K40 [249] 
FAK FERM domain X-ray diffraction 2AEH, 2AL6 [250] 
FAK kinase domain X-ray diffraction 1MP8 [251] 
FAK FERM and kinase 
domains 
X-ray diffraction 2J0J, 2J0L [252] 
Src SH3 domain NMR 1SRL [253] 
Src SH3 domain NMR 1RLQ, 1PRM [39] 
Src SH2 domain NMR 1HCS [254] 
FAK FAT domain NMR 1KTM [255] 
FAK FAT domain NMR 1PV3 [256] 
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Figure 6.1. FAK domain organization. The underlined region corresponds to the fragment of FAK 
studied in this chapter (the catalytic domain and the linker region containing the SH2-binding site). 
 
Experimental procedures 
Protein expression and purification 
FAK kinase domain was produced and purified as described in chapter 6, and non-
deuterated SH2 domain was produced as described in chapter 3. For production of 
deuterated SH2 Escherichia coli BL21 cells were transformed with SH2-pET28 
and incubated overnight in LB medium supplemented with 50 mg/L kanamycin at 
37°C while shaking at 250 rpm. The preculture was diluted 1:100 into D2O-M9 
minimal medium with 50 mg/L kanamycin (M9 salts prepared in 100% D2O, trace 
elements and other supplements prepared in H2O, non-deuterated carbon source) 
using 
15
NH4Cl as the sole nitrogen source. Cultures were incubated at 37°C and 
250 rpm until an OD600 of 0.6, the temperature was reduced to 25 °C and protein 
expression was induced with 0.5 mM IPTG. After 13 h cells were harvested via 
centrifugation. The SH2 domain was purified as described in chapter 3. 
NMR sample preparation and experiments 
NMR experiments were recorded at 293 K on a Bruker DMX600 spectrometer 
equipped with a TCI-Z-GRAD cryoprobe (Bruker, Karlsruhe, Germany). The data 
were processed with Azara (http://www.bio.cam.ac.uk/azara/) and analyzed using 
Ansig For Windows [142]. 
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To assess the degree of deuteration of the SH2 domain a 1D NMR spectrum was 
recorded, from this it was estimated that 70 % of the protein was deuterated (Fig. 




N-SH2 in 20 mM HEPES pH 7, 150 
mM NaCl, 4 mM MgCl2, 1 mM TCEP (with 0.1 mM Na3VO4 for experiments with 
phosphorylated kinase domain). To the SH2 domain samples phosphorylated or 




H] TROSY spectra 
were recorded. 
For peptide titrations, a stock solution of 5 mM peptide (for synthesis see chapter 
3) was prepared by dissolving peptide in 20 mM HEPES pH 7, 150 mM NaCl, 4 
mM MgCl2 and 1 mM TCEP, and adjusting the pH to 7 with small aliquots of 0.1–
0.5 M solutions of NaOH. Titrations were performed by the addition of microliter 








N SH2 together with 50 µM unlabelled FAK kinase domain in 20 mM HEPES 




H] TROSY spectra were 
recorded at the start of the titration and after each addition of peptide. 
 
Figure 6.2. 1H NMR spectrum of SH2 domain purified from E.coli cultured in deuterated minimal 
medium (see Exp. Procedures). 
Chemical shift perturbation analysis 
The average chemical shift perturbations, Δδavg, were calculated according to Eq. 2: 
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binding are the chemical shift perturbations of the amide 
nitrogen and amide proton, respectively. 
For competitive binding experiments peptides were titrated into samples containing 
either only SH2 domain or SH2 domain and kinase domain at a 1:1 molar ratio. 
Chemical shift perturbations of amide resonances were plotted against the molar 
ratio of peptide-to-protein. A non-linear least-squares global fit to a single-site 










In Eq. 2, R is the molar ratio of peptide-to-protein, Δδbinding is the chemical shift 
perturbation at a given ratio, Δδ∞ is the chemical shift perturbation at 100% bound 
protein, L is the initial concentration of 
15
N-labelled protein, U is the concentration 
of the peptide stock solution and Ka is the association constant of the complex. The 
error in Ka was estimated by determining the range of Ka values that produced 
acceptable fits given the uncertainty in binding. For the peptide titration in the 
presence of the kinase domain, Δδ∞ values were fixed to the corresponding values 





Competitive binding model and chemical shift perturbation simulations 
In order to estimate the dissociation constant of the kinase-SH2 domain complex, 
chemical shift perturbation simulations were performed and compared to data from 
the competitive binding experiments. Assuming a model in which the SH2 domain 
either binds to the peptide or to the kinase domain (Fig. 6.3) the equilibrium 












K    (3b) 
where K1 is the equilibrium association constant for the SH2-peptide complex, 
SH2*P denotes SH2 domain bound to peptide, SH2 is free SH2 domain, P is free 
peptide, K2 is the equilibrium association constant for the SH2-kinase complex, 
SH2*K denotes SH2 domain bound to the kinase and K is free kinase domain. 
 
Figure 6.3. Peptide and kinase domain competing for binding to the SH2 domain. SH2 = SH2 
domain, P = peptide and K = kinase. 
If, at a given point in the titration, we let x be the concentration of SH2 domain 
bound to peptide, y the concentration of SH2 domain bound to kinase, A, B and C 
be the total concentration of SH2 domain, peptide and kinase domain, respectively, 














   (4b) 
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                  (5) 
In Eq. 5, B and C are known from the experimental parameters, and K1 can be 
fixed to the value determined from the titration in the absence of the kinase 
domain. Using the value of x from Eq. 5 as input in Eq. 4a, y was varied until the 
value of K1 calculated from Eq. 4a matched the fixed value used in Eq. 5. This way 
x, the concentration of SH2 domain bound to peptide, could be determined at each 
titration point for a given value of K2, the equilibrium association constant of the 
SH2 domain-kinase domain complex. The chemical shift perturbation, x, for an 




x                    (6) 
where x is the concentration of SH2 domain bound to peptide determined using 
Eqs. 4 and 5, A is the total concentration of SH2 domain in the sample and  is 
the chemical shift perturbation for the residue at 100% bound protein, obtained 
from fitting the data from the titration in the absence of the kinase domain to the 
model described by Eq. 2. By varying K2 the predicted chemical shift perturbations 








N SH2 domain lead to the 
majority of the resonances in the HSQC spectrum being broadened beyond 
detection (Fig. 6.4), indicating that the proteins associate but that the protein 
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complex is too large to be observed using this method (approximately 48 kDa). To 
reduce the linewidth of the amide protons deuterated SH2 was produced and 
TROSY experiments were performed. 
 
Figure 6.4. Overlaid HSQC spectra of free 1H,15N 
SH2 domain (red) and 1H,15N SH2 after addition of 
kinase domain at a ratio of 2:1 kinase to SH2 
(blue). The majority of the SH2 peaks disappear 




Comparison of the spectrum of free SH2 domain with the spectrum of a sample 
containing SH2 domain and phosphorylated FAK kinase domain at a molar ratio of 
1:1 reveals small chemical shift perturbations for a large number of backbone 
amide resonances (Fig. 6.5). Although reminiscent of a calibration problem, the 
chemical shift perturbations were found to be highly reproducible. The shift 
changes caused by the kinase domain differ from those typically caused both by 
nonphosphorylated (Fig. 6.6B) and phosphorylated (Fig. 6.6C) peptides binding to 
the SH2 domain. Chemical shift perturbations caused by the kinase domain are 
smaller and affect a larger fraction of the SH2 resonances. Mapping the chemical 
shift perturbations caused by the kinase domain onto the surface of the SH2 
domain shows that the general pattern of shifts does not match that seen with 
peptide binding and that some SH2 domain residues that are strongly affected by 
peptide binding are not affected by the interaction with the kinase domain (Fig. 
6.7). NMR spectra of the SH2 domain together with unphosphorylated kinase 
domain show a chemical shift perturbation pattern very similar to that caused by  
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Figure 6.5. Overlaid TROSY 
spectra of 2H,15NSrc SH2 in the 
absence of kinase domain (blue) 
and in the presence of 
phosphorylated FAK kinase domain 







Figure 6.6. A) Detail of TROSY spectrum of free SH2 domain (blue) overlaid with spectrum of a 1:1 
mixture of SH2 and FAK kinase domain (red). Spectra recorded at T=293 K and pH=7.0. B) Detail of 
overlaid HSQC spectra from titration of SH2 domain with peptide ETDDYAEIIDEED, T=303K and 
pH=6.5. C) Detail of overlaid HSQC spectra from titration of SH2 domain with peptide 
ETDDpYAEIIDEED, T=303K and pH=6.5. 
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the phosphorylated kinase domain, but with generally larger shift changes (Figs. 
6.8 and 6.9). 
A competitive binding experiment was performed where the unphosphorylated 
peptide ETDDYAEIIDEED (chapter 3) was titrated into either a 1:1 mixture of 
SH2 and phosphorylated kinase or into SH2 alone. Titration of peptide into SH2 
domain causes significant chemical shift perturbations of some SH2 resonances 
(Fig. 6.10A), while addition of equal amounts of peptide to the SH2–kinase 
mixture produced much smaller chemical shift changes (Fig. 6.10B). Some peaks 
that are shifted in the SH2:kinase complex relative to free SH2 are not affected by 
peptide binding to SH2 only. When peptide is added to the SH2:kinase complex 
these resonances start to shift towards the corresponding position in free or peptide 
bound SH2 (Fig. 6.10C). Both these observations indicate that the peptide is 
competing with the kinase domain for binding to the SH2 domain. Fitting of the 
chemical shift perturbations for the titration of SH2 domain with peptide to a 1:1 
binding model yields a dissociation constant of 0.17 ± 0.03 mM (Fig 6.11A). This 
value agrees within the error margins with the previously reported value (chapter 
3), despite differences in buffer, pH and temperature. For the titration of SH2 
domain with the same peptide in the presence of kinase domain it was assumed that 
the chemical shift perturbation for fully bound protein, , for each residue would 
be the same as in the titration without the kinase domain. By fitting the titration 
data using fixed  values obtained from the fit in Fig. 6.11A, an apparent Kd of 
2.2 ± 0.4 mM was determined (Fig 6.11B). Including the kinase domain at a ratio 
of 1:1 with the SH2 domain thus leads to an apparent affinity of the SH2 domain 
for the peptide that is 13-fold lower than the binding affinity without the kinase 
domain present. 
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Figure 6.7. Chemical shift perturbations of SH2 domain residues upon addition of phosphorylated 
FAK kinase domain (top panel) and peptide ETDDpYAEIIDEED (bottom panel), mapped onto the 
surface of the SH2 domain (PDB structure 1HCS [257]). Residues are coloured according to the size 
of the average chemical shift perturbation, Δδavg. Red: Δδavg≥0.3 ppm; orange: 0.3>Δδavg≥0.1 ppm; 
yellow: 0.1>Δδavg≥0.04 ppm; blue: Δδavg<0.04 ppm. Non-assigned residues are shown in grey. 
 
Figure 6.8. Chemical shift perturbations of SH2 domain residues upon addition of unphopshorylated 
FAK kinase domain at a kinase:SH2 ratio of 1:1, mapped onto the surface of the SH2 domain (PDB 
structure 1HCS [258]). Residues are coloured according to the size of the average chemical shift 




Figure 6.9. Detail of overlaid TROSY spectra of the SH2 domain, showing free SH2 (black), SH2 in 
complex with phosphorylated kinase (red) and unphosphorylated kinase (blue). 
 
Figure 6.10. Competitive binding experiments, detail of overlaid TROSY spectra of the SH2 domain. 
A) Titration with peptide ETDDYAEIIDEED in the absence of kinase domain. Molar ratios of 
peptide to SH2 domain are indicated in the figure. B) Titration with peptide ETDDYAEIIDEED, in 
the presence of FAK kinase domain. Molar ratios of peptide to SH2 domain are indicated in the 
figure. C) Black: free SH2 domain. Purple: SH2 domain in presence of peptide, molar ratio 20:1 
peptide to protein. Blue: SH2 domain in the presence of kinase domain, molar ratio 1:1. Red: SH2 
domain in the presence of kinase domain, molar ratio 1:1 and peptide added at a molar ratio of 20:1 
peptide to protein. Resonances that are not affected by peptide binding (black and purple peaks) but 
that are shifted in the presence of kinase domain (blue peaks) start to shift towards the position they 
have in free and peptide-bound SH2 domain upon addition of a large excess of peptide (red peaks). 
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To estimate the affinity of the SH2 domain for the kinase domain, chemical shift 
perturbation simulations were performed using a competitive binding model (see 
Exp. Procedures for details). Chemical shift perturbations for a residue in the SH2 
domain upon peptide titration in the presence of the kinase domain were simulated 
for a range of SH2-kinase domain binding affinities (Fig. 6.12). A comparison with 
the experimental data indicates that the kinase domain binds the SH2 domain with 
a Kd close to 1 µM (RMSD = 0.03 ppm). 
 
Discussion 
The fact that the chemical shift perturbations seen for the interaction of kinase 
domain with SH2 domain differ completely from the shifts seen for SH2 binding to 
peptides derived from FAK, suggests that the interaction of the kinase domain with 
the SH2 domain is independent of the Y397 binding site. The shift changes are 
small and spread out over a larger portion of the SH2 domain. This is typically 
observed for dynamic complexes where electrostatics is the main force driving the 
interaction [259]. The chemical shift perturbations observed for unphosphorylated 
kinase domain binding to the SH2 domain show the same pattern of shifts, only 
slightly larger. This difference in size of the chemical shift perturbations may be 
due to the additional charges on the phosphate group influencing the electrostatics 
of the interaction. It was already demonstrated that electrostatics play an important 





Figure 6.11. 15N chemical shift perturbations of SH2 resonances upon titration with peptide 
ETDDYAEIIDEED. The curves represent the best global fit to a 1:1 binding model. A) peptide added 
to SH2 domain only, Kd = 0.17 ± 0.03 mM B) peptide added to a 1:1 mix of SH2 domain and FAK 
kinase domain. 
Even at a 20:1 molar ratio of peptide to SH2, the chemical shift perturbations of the 
SH2 amides in the kinase - SH2 mixture are significantly smaller than those seen 
for the sample with SH2 domain only. In other words the kinase domain is 
efficiently competing with peptide for binding the SH2 domain, and the SH2 
domain displays a considerably higher affinity for the kinase domain than for the 
unphosphorylated peptide. The Kd of 0.5-1 µM estimated from the chemical shift 
perturbation simulations indicates a surprisingly high binding affinity, which is 
unusual for highly dynamic electrostatic complexes. However, previous studies 
involving the Src SH2 domain binding to peptides have shown that the high-
affinity nature of some SH2 domain interactions does not imply that the interaction 
is static (chapter 3). 
There are several possibilities as to why the Y397 binding site is not available for 
SH2 domain binding. The kinase domain is capable of autophosphorylation of 
Y397 both in cis and trans in vitro and it is thus possible that the linker is bound to 
the active site of the kinase domain of the same molecule or of another kinase 
molecule. 
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Figure 6.12. 15N chemical shift perturbations of SH2 residue Y204 upon titration with peptide 
ETDDYAEIIDEED in the presence of the kinase domain (filled circles), together with chemical shift 
perturbations for the same residue in the presence of the kinase domain simulated for different 
dissociation constants of the kinase-SH2 domain complex. For comparison, chemical shift 
perturbations for Y204 upon titration with the same peptide in the absence of the kinase domain are 
shown as filled squares. 
 
Conclusions 
The Src SH2 domain is capable of binding with a high affinity to the catalytic 
domain of FAK, in a way that does not involve the Y397 region in FAK, and the 
interaction appears to be highly dynamic and mainly governed by electrostatics. 
The kinase domain is able to effectively compete with peptides derived from the 
Y397 binding site for binding to the SH2 domain. The fact that the SH2 domain 
interacts with the kinase domain with a high affinity independently of the Y397 
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binding site, suggests that there is still much to be learnt about the interaction of 





Src-based reporter constructs for fluorescence 





The localization of green fluorescent protein-labelled SH domain constructs in 
fixed and live cells is studied. Constructs containing two SH2 domains in tandem 
and constructs containing an SH3 and an SH2 domain in tandem are both found to 
localize to focal adhesions, although the former shows a clearer localization, 
reflecting the difference in binding affinity of the SH2 domain and the SH3 domain 
for focal adhesion components. Overexpression of the phosphotyrosine-binding 
dual SH2 domain construct is found to lead to increased levels of phosphotyrosine 
in cells. 
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Introduction 
There is growing interest in the use of fluorescence microscopy in cell biology 
research, owing to the development of genetically encoded fluorescent markers 
such as green fluorescent protein (GFP) together with methods such as 
fluorescence resonance energy transfer (FRET), fluorescence recovery after 
photobleaching (FRAP), fluorescence loss in photobleaching (FLIP), fluorescence 
lifetime imaging microscopy (FLIM) and fluorescence correlation spectroscopy 
(FCS) [260-264]. Using these methods it is possible to study macromolecular 
mobility and dynamics as well as interactions between macromolecules in live cells 
[265]. FRET-based biosensors involving a range of serine, threonine and tyrosine 
kinases have been developed [266-272], including a sensor for monitoring the 
activation of Src in response to epidermal growth factor or mechanical stimulation 
[273]. Recently, fluorescence microscopy has been used to study tyrosine 
phosphorylation in focal adhesions and the dynamics of focal adhesion components 
[274-276]. Kirchner and co-workers [276] developed an approach for monitoring 
phosphotyrosine levels in live cells, based on a „phosphotyrosine reporter‟, 
consisting of yellow fluorescent protein (YFP) fused to two Src SH2 domains in 
tandem. This construct was shown to localize to focal adhesions, and its intensity 
was linearly correlated with that of an anti-phosphotyrosine antibody labelling. 
Here, GFP-labelled SH2 domain-SH2 domain (dSH2) and SH3 domain-SH2 
domain (SH32) constructs are designed, and their localization in live and fixed 
LLC-PK1 cells is characterized. We find that both the dSH2 and SH32 constructs 








Using the plasmid pET28-SH32 (Chapter 4) as a template, DNA encoding the SH3 
and SH2 domains of mouse Src (residues 147-250) were amplified by PCR. The 
PCR product was ligated into the vector pEGFP-C1 (Clontech) using the EcoRI 
and BamHI restriction sites, resulting in the construct GFP-SH32. For the construct 
GFP-dSH2, comprising GFP followed by two Src SH2 domains in tandem, DNA 
encoding the SH2 domain was amplified by PCR. In order to facilitate control of 
the integrity of the construct by restriction two different sets of primers were used, 
providing a unique restriction site between the SH2 domains as well as on both 
sides of the tandem domains. The PCR products were restricted with EcoRI and 
SalI or with SalI and BamHI, and ligated into pEGFP-C1 restricted with EcoRI and 
BamHI. The GFP-SH32 and GFP-dSH2 constructs were verified by sequencing. 
Cells from the porcine renal epithelial cell line LLC-PK1 were cultured in DMEM 
supplemented with 10% (v/v) fetal calf serum and penicillin/streptomycin, and 
maintained at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide. 
For live-cell imaging, cells were plated in tissue culture dishes with a collagen-
coated cover slip bottom and left to adhere for 24 h. For immunofluorescence, cells 
were plated on collagen-coated glass cover slips in 24-wells plates and incubated 
for 24 h before transfection. Cells were transfected with 0.8 µg of GFP-SH32 or 
GFP-dSH2 DNA using Lipofectamine Plus transfection reagent (Invitrogen) 
following the manufacturer‟s instructions. YFP-dSH2 DNA [276] was used as a 
control. Cells were fixed in 3.7% formaldehyde and washed with phosphate 
buffered saline (PBS), followed by permeabilisation and blocking in 0.1% (v/v) 
Triton X-100 and 0.5% (w/v) bovine serum albumin in PBS (TBP). Cells were 
incubated with anti-phosphotyrosine antibody (1:2000 PY99, mouse monoclonal, 
Santa Cruz Biotechnology), anti-FAK pY397 antibody (1:500 rabbit polyclonal, 
Biosource) or anti-paxillin pY118 antibody (1:375 rabbit polyclonal, Biosource) in 
TBP overnight at 4°C. After washing with TBP three times, cells were incubated 
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with Cy3-labelled secondary antibodies (1:1000 goat anti-mouse or anti-rabbit, 
Jackson Laboratories) in TBP for 1h at RT. Cover slips were washed twice with 
TBP and once with PBS, and mounted on glass slides using Aqua-Poly/Mount 
(Polysciences, Warrington, PA). Cells were analyzed for immunofluorescence 
using a confocal laser scanning system (Bio-rad Radiance 2100, Bio-Rad, 
Hercules, CA) equipped with a Nikon Eclipse TE2000-U inverted microscope and 
a 60x Plan Apo oil-immersion objective (NA 1.4; Nikon, Melville, NY). Images 
were processed using Corel Draw. 
Live cell imaging was performed at 37°C in 5% CO2 in a climate control unit built 
up on the stage of a Nikon Eclipse TE2000-U inverted microscope, images were 
taken using a Bio-Rad Radiance 2100 confocal system with a 60 X Plan Apo (NA 
1.4; Nikon) objective lens. Sylvia Le Dévédec is gratefully acknowledged for help 
with fluorescence microscopy. 
 
Results and discussion 
Fluorescence imaging of fixed LLC-PK1 cells after transfection with GFP-dSH2 
shows that the construct localizes to focal adhesions (Fig. 7.1a), which are the 
prime sites of tyrosine phosphorylation in the cell. The GFP-SH32 construct is also 
found to localize to focal adhesions, although to a lesser extent than the double 
SH2 domains (Fig. 7.1b), reflecting the higher binding affinity of the SH2 domain 
for phosphotyrosine sequences compared to the affinity of SH3 domains for their 
proline-rich target sequences. A single SH2 domain YFP construct has been shown 
not to exhibit clear localization to focal adhesions [276], but the presence of the 
SH3 domain in GFP-SH32 contributes sufficiently to the binding affinity for the 




Figure 7.1. Fluorescence images of fixed LLC-PK1 cells transiently transfected with A) GFP-dSH2, 
B) GFP-SH32 and C) YFP-dSH2. The dSH2 constructs localize more clearly to focal adhesions than 
the SH32 construct. 
The distinct localization of GFP-dSH2 to focal adhesions can also be observed in 
live cells (Fig. 7.2), making the construct a potentially useful tool for studying 
dynamic processes involving tyrosine phosphorylation in cells. 
Immunofluorescence experiments show that the GFP-dSH2 construct colocalizes 
with anti-phosphotyrosine antibody labelling of fixed cells as well as with labelling 
with an antibody specific for phosphorylation of Y397 in FAK and Y118 in 
paxillin (Fig. 7.3). Comparison of phosphotyrosine labelling in cells with different 
expression levels of GFP-dSH2 shows that the presence of high amounts of GFP-
dSH2 leads to higher phosphotyrosine levels at focal adhesions (Fig. 7.4). Most 
likely, SH2 domain binding protects phosphorylated tyrosine residues from the 
action of cellular phosphatases, thereby causing the increase in tyrosine 
phosphorylation. This means that if the GFP-dSH2 construct will be used as 
phosphotyrosine reporter, care has to be taken to select cells expressing the 
construct at moderate levels, as to avoid the construct influencing the 
phosphotyrosine levels [276]. 
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Figure 7.2. Live cell images of  LLC-PK1 cells transiently transfected with GFP-dSH2, showing 
clear localization of GFP-dSH2 to focal adhesions. 
 
Figure 7.3. Fixed LLC-PK1 cells after transient transfection with GFP-dSH2. Top panel: GFP 
fluorescence Bottom panel: Staining with Cy3 using antibodies against A) phosphotyrosine B): FAK 







Figure 7.4. Fixed LLC-PK1 cells after transient transfection with GFP-dSH2. Top panel: GFP-
fluorescence Bottom panel: Cy-3 staining using anti-phosphotyrosine antibody. Cells that are 
expressing GFP-dSH2 at high levels show an increase in phosphotyrosine labelling. 
 
Conclusions 
Both the GFP-dSH2 and GFP-SH32 constructs localize to focal adhesions, 
although the dSH2 construct localizes to a higher degree. High expression levels of 
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The interaction of the PI3K SH3 domain with a cyclic photocleavable peptide and 
the linear peptide resulting from UV-irradiation of the cyclic peptide has been 
studied using NMR spectroscopy. The affinity of the cyclic peptide for the SH3 
domain was found to be fourfold lower than the affinity of the photo-irradiated 
peptide, showing that it is possible to optically modify the strength of the peptide-
protein interaction. 
 
This chapter has been published as part of: 
I. Takahashi, S. Kuroiwa, H.E. Lindfors, L.A. Ndamba, Y. Hiruma, T. Yajima, N. 
Okishio, M. Ubbink and S. Hirota (2009). Modulation of protein-ligand 
interactions by photocleavage of a cyclic peptide using phosphatidylinositol 3-
kinase SH3 domain as model system. J. Pept. Sci. 15, 411-416. 
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Introduction 
The use of photoactive molecules as biochemical tools has become increasingly 
popular in recent years [277-296]. For example, introduction of photocleavable 
molecules into proteins has enabled studies of the mechanism of protein folding 
[282;289;290]. In these studies a protein was modified with a photocleavable 
compound, resulting in partial denaturation. Irradiation with light initiates rapid 
refolding to the native structure. Photoactive molecules offer the possibility of 
spatially and temporally controlling peptide-protein interactions inside cells [297]. 
Caged species can be introduced into the cell in an inactive form, and subsequently 
be activated by irradiation. This has for example been shown for a phosphorylated 
peptide that competes with focal adhesion kinase (FAK) for binding to its partner 
proteins [283]. Phosphate groups in peptides tend to be quickly removed by 
cellular phosphatases, but by caging the phosphate group the peptides could remain 
inert until activated. The activated phosphopeptide interferes with the interaction of 
FAK with downstream signalling proteins, resulting in halting of cell migration. 
Phosphoinositide 3-kinase (PI3K) generates 3‟-phosphorylated inositol lipids that 
are key mediators of intracellular signalling [298]. Apart from a catalytical subunit 
(p110), PI3K also contains a regulatory/adaptor subunit (p85), consisting of two 
SH2 domains and one SH3 domain. The SH3 domain of PI3K binds to proline-rich 
motifs with a left-handed type II polyproline (PPII) helix conformation, with the 
sequence RKLPPRPSK [299]. 
Here we have studied how the interaction of the SH3 domain of PI3K with its 
peptide ligand RKLPPRPSK can be controlled optically. To this end we have used 
a peptide modified with a photocleavable linker which forces the peptide to assume 
a cyclic conformation [300] (Fig. 8.1). This peptide can be converted into the linear 
form through light-irradiaton of an appropriate wave-length. Using NMR 
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spectroscopy we find that the affinity of the SH3 domain for the cyclic peptide is 
reduced compared to the linear peptide, but surprisingly by a mere factor of four. 
 
 
Figure 8.1. Schematic views of a) formation of the photocleavable cyclic peptide and b) photocontrol 




The peptide cyclic-1 consisted of the preferred motif for PI3K SH3 domain 
binding, RKLPPRPSK, to which cysteines had been added to both termini and the 
peptide had been further modified with a photolabile linker (2,5-
bis(bromomethyl)nitrobenzene), resulting in a photocleavable cyclic peptide. 
Cyclic-1 peptide and photo-irradiated cyclic-1 peptide (cyclic-1 that had been 
irradiated with a 355 nm light pulse from a Nd:YAG laser, resulting in a linear 
peptide) [302] were provided by Prof. Shun Hirota and coworkers (Nara Institute 
of Science and Technology, Japan). Peptides were received in dry form, with 
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buffer components already added to yield a 5 mM peptide solution in 50 mM NaPi 
pH 7.0 upon addition of 100 μL water. In order for the peptide and protein buffers 
to match, the peptides were instead dissolved in a 100 mM NaCl solution, yielding 
peptide stock solutions of 5 mM peptide in 50 mM NaPi pH 7.0, 100 mM NaCl. 
 
Protein expression and purification 
DNA encoding the PI3K SH3 domain, amino acid residues 3-81, with Escherichia 
coli optimized codon usage was purchased from GENEART and ligated into the 
plasmid pET28a, creating a His-tag at the C-terminus. The resulting construct was 
verified by sequencing. His-tagged 
15
N-labelled SH3 domain was produced by 
culturing freshly transformed E. coli BL21 (DE3) cells in M9 minimal medium (50 
μg/ml kanamycin) containing 
15
NH4Cl as the sole nitrogen source. Cells were 
incubated at 37°C while shaking at 250 rpm until an OD600 of 0.8 was reached. 
Protein expression was induced by the addition of 0.5 mM IPTG and cells were 
incubated at 22°C for an additional 20 h. Cells were harvested by centrifugation, 
resuspended in lysis buffer containing 20 mM NaPi pH 7.0, 500 mM NaCl, 1 mM 
PMSF and 50 μg/ml DNAse, and lysed by sonication. The cell lysate was 
centrifuged at 15000 rpm and 4°C for 1 h, and the supernatant was loaded onto an 
immobilized-metal affinity column (HisTrap, GE Health care) equilibrated with 20 
mM Tris pH 7.6, 0.5 M NaCl and 5 mM imidazole. After washing with the same 
buffer containing 60 mM imidazole the protein was eluted using a 500 mM 
imidazole buffer. The protein was further purified using a size-exclusion 
chromatography column (Superose 12, GE Healthcare) equilibrated with 50 mM 
NaPi pH 7.0, 100 mM NaCl. The protein concentration was determined using a 




 [140]. The purity was 





NMR experiments were recorded at 298 K on a Bruker DMX600 spectrometer 
equipped with a TCI-Z-GRAD cryoprobe (Bruker, Karlsruhe, Germany). The data 
were processed with Azara (http://www.bio.cam.ac.uk/azara/) and analyzed using 









H] TOCSY-HSQC spectra were recorded on 
a 1 mM 
15
N SH3 sample in 50 mM NaPi pH 7.0, 100 mM NaCl containing 6% 
D2O for lock. Resonances were assigned using published assignments for the PI3K 
SH3 domain [303]. Lionel Ndamba is gratefully acknowledged for help with 
resonance assignments. Microliter aliquots of peptide were added to a 0.12 mM 
sample of 
15




H] HSQC spectra were recorded at each titration 
point. After titration with cyclic-1 the NMR sample was placed on ice and 
irradiated with a 365 nm UV/VIS lamp (Spectroline E-series EF-260C) for 20 




H] HSQC spectrum was recorded of the irradiated 
sample. 
The chemical shift perturbations were analyzed as described in chapter 6. 
 
Results 
Titration of the photocleavable cyclic peptide (cyclic-1) and the linear peptide 
resulting from light irradiation of cyclic-1 (photo-irradiated cyclic-1) into 
15
N-
labelled SH3 domain both resulted in significant chemical shift perturbations of 
certain backbone amide resonances in the SH3 domain (Fig. 8.2). At a given 
peptide-to-protein ratio the linear peptide caused larger shift changes than the 
cyclic peptide did, indicating a stronger interaction with the SH3 domain for the 
linear peptide. A comparison of the average chemical shift perturbations in the SH3 
domain upon addition of either cyclic-1 or photo-irradiated cyclic-1 at the same 
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peptide-to-protein ratio shows that all shift changes caused by cyclic-1 are smaller 
than those caused by photo-irradiated cyclic-1 (Fig. 8.3). The general shift pattern 
is the same for both peptides; residues displaying the largest chemical shift 
perturbations in the titration with one peptide also display the largest perturbations 
in the titration with the other peptide. 
 
Figure 8.2. Comparison of average chemical shift perturbations of amide nuclei of the PI3K SH3 
domain at a molar ratio of peptide to protein of 8.4:1 Open bars: peptide cyclic-1, filled bars: 
photoirradiated cyclic-1. Missing residues could not be assigned at this point in the titration (prolines 
or exchange broadened residues). 
 
Fitting the amide nitrogen chemical shift perturbation data for several resonances 
to a 1:1 binding model yielded dissociation constants (Kd) of 3.4±1.7 mM and 
0.9±0.3 mM for cyclic-1 and photo-irradiated cyclic-1, respectively (Fig. 8.4). 
Thus, linearization of the cyclic peptide by UV-irradiation results in a four-fold 
stronger binding of the peptide to the SH3 domain. This is further demonstrated by 
UV-irradiation of the NMR sample containing the SH3 domain and cyclic-1 (see 
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experimental procedures); a spectrum recorded after UV-irradiation shows much 
larger chemical shift perturbations than a spectrum recorded of the same sample 
before irradiation (Fig. 8.5). 
 
Figure 8.3. Overlay of a region of SH3 domain HSQC spectra from titration with photoirradiated 
cyclic-1 (A) and cyclic-1 (B). Spectra of free SH3 domain are shown in black and spectra of final 
titration points in blue (final molar ratio of peptide: protein = 8.4:1). 
 
Based on the chemical shift perturbation data fits, the average chemical shift 
perturbations for all amide resonances were extrapolated to 100% bound protein. A 
comparison between cyclic-1 and photo-irradiated cyclic-1 shows that although the 
chemical shift perturbations differ a lot in size at a particular titration point, the 
values extrapolated to fully bound protein are more similar in size (Fig. 8.6). 
Mapping of the extrapolated shift changes onto the SH3 domain shows that cyclic-
1 and photo-irradiated cyclic-1 bind at the regular peptide-binding face of the SH3 
domain, and that the peptides bind in a similar fashion (Fig. 8.7). 
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Figure 8.4. Global fit to a one-site 
binding model (Eq. 1), titration with 
(A) peptide cyclic-1, yielding a 
dissociation constant of 3.4 ± 1.7 mM 
and (B) photoirradiated cyclic-1 with a 










Figure 8.5. Effect of UV-irradiation on 
chemical shift perturbations of SH3 domain in 
complex with cyclic-1. Overlay of a region of 
SH3 domain HSQC spectra from titration with 
cyclic-1. Spectrum of free SH3 domain is 
shown in black and the final titration point is 
shown in blue. In purple is shown the spectrum 
of the sample from the final titration point, after 





Figure 8.6. Average chemical shift perturbations of amide nuclei of the PI3K SH3 domain 
extrapolated to fully bound protein. Open bars: peptide cyclic-1, filled bars: photoirradiated cyclic-1. 




Conversion of the cyclic peptide to a linear peptide by light irradiation results in a 
stronger interaction with the protein (Fig. 8.1B). Whether linear or cyclic, the 
peptide interacts with the same site on the SH3 domain and seems to bind in a 
similar way. It is likely that reduced conformational flexibility of the cyclic peptide 
prevents it from assuming the optimal conformation for interacting with the SH3 
domain, leading to the reduced binding affinity. Differences in circular dichroism 
spectra indicate that the precise binding mode is slightly different for the cyclic and 
photo-irradiated peptides [304]. The dissociation constant of 0.9±0.3 mM 
determined for the photo-irradiated peptide binding to the SH3 domain is much 
larger than the Kd of 9.1 μM reported for the peptide RKLPPRPSK [305]. This  
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Figure 8.7. Chemical shift 
perturbations upon titration with 
peptides cyclic-1 (A) and 
photoirradiated cyclic-1 (B) 
mapped onto the surface of PI3K 
SH3 domain (PDB entry 1PKS 
[306]). Shift changes were 
extrapolated to 100% bound protein 
and SH3 residues were coloured 
according to the size of the average 
chemical shift perturbation (Eq. 2), 
Δδavg. Red: Δδavg≥0.3 ppm; orange: 
0.3>Δδavg≥0.1 ppm; yellow: 
0.1>Δδavg≥0.04 ppm; blue: 
Δδavg<0.04 ppm. Shown in grey are 
residues that could not be assigned (proline residues or residues that were exchange-broadened 
beyond detection at the point of extrapolation). 
 
Figure 8.8. Average chemical shift perturbations extrapolated to 100% bound protein and mapped 
onto the protein structure for titrations of photo-irradiated cyclic-1 peptide into PI3K SH3 (PDB entry 
1PKS [307]) (A) and peptide P3 (sequence RALPSIPKL, see chapter 2) into Src SH3 (PDB entry 





may be the result of steric repulsion between the protein and the attached benzyl 
derivatives and/or the two cysteine residues of the modified peptide. 
The interaction of PI3K SH3 with the linearized peptide can be compared with the 
interaction of Src SH3 with the proline-rich peptide RALPSIPKL (chapter 2). 
Alignment of the two SH3 domains with chemical shift perturbations mapped onto 
the proteins shows that residues in corresponding regions of the proteins are 
involved in peptide binding (Fig. 8.8), indicating that the peptides bind the 
respective SH3 domains in a similar way. 
 
Conclusions 
The results show that the peptide-protein interaction can be optically controlled by 
using a photocleavable linker, offering a powerful tool for modulating the 
interaction between a peptide and a protein. This may also be applicable to other 
biomolecular interactions. However, the modification lowers the affinity of the 
peptide, resulting in very weak binding and only a fourfold difference between 










The work described in this thesis focuses on protein-peptide and protein-protein 
interactions mediated by SH2 and SH3 domains. These domains are prototypical 
protein interaction domains found in cytoplasmic tyrosine kinases, where they are 
involved both in target recognition and control of kinase activity via intramolecular 
interactions. Studies of these modular interaction domains and their target 
sequences has greatly enhanced our understanding of how biological processes are 
regulated by protein interactions [308-310]. The core peptide sequences recognized 
by these domains are well-known, but the possibility of interactions outside the 
core recognition motifs that may modulate binding affinity and protein activity 
largely remains unexplored, with only a few exceptions [311;312]. The aim of this 
study was to address this question, to explore the dynamics of SH2 and SH3 
mediated interactions, and to investigate how the domains function together with 
other domains in intra- and intermolecular interactions. 
 
Peptide interactions with isolated SH3 or SH2 domains 
The dynamics of peptides derived from FAK interacting with Src SH3 and SH2 
domains was investigated in chapters 2 and 3, using paramagnetic NMR methods. 
Contrary to what might be expected, these experiments demonstrate that although 
the peptide from the SH3 binding site in FAK binds to the SH3 domain with a low 
affinity, the peptide binds in a highly specific position and little dynamics is 
observed. In contrast to this, the peptide derived from SH2-binding site in FAK, 
which binds to the Src SH2 domain with a very high affinity, interacts with the 
SH2 domain in a much more dynamic way. This shows that the affinity of an 
interaction is not necessarily related to the degree of dynamics in the complex. 
Peptides binding to SH3 domains can be divided into two groups, depending on the 
position of an arginine residue relative to the core proline-rich motif. The two 
classes bind to the SH3 domain in opposite orientations [39]. Paramagnetic effects 
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observed for a particular aspartic acid residue in the SH3 domain suggest that the 
peptide derived from FAK, a class I peptide, may for a small fraction of the time 
also interact with the SH3 domain in the opposite orientation seen for class II 
peptides. Interestingly, in a recently published molecular dynamics study on the 
interaction of the N-terminal SH3 domain of C-CRK with a proline-rich motif 
some simulations also converged to an opposite binding orientation than that seen 
in the crystal structure of the complex [313]. In these simulations a peptide arginine 
formed a salt bridge with an aspartic acid residue, in a position where aspartic acid 
residues are often found for SH3 domains. This corresponds to the same residue for 
which we noted the unexpected paramagnetic effects, supporting our findings. 
The SH2 binding-site in FAK contains a phosphotyrosine in a sequence that 
conforms to a high-affinity SH2 binding motif. The core binding motif is flanked 
by a number of negatively charged residues on both sides. Including these residues 
in a peptide increases the binding affinity around 30-fold compared to a peptide 
only containing the core binding motif, showing that residues outside the core 
binding motif can have a significant effect on binding. The increase in binding 
affinity is most likely due to long-range electrostatic interactions between the 
negative charges in the peptide and the many positively charged residues in the 
SH2 domain. This would increase the formation of an encounter complex by 
recruiting the peptide to the protein, but the charge interactions likely also make the 
energy difference between the different encounter complex orientations and the 
specific complex small, which could explain the high degree of dynamics observed 
for this interaction. 
For both the SH2- and SH3-peptide interactions including the spin-label has an 
effect on the binding affinity. The effect is larger if the spin-label is introduced in 
the core binding motif, some effect can be seen also when the spin-label is placed 
outside the core binding sequence. Introducing a spin-label does not affect the 
observed chemical shift perturbations compared to unlabelled peptides, suggesting 
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that the mode of binding is still comparable to unlabelled peptide. This is also 
observed in chapter 8 for the SH3 domain from PI3K binding to a peptide for 
which the peptide conformation can be optically modified. The peptide can either 
have a circular structure which prevents the peptide from assuming the optimal 
conformation for SH3 domain-binding, or a linear structure which binds more 
efficiently. The introduced modifications are situated outside the core binding 
motif, but their presence significantly lowers the binding affinity compared to 
reported values [314]. 
 
Interactions involving tandem domains 
The SH3- and SH2-binding sites in FAK are separated by a linker that is much 
longer than what is needed to span the distance between the SH3 and SH2 domains 
of Src. A long peptide derived from this region of FAK binds to the SH32 tandem 
with a high affinity (chapter 4), and the interaction is restricted to the canonical 
SH3- and SH2-binding sites. The binding affinity of the single SH3 domain for its 
target sequence is low compared to single SH2 domain-peptide interactions 
(chapters 2 and 3). Including the SH3 domain in tandem with the SH2 domain in a 
GFP-construct does however improve the localization of the construct to focal 
adhesions in cells (chapter 7), compared to a single-domain construct, YFP-SH2, 
that has shown poor localization to focal adhesions [276]. Reflecting the difference 
in binding affinity, a construct with two SH2 domains in tandem, GFP-dSH2, 
localizes even more clearly than GFP-SH32 to focal adhesions (chapter 7). 
Reducing the length of the linker separating the SH3- and SH2-bidning sites in 
FAK to a point where the peptide cannot bind simultaneously to both the SH2 and 
SH3 domain makes the domain compete for peptide binding. Contrary to what 
would be expected based on the difference in binding affinity, a significant fraction 
of the peptide still binds to the SH3 domain also at low peptide concentrations 
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(chapter 4). This suggests that the presence of the SH2 domain and the SH2-
binding sequence in the peptide increases the affinity of the SH3 domain for the 
peptide as well, although the peptide cannot bind both domains at the same time. 
The model we propose for this is based on the observation that the negative charges 
surrounding the SH2 core binding site in the peptide increase the affinity of the 
interaction, but likely also the dynamics. It is perceivable that the peptide and 
protein forms an encounter complex from which the peptide can either bind the 
SH3 or SH2 domain, thereby yielding a lower equilibrium dissociation constant for 
the peptide-SH3 interaction as well. Further experiments and modelling is needed 
to yield more insights into the process. 
 
Interaction between the Src SH2 domain and the catalytic domain of FAK 
Chemical shift perturbations of SH2 domain resonances upon addition of FAK 
kinase domain show that the SH2 domain binds the kinase domain in a way that 
differs from how the SH2 domain interacts with peptides derived from FAK 
(chapter 6). The SH2-binding site in the FERM-kinase linker region of FAK 
appears to be unavailable for SH2 domain binding in our protein, most likely the 
linker binds to another region of the kinase domain, either within the same 
molecule or to another molecule. The observed chemical shift perturbations are 
small and spread out over a large portion of the SH2 domain, which is typical for 
dynamic interactions governed by electrostatics. The kinase domain is able to 
compete with a peptide for binding to the SH2 domain and the estimated binding 
affinity is surprisingly high. Together this demonstrates that the SH2 domain and 
the kinase domain can interact in a way that is independent of the SH2-binding site 
in FAK, with a relatively high affinity, and that domain-domain contacts exist 
outside the core peptide-binding site. Again, electrostatics appears to be an 
important factor in interactions mediated by the Src SH2 domain. 
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Including not only the SH2-binding site but also the part of the linker that contains 
the proline-rich SH3-binding motif in the kinase construct might make both the 
SH2- and SH3-binding sites available for SH32 binding and could help shed 
further light on the FAK-Src interaction. 
In conclusion, despite the wealth of information available on the SH-domains, this 
work illustrates that we still understand surprisingly little of the mechanisms that 





In order for multicellular life to be possible, cells within an organism need to be 
able to communicate with each other and respond to signals in their environment. 
Signal transduction is the process in which a stimulus received from the outside is 
converted into a response inside the cell. When an external ligand, such as a 
hormone, binds to a receptor present in the cell membrane a chain of events is 
initiated in the cell, leading to changes for example in gene expression or enzyme 
activity. Protein-protein interactions play a central part in signalling cascades and 
are of vital importance in controlling biological processes. 
The work described in this thesis focuses on the interactions mediated by Src 
homology (SH) domains, a group of protein interaction domains found in proteins 
involved in phosphotyrosine signalling. Tyrosine phosphorylation, the addition of a 
phosphate group to tyrosine amino acid residues in proteins, can change the 
structure and activity of an enzyme and create new protein-interaction sites. This 
reaction, which is frequently a part of signal transduction pathways, is catalyzed by 
protein tyrosine kinases, a group of enzymes that often contain SH domains. Src 
homology 2 (SH2) domains recognise and bind to phosphorylated tyrosine 
residues, and proteins that contain SH2 domains will therefore be recruited to other 
proteins that have become phosphorylated in response to an external signal. This 
can help bring the catalytic domain of the kinase close to its substrate targets for a 
next round of phosphorylation reactions, transmitting the signal further. Src 
homology 3 (SH3) domains also function in bringing the appropriate proteins 
together, by recognizing regions that contain certain sequences rich in the amino 
acid proline. In addition to recruiting the kinase to the right part of the cell, SH2 
and SH3 domains are also involved in regulating the activity of the kinase. 
The protein tyrosine kinases focal adhesion kinase (FAK) and Src are involved in 
processes such as cell proliferation, migration and survival. Their implication in 
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several types of human cancer makes them important drug targets, and it is thus of 
general interest to learn more about the details of their interaction. Studying these 
proteins can also further our understanding of modular signalling proteins in 
general and of the behaviour of SH domains in protein interactions in particular. 
Using nuclear magnetic resonance (NMR) spectroscopy and isothermal titration 
calorimetry (ITC) as the main tools, the interaction of the FAK and Src via the SH2 
and SH3 domains of Src has been investigated. To this end, a range of model 
systems was employed.  
Chemical shift perturbation mapping and paramagnetic relaxation enhancement 
(PRE) NMR was used to study the interaction of the Src SH3 domain with a 
peptide derived from a proline-rich site in FAK, using peptides containing the spin-
labelled amino acid TOAC (chapter 2). Despite the low binding affinity of the 
peptide for the SH3 domain the peptide was found to bind the SH3 domain in a 
very well-defined way, with little mobility observed in the complex. The SH2 
domain of Src was found to bind with a high-affinity to peptides derived from FAK 
(chapter 3). Residues flanking the region that is generally regarded as the SH2 
binding-motif were found to have a large influence on the binding affinity; 
including these residues in the peptide lead to a significant increase in binding 
affinity. Contrary to what was expected for a high-affinity complex, PRE NMR 
studies with spin-labelled peptides showed that the interaction between the peptide 
and protein was remarkably dynamic. Given the fact that the flanking residues are 
mostly negatively charged, whereas the binding face of the SH2 domain contains 
many positively charged residues, the increase in affinity is likely due to 
electrostatic interactions that increase the formation of an encounter complex 
between the peptide and the SH2 domain. 
Chemical shift perturbation NMR and ITC studies of peptides containing both the 
SH3- and SH2-binding sites in FAK together with a Src SH3-SH2 domain tandem 
(SH32) showed that including both binding sites in the peptide increased the 
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affinity for the SH32 compared to the individual binding sites (chapter 4). This is 
also shown in mammalian cells transfected with SH domain constructs, where the 
SH32 domain tandem localizes to a higher degree to specific regions in the cell, 
compared to an isolated SH2 domain (chapter 7). The distance between the binding 
sites as they are present in FAK is much larger than what is required to span the 
distance between the peptide-binding faces on the SH3 and SH2 domains. We have 
investigated how decreasing this distance affects the interaction with the SH32. 
Interestingly, peptides in which the distance between the binding sites is too small 
to allow simultaneous binding to both the SH2 and SH3 domains, bind the SH3 
domain to a much higher extent than what would be expected based on the 
difference in binding affinity between the isolated SH2 and SH3 domains. Based 
on these data we have proposed a model for the interaction, describing a new 
mechanism for peptide-protein complex formation. In this model, the charges on 
the peptide help recruit the peptide into an encounter complex with the SH32. From 
the encounter complex the peptide can proceed to form a final complex with either 
the SH2 domain or the SH3 domain, and this way the charges in the peptide lead to 
an increase in complex formation with the SH3 domain as well. 
A protocol for expressing the catalytic domain of FAK using a baculovirus 
expression system was developed, together with a purification protocol and a 
method for manipulating the phosphorylation state of the kinase domain in vitro 
(chapter 5). This enabled studies of the interaction of the Src SH2 domain together 
with the entire catalytic domain of FAK, including the SH2 binding site (chapter 
6). From chemical shift perturbation data it was shown that the SH2 domain binds 
the kinase domain, but that the regular SH2-binding site is not available for SH2 
binding. Instead, the chemical shift perturbations are typical of dynamic complexes 
for which the interaction is governed mainly by electrostatics. A competition 
experiment involving a peptide derived from FAK showed that the apparent 
binding affinity of the SH2 domain for this peptide is substantially lower in the 
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presence of the FAK kinase domain than in the absence of the kinase domain. 
Together these data indicate that the kinase domain binds the SH2 domain tightly, 
in a way that precludes SH2 domain binding to the added peptide, but that the 
regular SH2 binding site in FAK is not involved. It is possible that the kinase 
domain binds (intra- or intermolecularly) to this site itself, thereby sequestering it 
from SH2 domain binding. 
In addition to interactions mediated by the Src SH3 and SH2 domains, the binding 
of the SH3 domain from the PI3K p85 subunit to proline-rich peptides with 
different structural conformations has been investigated (chapter 8). The interaction 
of the SH3 domain with peptides that had been modified with a photo-labile linker 
to assume a cyclic conformation was compared to the interaction with peptides 
after photo-irradiation, making the peptides return to a linear conformation. It was 
found that although the peptides bind in similar ways to the SH3 domain the 
binding affinity for the linear peptides was increased relative to the cyclic peptides, 
offering a way to control the affinity of the peptide-protein interaction using photo-
irradiation.  
From the results presented in this thesis we learn that in macromolecular 
complexes a high binding affinity does not always correlate with well-defined 
complex orientation: tight binding can still involve mobility of the molecules 
relative to each other in the complex, just as weakly interacting molecules can have 
well-defined relative positions. Furthermore, these studies have increased our 
understanding of interactions mediated by the Src SH2 domain, and it is shown that 
these interactions are more complex than what is generally believed. The 
interactions involve more than the canonical SH2 binding motif: residues outside 
this region can have a large impact on the binding affinity and electrostatic 
interactions are important for the binding. Also the combination of SH3 and SH2 
domains results in binding behaviour that differs from that expected merely on the 
basis of the individual binding motifs and isolated domains. The non-additive 
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nature of the interactions is further illustrated by the observation that the Src SH2 
domain can bind the FAK kinase domain independent of the regular SH2 binding 





Meercellig leven is alleen mogelijk als de cellen binnen een organisme in staat zijn 
om met elkaar te communiceren en te reageren op de signalen uit hun omgeving. 
Signaaltransductie is een proces waarin een externe prikkel wordt vertaald naar een 
reactie binnen de cel. Als een extern ligand, zoals een hormoon, aan een receptor in 
het celmembraan bindt, leidt dit tot een keten van gebeurtenissen. Dit leidt 
uiteindelijk tot veranderingen in bijvoorbeeld genexpressie of de activiteit van 
enzymen. Eiwit-eiwitinteracties spelen een centrale rol in signaleringscascades en 
zijn van vitaal belang in de regulatie van biologische processen. 
Dit proefschrift richt zich op interacties gemedieerd door Src homologie (SH) 
domeinen, een groep eiwitinteractiedomeinen die voorkomen in eiwitten die 
betrokken zijn bij fosfotyrosine signaaltransductie. Tyrosinefosforylatie, het 
verbinden van een fosfaatgroep met een tyrosineresidu in een eiwit, kan de 
structuur en de activiteit van een enzym veranderen en nieuwe locaties voor eiwit-
interacties creëren. Deze reactie wordt gekatalyseerd door eiwit-tyrosinekinasen, 
een groep van enzymen die vaak SH-domeinen bevatten. Tyrosinefosforylatie 
maakt onderdeel uit van vele signaaltransductieketens. 
Src homologie 2 (SH2) domeinen herkennen en binden aan gefosforyleerde 
tyrosineresiduen. Eiwitten die SH2-domeinen bevatten kunnen daarom andere 
eiwitten, die gefosforyleerd zijn als resultaat van een externe prikkel, herkennen en 
binden. Dit kan helpen om het katalytische domein van het tyrosinekinase dicht bij 
zijn substraat te brengen voor een nieuwe ronde van fosforylatiereacties, wat het 
signaal doorstuurt. De functie van Src homolgie 3 (SH3) domeinen is ook om de 
juiste eiwitten bij elkaar te brengen, door bepaalde prolinerijke regio‟s in eiwitten 
te herkennen. Naast het sturen van de kinase naar het juiste deel van de cel zijn 




De eiwit-tyrosinekinasen focal adhesion kinase (FAK) en Src zijn betrokken bij 
processen zoals celproliferatie, celmigratie en het overleven van de cel. Hun 
betrokkenheid bij diverse soorten kanker bij de mens maakt hen belangrijke 
aangrijpingspunten voor geneesmiddelen, en het is dus van algemeen belang om 
meer over de details van hun interactie te leren. Het bestuderen van deze eiwitten 
kan in het algemeen ons begrip van modulaire signaleringeiwitten verbeteren en in 
het bijzonder het gedrag van SH-domeinen in eiwitinteracties. Met behulp van 
kernspinresonantie (NMR) spectroscopie en isotherme titratie calorimetrie (ITC) 
als de belangrijkste instrumenten werd de interactie van FAK en Src door middel 
van de SH2 en SH3 domeinen van Src bestudeerd. Voor dit doeleinde werden een 
aantal modelsystemen gebruikt. 
Het in kaart brengen van verstoringen van de chemische verschuivingen (CSP) 
werd samen met paramagnetische relaxatie-versnelling (PRE) NMR spectroscopie 
gebruikt om de interactie van het Src SH3-domein met een peptide afgeleid van 
een proline-rijke plaats in FAK te bestuderen. Hierbij werd gebruik gemaakt van 
peptiden die de spin-gelabelde aminozuur TOAC bevatten (hoofstuk 2). Ondanks 
de lage affiniteit waarmee het peptide bond aan het SH3-domein, bleek het peptide 
te binden op een zeer specifieke manier en werd er weinig mobiliteit waargenomen 
in het complex. Het SH2 domein van Src bleek met een hoge affiniteit te binden 
aan peptiden afgeleid van FAK (hoofdstuk 3). Residuen vlak buiten de regio die in 
het algemeen wordt beschouwd als het SH2-bindend motief bleken een grote 
invloed te hebben op de bindingsaffiniteit en het includeren van deze residuen 
leidde tot een aanzienlijk verhoogde affiniteit. In tegenstelling tot wat werd 
verwacht voor een complex van hoge affiniteit, is met PRE NMR studies met spin-
gelabelde peptiden vastgesteld dat de interactie tussen het peptide en proteïne 
opmerkelijk dynamisch was. Gezien dat vele van de flankerende residuen negatief 
geladen zijn, terwijl de plaats waar het peptide bindt aan het SH2-domein 
overwegend positief geladen is, is de verhoogde affiniteit waarschijnlijk te wijten 
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aan elektrostatische interacties die de formatie van een ontmoetingscomplex tussen 
het peptide en het SH2-domein verhogen. 
CSP NMR en ITC studies van peptiden die zowel de SH3- als de SH2-
bindingsplaatsen van FAK bevatten samen met een Src SH3-SH2 tandem domein 
(SH32) toonden aan dat het includeren van allebij de bindingsplaatsen in het 
peptide tot een verhoogde affiniteit voor SH32 leidde, ten opzichte van de 
individuele bindingsplaatsen (hoofdstuk 4). Dit werd ook aangetoond in 
zoogdiercellen getransfecteerd met SH-domein constructen, waarin het SH32-
tandem domein in een hogere mate lokaliseerde naar specifieke regio‟s in de cel in 
vergelijking met een geïsoleerd SH2-domein (hoofdstuk 7). De afstand tussen de 
bindingsplaatsen zoals aanwezig in FAK is veel groter dan wat nodig is om de 
afstand tussen de peptide-bindende plaatsen op de SH3- en SH2-domeinen te 
overbruggen. Wij hebben onderzocht hoe het verminderen van deze afstand in het 
peptide de interactie met SH32 beïnvloed. Interessant genoeg blijken peptiden, 
waarin de afstand tussen de bindingsplaatsen te klein is om gelijktijdig aan zowel 
de SH2- en de SH3-domein te binden, in veel hogere mate aan de SH3-domein te 
binden dan wat men zou verwachten op basis van het verschil in bindingsaffiniteit 
tussen de geïsoleerde SH2- en SH3-domeinen. Op basis van deze data hebben wij 
een model voor de interactie voorgesteld, waarin een nieuw mechanisme voor 
peptide-eiwit complex formatie wordt beschreven. In dit model helpen de 
(elektrische) ladingen het peptide naar een ontmoetingscomplex met SH32 te 
brengen. Vanuit dit ontmoetingscomplex kan het peptide verder met of het SH2-
domein of  het SH3-domein het uiteindelijke complex vormen. Hierdoor leiden de 





Een protocol voor de expressie van het katalytische domein van FAK door middel 
van een baculovirus expressie systeem werd ontwikkeld, samen met een 
zuiveringsprotocol en een methode voor het in vitro manipuleren van de 
fosforyleringsstaat van het kinase-domein (hoofdstuk 5). Dit maakte studies van de 
interactie van het Src SH2 domein met het hele katalytische domein van FAK 
inclusief de SH2 bindingsplaats mogelijk (hoofdstuk 6). Op basis van CSP data 
werd aangetoond dat het SH2 domein het kinase domein bindt, maar dat de 
normale SH2-bindingsplaats niet toegankelijk is voor SH2 binding. De 
verstoringen van de chemische verschuivingen waren typisch voor dynamische 
complexen waarin de interactie voornamelijk wordt gedreven door elektrostatica. 
Uit een competitie experiment met een peptide afkomstig van FAK is gebleken dat 
de schijnbare bindingsaffiniteit van het SH2-domein voor dit peptide aanzienlijk 
lager is in de aanwezigheid van het FAK kinase-domein dan in de afwezigheid van 
het kinase-domein. Samen duiden deze gegevens erop dat het kinase-domein het 
SH2 domein met een hoge affiniteit bindt, waardoor het binden van het SH2-
domein aan het toegevoegde peptide onmogelijk is, maar dat de normale SH2 
bindingsplaats in FAK er niet bij betrokken is. Het is mogelijk dat het kinase-
domein zelf aan deze plaats (intra- of intermoleculair) bindt, waardoor het SH2-
domein er niet aan kan binden. 
Naast de interacties die gemedieerd worden door de Src SH3- en SH2-domeinen, 
werd de binding van het SH3-domein van het PI3K p85-onderdeel aan proline-rijke 
peptiden met verschillende structurele conformaties onderzocht (hoofdstuk 8). De 
interactie van het SH3-domein met peptiden die gemodificeerd waren met een foto-
labiele linker, waardoor zij een cyclische conformatie aan hadden genomen, werd 
vergeleken met de interactie met de peptiden na bestraling met UV-licht, waardoor 
de peptiden weer een lineaire conformatie aan hadden genomen. Er werd 
vastgesteld dat, hoewel de peptiden in soortgelijke manieren aan het SH3-domein 
bonden, de bindingsaffiniteit voor de lineaire peptiden verhoogd was ten opzichte 
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van de cyclische peptiden. Deze methode biedt dus een manier om de affiniteit van 
de peptide-eiwit interacties te controleren met behulp van bestraling met UV-licht.  
Uit de resultaten die in dit proefschrift gepresenteerd zijn kunnen we vaststellen dat 
in macromoleculaire complexen een hoge bindingsaffiniteit niet altijd gecorreleerd 
is met een duidelijk gedefinieerde oriëntatie in het complex: sterke binding kan 
alsnog mobiliteit van de moleculen ten opzichte van elkaar met zich mee brengen, 
net als zwak bindende moleculen duidelijk gedefinieerde relatieve posities in het 
complex kunnen hebben. Verder hebben deze studies ons begrip van interacties 
door bemiddeling van het Src SH2-domein bevorderd, en het is aangetoond dat 
deze interacties complexer zijn dan wat vaak gedacht wordt. De interacties 
omvatten meer dan het canonieke SH2-bindende motief: residuen buiten dit gebied 
kunnen een grote invloed hebben op de bindingsaffiniteit en elektrostatische 
interacties zijn belangrijk voor de binding. Ook resulteerde de combinatie van 
SH3- en SH2-domeinen in bindingsgedrag dat afwijkt van wat verwacht werd op 
basis van de individuele bindingsmotieven en geïsoleerde domeinen. De niet-
additieve aard van de interacties wordt verder geïllustreerd door de observatie dat 
het Src SH2-domein onafhankelijk van de normaale SH2 bindingsplaats kan binden 
aan het FAK-kinase domein, waarbij het kinase-domein contact maakt met een 
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XPLOR-NIH restraint files belonging to chapter 2 
 
! Distances derived from R2 data from Src SH3 binding to peptide 
P3Tm 
! store1 = fixed value for atoms that dissappear 
! store2 = fixed distance for atoms that dissappear 
! store3 = fixed value for atoms that are unaffected 
! store4 = fixed distance for atoms that are unaffected 
! store5 = observed R(para) value 
! store6 = derived experimental distance 
 
set mess=on end 
set echo=off end 
eval ($ide =1) 
!-------------------------------------------------------------------
------ 




!Residue numbering as in PDB 1RLQ (+5 compared to our protein) 
  
vector do (store1=96.03) (atom "    "  59 HN) 
  
NOE 
   nres=20000 
   class CL1 
   averaging CL1 R-6 
   potential CL1 square 
   sqconstant CL1 $a9 
   sqoffset CL1 0.0 
   scale CL1 $a10 
   sqexponent CL1 2 




for $ide in ID (store1) 
loop store_values 
        vector show element (STORE1) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $a4 $a5 
 end 
  vector do (store2=$dist01) (ID $ide) 










 vector do (store3=2.60) (atom "    "  9 HT1) !first aa in pdb, not 
in protein, so really an amide 
 vector do (store3=2.60) (atom "    "  10 HN) 
 vector do (store3=2.60) (atom "    "  11 HN) 
 vector do (store3=2.60) (atom "    "  12 HN) 
 vector do (store3=2.60) (atom "    "  21 HN) 
 vector do (store3=2.60) (atom "    "  22 HN) 
 vector do (store3=2.60) (atom "    "  27 HN) 
 vector do (store3=2.60) (atom "    "  31 HN) 
 vector do (store3=2.60) (atom "    "  32 HN) 
 vector do (store3=2.60) (atom "    "  33 HN) 
 vector do (store3=2.60) (atom "    "  34 HN) 
 vector do (store3=2.60) (atom "    "  35 HN) 
 vector do (store3=2.60) (atom "    "  36 HN) 
 vector do (store3=2.60) (atom "    "  38 HN) 
 vector do (store3=2.60) (atom "    "  39 HN) 
 vector do (store3=2.60) (atom "    "  40 HN) 
 vector do (store3=2.60) (atom "    "  44 HN) 
 vector do (store3=2.60) (atom "    "  45 HN) 
 vector do (store3=2.60) (atom "    "  46 HN) 
 vector do (store3=2.60) (atom "    "  47 HN) 
 vector do (store3=2.60) (atom "    "  48 HN) 
 vector do (store3=2.60) (atom "    "  49 HN) 
 vector do (store3=2.60) (atom "    "  50 HN) 
 vector do (store3=2.60) (atom "    "  51 HN) 
 vector do (store3=2.60) (atom "    "  52 HN) 
 vector do (store3=2.60) (atom "    "  62 HN) 
 vector do (store3=2.60) (atom "    "  55 HN) 
 vector do (store3=2.60) (atom "    "  56 HN) 
   
  
NOE 
   class CL2 
   averaging CL2 R-6 
   potential CL2 square 
   sqconstant CL2 $a9 
   sqoffset CL2 0.0 
   scale CL2 $a11 




for $ide in ID (store3) 
loop store_values 
        vector show element (STORE3) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/




     assign (ID $ide) (name TC) $dist01 $a7 $a8 
 end 
  vector do (store4=$dist01) (ID $ide) 











! store R2(para) values as measured  
 
 vector do (store5=27.63) (atom "    "  13 HN) 
 vector do (store5=51.42) (atom "    "  14 HN) 
 vector do (store5=108.08) (atom "    "  15 HN) 
 vector do (store5=21.41) (atom "    "  16 HN) 
 vector do (store5=45.32) (atom "    "  17 HN) 
 vector do (store5=11.59) (atom "    "  28 HN) 
 vector do (store5=6.15) (atom "    "  29 HN) 
 vector do (store5=3.73) (atom "    "  30 HN) 
 vector do (store5=15.16) (atom "    "  41 HN) 
 vector do (store5=55.32) (atom "    "  60 HN) 




   class CL3 
   averaging CL3 r-6 
   potential CL3 square 
   sqconstant CL3 $a9 
   sqoffset CL3 0.0 
   scale CL3 $a12 
   sqexponent CL3 2 
 end 
  
! calculate distance from R2(para), incl. %bound factors 
! store distances  
  
for $ide in ID (store5) 
loop store_values 
        vector show element (STORE5) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $a1 $a2 
 end 
  vector do (store6=$dist01) (ID $ide) 
end loop store_values 
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! Distances derived from R2 data from Src SH3 binding to peptide 
P3Te 
 
! store1 = fixed value for atoms that dissappear 
! store2 = fixed distance for atoms that dissappear 
! store3 = fixed value for atoms that are unaffected 
! store4 = fixed distance for atoms that are unaffected 
! store5 = observed R(para) value 
! store6 = derived experimental distance 
 
set mess=on end 
set echo=off end 
eval ($ide =1) 
!-------------------------------------------------------------------
------ 




 !Residue numbering as in PDB 1RLQ (+5 compared to our protein) 
 vector do (store1=142.50) (atom "    "  41 HN) 




   nres=20000 
   class CL1 
   averaging CL1 R-6 
   potential CL1 square 
   sqconstant CL1 $a9 
   sqoffset CL1 0.0 
   scale CL1 $a10 
   sqexponent CL1 2 




for $ide in ID (store1) 
loop store_values 
        vector show element (STORE1) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $a4 $a5 
 end 
  vector do (store2=$dist01) (ID $ide) 










 vector do (store3=2.60) (atom "    "  9 HT1) !first aa in pdb, not 
in protein, so really an amide 
 vector do (store3=2.60) (atom "    "  10 HN) 
 vector do (store3=2.60) (atom "    "  11 HN) 
 vector do (store3=2.60) (atom "    "  12 HN) 
 vector do (store3=2.60) (atom "    "  13 HN) 
 vector do (store3=2.60) (atom "    "  14 HN) 
 vector do (store3=2.60) (atom "    "  16 HN) 
 vector do (store3=2.60) (atom "    "  25 HN) 
 vector do (store3=2.60) (atom "    "  27 HN) 
 vector do (store3=2.60) (atom "    "  28 HN) 
 vector do (store3=2.60) (atom "    "  29 HN) 
 vector do (store3=2.60) (atom "    "  30 HN) 
 vector do (store3=2.60) (atom "    "  31 HN) 
 vector do (store3=2.60) (atom "    "  32 HN) 
 vector do (store3=2.60) (atom "    "  33 HN) 
 vector do (store3=2.60) (atom "    "  34 HN) 
 vector do (store3=2.60) (atom "    "  36 HN) 
 vector do (store3=2.60) (atom "    "  46 HN) 
 vector do (store3=2.60) (atom "    "  47 HN) 
 vector do (store3=2.60) (atom "    "  48 HN) 
 vector do (store3=2.60) (atom "    "  49 HN) 
 vector do (store3=2.60) (atom "    "  50 HN) 
 vector do (store3=2.60) (atom "    "  51 HN) 
 vector do (store3=2.60) (atom "    "  52 HN) 
 vector do (store3=2.60) (atom "    "  54 HN) 
 vector do (store3=2.60) (atom "    "  58 HN) 
 vector do (store3=2.60) (atom "    "  59 HN) 
 vector do (store3=2.60) (atom "    "  60 HN) 
 vector do (store3=2.60) (atom "    "  61 HN) 
 vector do (store3=2.60) (atom "    "  62 HN) 





   class CL2 
   averaging CL2 R-6 
   potential CL2 square 
   sqconstant CL2 $a9 
   sqoffset CL2 0.0 
   scale CL2 $a11 




for $ide in ID (store3) 
loop store_values 
        vector show element (STORE3) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/




     assign (ID $ide) (name TC) $dist01 $a7 $a8 
 end 
  vector do (store4=$dist01) (ID $ide) 











! store R2(para) values as measured  
 
  
 !vector do (store5=8.38) (atom "    "  15 HN) 
 vector do (store5=3.72) (atom "    "  18 HN) 
 vector do (store5=14.10) (atom "    "  19 HN) 
 vector do (store5=21.12) (atom "    "  20 HN) 
 vector do (store5=34.40) (atom "    "  21 HN) 
 vector do (store5=91.82) (atom "    "  22 HN) 
 vector do (store5=75.26) (atom "    "  23 HN) 
 vector do (store5=11.41) (atom "    "  24 HN) 
 vector do (store5=5.08) (atom "    "  38 HN) 
 vector do (store5=26.81) (atom "    "  39 HN) 
 vector do (store5=60.31) (atom "    "  40 HN) 
 vector do (store5=5.95) (atom "    "  43 HN) 
 vector do (store5=7.66) (atom "    "  44 HN) 
 vector do (store5=37.91) (atom "    "  55 HN) 




   class CL3 
   averaging CL3 r-6 
   potential CL3 square 
   sqconstant CL3 $a9 
   sqoffset CL3 0.0 
   scale CL3 $a12 
   sqexponent CL3 2 
 end 
  
! calculate distance from R2(para), incl. %bound factors 
! store distances  
  
for $ide in ID (store5) 
loop store_values 
        vector show element (STORE5) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/




     assign (ID $ide) (name TC) $dist01 $a1 $a2 
 end 
  vector do (store6=$dist01) (ID $ide) 






XPLOR-NIH restraint files belonging to chapter 3 
 
 
! Refining using individual error margins 
! Distances derived from R2 data from SH2 binding to ETDDYAEI-Toac-
DEED 
! this file: restraints.xpl 
! store1 = fixed value for atoms that dissappear 
! store2 = fixed distance for atoms that dissappear 
! store3 = fixed value for atoms that are unaffected 
! store4 = fixed distance for atoms that are unaffected 
! store5 = observed R(para) value 
! store6 = derived experimental distance 
! store7 = upper limit R(para) 
! store8 = lower limit R(para) 
 
set mess=on end 
set echo=on end 
eval ($ide =1) 
!-------------------------------------------------------------------
------ 





 !Rpara for target distance to store1 
  
  
 vector do (store1=97.14) (atom "    "  201 HN) 
 vector do (store1=84.84) (atom "    "  203 HN) 
 vector do (store1=92.77) (atom "    "  215 HN) 
 vector do (store1=96.18) (atom "    "  236 HN) 
  
  
 !lower Rpara to store 8 
 vector do (store8=71.11) (atom "    "  201 HN) 
 vector do (store8=59.18) (atom "    "  203 HN) 
 vector do (store8=67.20) (atom "    "  215 HN) 
 vector do (store8=71.40) (atom "    "  236 HN) 
  
NOE 
   nres=20000 
   class CL1 
   averaging CL1 R-6 
   potential CL1 square 
   sqconstant CL1 $a9 
   sqoffset CL1 0.0 
   scale CL1 $a10 
   sqexponent CL1 2 





    
for $ide in ID (store1) 
loop store_values 
        vector show element (STORE1) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
        vector show element (STORE8) (ID $ide) 
 eval ($r01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 eval ($dist02 = $r01 - $dist01) 
 eval ($dist03 = $dist01 - 3.5) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $dist03 $dist02 
 end 
  vector do (store2=$dist01) (ID $ide) 










 vector do (store3=3.11) (atom "    "  147 HN)  
 vector do (store3=3.11) (atom "    "  148 HN) 
 vector do (store3=3.11) (atom "    "  150 HN) 
 vector do (store3=3.11) (atom "    "  151 HN) 
 vector do (store3=3.11) (atom "    "  154 HN) 
 vector do (store3=3.11) (atom "    "  158 HN) 
 vector do (store3=3.11) (atom "    "  159 HN) 
 vector do (store3=3.11) (atom "    "  160 HN) 
 vector do (store3=3.11) (atom "    "  161 HN) 
 vector do (store3=3.11) (atom "    "  162 HN) 
 vector do (store3=3.11) (atom "    "  163 HN) 
 vector do (store3=3.11) (atom "    "  164 HN) 
 vector do (store3=3.11) (atom "    "  165 HN) 
 vector do (store3=3.11) (atom "    "  166 HN) 
 vector do (store3=3.11) (atom "    "  167 HN) 
 vector do (store3=3.11) (atom "    "  170 HN) 
 vector do (store3=3.11) (atom "    "  171 HN) 
 vector do (store3=3.11) (atom "    "  172 HN) 
 vector do (store3=3.11) (atom "    "  173 HN) 
 vector do (store3=3.11) (atom "    "  174 HN) 
 vector do (store3=3.11) (atom "    "  175 HN) 
 vector do (store3=3.11) (atom "    "  176 HN) 
 vector do (store3=3.11) (atom "    "  177 HN) 
 vector do (store3=3.11) (atom "    "  183 HN) 
 vector do (store3=3.11) (atom "    "  185 HN) 
 vector do (store3=3.11) (atom "    "  189 HN) 
 vector do (store3=3.11) (atom "    "  190 HN) 
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 vector do (store3=3.11) (atom "    "  191 HN) 
 vector do (store3=3.11) (atom "    "  192 HN) 
 vector do (store3=3.11) (atom "    "  194 HN) 
 vector do (store3=3.11) (atom "    "  195 HN) 
 vector do (store3=3.11) (atom "    "  196 HN) 
 vector do (store3=3.11) (atom "    "  198 HN) 
 vector do (store3=3.11) (atom "    "  207 HN) 
 vector do (store3=3.11) (atom "    "  208 HN) 
 vector do (store3=3.11) (atom "    "  209 HN) 
 vector do (store3=3.11) (atom "    "  210 HN) 
 vector do (store3=3.11) (atom "    "  212 HN) 
 vector do (store3=3.11) (atom "    "  213 HN) 
 vector do (store3=3.11) (atom "    "  220 HN) 
 vector do (store3=3.11) (atom "    "  222 HN) 
 vector do (store3=3.11) (atom "    "  225 HN) 
 vector do (store3=3.11) (atom "    "  226 HN) 
 vector do (store3=3.11) (atom "    "  227 HN) 
 vector do (store3=3.11) (atom "    "  228 HN) 
 vector do (store3=3.11) (atom "    "  229 HN) 
 vector do (store3=3.11) (atom "    "  230 HN) 
 vector do (store3=3.11) (atom "    "  231 HN) 
 vector do (store3=3.11) (atom "    "  233 HN) 
 vector do (store3=3.11) (atom "    "  241 HN) 
 vector do (store3=3.11) (atom "    "  242 HN) 
 vector do (store3=3.11) (atom "    "  243 HN) 
 vector do (store3=3.11) (atom "    "  245 HN) 




   class CL2 
   averaging CL2 R-6 
   potential CL2 square 
   sqconstant CL2 $a9 
   sqoffset CL2 0.0 
   scale CL2 $a11 
   sqexponent CL2 2 
end 
 
for $ide in ID (store3) 
loop store_values 
        vector show element (STORE3) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $a7 $a8 
 end 
  vector do (store4=$dist01) (ID $ide) 













 !store R2(para) values as measured  
 
 vector do (store5=7.66) (atom "    "  149 HN) 
 vector do (store5=7.95) (atom "    "  152 HN) 
 vector do (store5=17.09) (atom "    "  156 HN) 
 vector do (store5=13.16) (atom "    "  169 HN) 
 vector do (store5=23.24) (atom "    "  178 HN) 
 vector do (store5=18.70) (atom "    "  179 HN) 
 vector do (store5=9.19) (atom "    "  181 HN) 
 vector do (store5=7.34) (atom "    "  182 HN) 
 vector do (store5=7.57) (atom "    "  186 HN) 
 vector do (store5=5.66) (atom "    "  188 HN) 
 vector do (store5=12.20) (atom "    "  193 HN) 
 vector do (store5=110.00) (atom "    "  199 HN) 
 vector do (store5=17.34) (atom "    "  200 HN) 
 vector do (store5=84.95) (atom "    "  202 HN) 
 vector do (store5=11.08) (atom "    "  205 HN) 
 vector do (store5=30.97) (atom "    "  206 HN) 
 vector do (store5=32.19) (atom "    "  214 HN) 
 vector do (store5=78.51) (atom "    "  217 HN) 
 vector do (store5=18.65) (atom "    "  218 HN) 
 vector do (store5=15.29) (atom "    "  219 HN) 
 vector do (store5=5.02) (atom "    "  221 HN) 
 vector do (store5=53.74) (atom "    "  223 HN) 
 vector do (store5=19.09) (atom "    "  234 HN) 
 vector do (store5=32.42) (atom "    "  235 HN) 
 vector do (store5=88.88) (atom "    "  238 HN) 
 vector do (store5=19.16) (atom "    "  239 HN) 
 vector do (store5=44.93) (atom "    "  240 HN) 
  
  
 !upper Rpara to store 7 
 vector do (store7=10.38) (atom "    "  149 HN) 
 vector do (store7=10.63) (atom "    "  152 HN) 
 vector do (store7=20.03) (atom "    "  156 HN) 
 vector do (store7=15.45) (atom "    "  169 HN) 
 vector do (store7=41.53) (atom "    "  178 HN) 
 vector do (store7=23.87) (atom "    "  179 HN) 
 vector do (store7=11.92) (atom "    "  181 HN) 
 vector do (store7=10.68) (atom "    "  182 HN) 
 vector do (store7=12.52) (atom "    "  186 HN) 
 vector do (store7=8.61) (atom "    "  188 HN) 
 vector do (store7=26.61) (atom "    "  193 HN) 
 vector do (store7=155.24) (atom "    "  199 HN) 
 vector do (store7=21.51) (atom "    "  200 HN) 
 vector do (store7=121.46) (atom "    "  202 HN) 
 vector do (store7=15.21) (atom "    "  205 HN) 
 vector do (store7=35.59) (atom "    "  206 HN) 
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 vector do (store7=44.18) (atom "    "  214 HN) 
 vector do (store7=94.80) (atom "    "  217 HN) 
 vector do (store7=21.63) (atom "    "  218 HN) 
 vector do (store7=18.22) (atom "    "  219 HN) 
 vector do (store7=8.48) (atom "    "  221 HN) 
 vector do (store7=66.32) (atom "    "  223 HN) 
 vector do (store7=22.34) (atom "    "  234 HN) 
 vector do (store7=36.51) (atom "    "  235 HN) 
 vector do (store7=123.38) (atom "    "  238 HN) 
 vector do (store7=22.01) (atom "    "  239 HN) 




 !lower Rpara to store 8 
 vector do (store8=5.09) (atom "    "  149 HN) 
 vector do (store8=5.41) (atom "    "  152 HN) 
 vector do (store8=14.35) (atom "    "  156 HN) 
 vector do (store8=11.00) (atom "    "  169 HN) 
 vector do (store8=8.75) (atom "    "  178 HN) 
 vector do (store8=14.00) (atom "    "  179 HN) 
 vector do (store8=6.62) (atom "    "  181 HN) 
 vector do (store8=4.19) (atom "    "  182 HN) 
 vector do (store8=3.00) (atom "    "  186 HN) 
 vector do (store8=2.86) (atom "    "  188 HN) 
 vector do (store8=0.001) (atom "    "  193 HN) 
 vector do (store8=86.84) (atom "    "  199 HN) 
 vector do (store8=13.48) (atom "    "  200 HN) 
 vector do (store8=64.02) (atom "    "  202 HN) 
 vector do (store8=7.25) (atom "    "  205 HN) 
 vector do (store8=26.77) (atom "    "  206 HN) 
 vector do (store8=22.26) (atom "    "  214 HN) 
 vector do (store8=66.64) (atom "    "  217 HN) 
 vector do (store8=15.84) (atom "    "  218 HN) 
 vector do (store8=12.52) (atom "    "  219 HN) 
 vector do (store8=1.77) (atom "    "  221 HN) 
 vector do (store8=43.94) (atom "    "  223 HN) 
 vector do (store8=16.07) (atom "    "  234 HN) 
 vector do (store8=28.71) (atom "    "  235 HN) 
 vector do (store8=69.36) (atom "    "  238 HN) 
 vector do (store8=16.49) (atom "    "  239 HN) 






   class CL3 
   averaging CL3 r-6 
   potential CL3 square 
   sqconstant CL3 $a9 
   sqoffset CL3 0.0 
   scale CL3 $a12 





! calculate distance from R2(para), incl. %bound factors 
! store distances  
  
for $ide in ID (store5) 
loop store_values 
        vector show element (STORE5) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
        vector show element (STORE7) (ID $ide) 
 eval ($r01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
        vector show element (STORE8) (ID $ide) 
 eval ($r02= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 eval ($dist03 = $dist01 - $r01) 
 eval ($dist02 = $r02 - $dist01) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $dist03 $dist02 
 end 
  vector do (store6=$dist01) (ID $ide) 




! Refining using individual error margins 
! Distances derived from R2 data from SH2 binding to ETDDpYAEI-Toac-
DEED 
! this file: restraints.xpl 
! store1 = fixed value for atoms that dissappear 
! store2 = fixed distance for atoms that dissappear 
! store3 = fixed value for atoms that are unaffected 
! store4 = fixed distance for atoms that are unaffected 
! store5 = observed R(para) value 
! store6 = derived experimental distance 
! store7 = upper limit R(para) 
! store8 = lower limit R(para) 
 
set mess=on end 
set echo=on end 
eval ($ide =1) 
!-------------------------------------------------------------------
------ 





 !Rpara for target distance to store1 
  
  
 vector do (store1=26.08) (atom "    "  179 HN) 
 vector do (store1=46.06) (atom "    "  202 HN) 
 vector do (store1=18.08) (atom "    "  215 HN) 
 vector do (store1=60.45) (atom "    "  217 HN) 
  
  
 !lower Rpara to store 8 
 vector do (store8=0.0001)   (atom "    "  179 HN) 
 vector do (store8=6.2)   (atom "    "  202 HN) 
 vector do (store8=0.0001)   (atom "    "  215 HN) 
 vector do (store8=31.4)  (atom "    "  217 HN) 
  
NOE 
   nres=20000 
   class CL1 
   averaging CL1 R-6 
   potential CL1 square 
   sqconstant CL1 $a9 
   sqoffset CL1 0.0 
   scale CL1 $a10 
   sqexponent CL1 2 
   ceil=30.0 
end 
 
    
for $ide in ID (store1) 
loop store_values 
        vector show element (STORE1) (ID $ide) 
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 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
        vector show element (STORE8) (ID $ide) 
 eval ($r01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 eval ($dist02 = $r01 - $dist01) 
 eval ($dist03 = $dist01 - 3.5) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $dist03 $dist02 
 end 
  vector do (store2=$dist01) (ID $ide) 










 vector do (store3=3.80) (atom "    "  147 HN)  
 vector do (store3=3.80) (atom "    "  148 HN) 
 vector do (store3=3.80) (atom "    "  149 HN) 
 vector do (store3=3.80) (atom "    "  154 HN) 
 vector do (store3=3.80) (atom "    "  155 HN) 
 vector do (store3=3.80) (atom "    "  158 HN) 
 vector do (store3=3.80) (atom "    "  160 HN) 
 vector do (store3=3.80) (atom "    "  162 HN) 
 vector do (store3=3.80) (atom "    "  164 HN) 
 vector do (store3=3.80) (atom "    "  165 HN) 
 vector do (store3=3.80) (atom "    "  166 HN) 
 vector do (store3=3.80) (atom "    "  167 HN) 
 vector do (store3=3.80) (atom "    "  172 HN) 
 vector do (store3=3.80) (atom "    "  173 HN) 
 vector do (store3=3.80) (atom "    "  174 HN) 
 vector do (store3=3.80) (atom "    "  183 HN) 
 vector do (store3=3.80) (atom "    "  197 HN) 
 vector do (store3=3.80) (atom "    "  208 HN) 
 vector do (store3=3.80) (atom "    "  209 HN) 
 vector do (store3=3.80) (atom "    "  210 HN) 
 vector do (store3=3.80) (atom "    "  211 HN) 
 vector do (store3=3.80) (atom "    "  212 HN) 
 vector do (store3=3.80) (atom "    "  221 HN) 
 vector do (store3=3.80) (atom "    "  222 HN) 
 vector do (store3=3.80) (atom "    "  226 HN) 
 vector do (store3=3.80) (atom "    "  231 HN) 
 vector do (store3=3.80) (atom "    "  244 HN) 









   class CL2 
   averaging CL2 R-6 
   potential CL2 square 
   sqconstant CL2 $a9 
   sqoffset CL2 0.0 
   scale CL2 $a11 
   sqexponent CL2 2 
end 
 
for $ide in ID (store3) 
loop store_values 
        vector show element (STORE3) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $a7 $a8 
 end 
  vector do (store4=$dist01) (ID $ide) 











 !store R2(para) values as measured  
 
 vector do (store5=10.89) (atom "    "  151 HN) 
 vector do (store5=6.38) (atom "    "  156 HN) 
 vector do (store5=6.32) (atom "    "  161 HN) 
 vector do (store5=5.18) (atom "    "  169 HN) 
 vector do (store5=5.86) (atom "    "  170 HN) 
 vector do (store5=16.49) (atom "    "  175 HN) 
 vector do (store5=29.38) (atom "    "  176 HN) 
 vector do (store5=12.29) (atom "    "  177 HN) 
 vector do (store5=8.06) (atom "    "  181 HN) 
 vector do (store5=5.54) (atom "    "  182 HN) 
 vector do (store5=9.38) (atom "    "  188 HN) 
 vector do (store5=6.36) (atom "    "  189 HN) 
 vector do (store5=6.49) (atom "    "  190 HN) 
 vector do (store5=11.66) (atom "    "  191 HN) 
 vector do (store5=7.30) (atom "    "  192 HN) 
 vector do (store5=5.53) (atom "    "  194 HN) 
 vector do (store5=7.49) (atom "    "  195 HN) 
 vector do (store5=6.02) (atom "    "  196 HN) 
 vector do (store5=6.44) (atom "    "  198 HN) 
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 vector do (store5=51.43) (atom "    "  199 HN) 
 vector do (store5=33.27) (atom "    "  200 HN) 
 vector do (store5=22.70) (atom "    "  205 HN) 
 vector do (store5=19.51) (atom "    "  206 HN) 
 vector do (store5=7.38) (atom "    "  207 HN) 
 vector do (store5=28.07) (atom "    "  213 HN) 
 vector do (store5=56.88) (atom "    "  214 HN) 
 vector do (store5=8.91) (atom "    "  220 HN) 
 vector do (store5=31.64) (atom "    "  223 HN) 
 vector do (store5=7.57) (atom "    "  228 HN) 
 vector do (store5=20.06) (atom "    "  230 HN) 
 vector do (store5=47.91) (atom "    "  234 HN) 
 vector do (store5=94.03) (atom "    "  235 HN) 
 vector do (store5=59.61) (atom "    "  239 HN) 
 vector do (store5=38.91) (atom "    "  240 HN) 




 !upper Rpara to store 7 
 vector do (store7=42.7) (atom "    "  151 HN) 
 vector do (store7=11.2) (atom "    "  156 HN) 
 vector do (store7=9.8) (atom "    "  161 HN) 
 vector do (store7=7.4) (atom "    "  169 HN) 
 vector do (store7=11.3) (atom "    "  170 HN) 
 vector do (store7=25.8) (atom "    "  175 HN) 
 vector do (store7=38.1) (atom "    "  176 HN) 
 vector do (store7=23.1) (atom "    "  177 HN) 
 vector do (store7=11.3) (atom "    "  181 HN) 
 vector do (store7=9.4) (atom "    "  182 HN) 
 vector do (store7=14.6) (atom "    "  188 HN) 
 vector do (store7=9.5) (atom "    "  189 HN) 
 vector do (store7=11.3) (atom "    "  190 HN) 
 vector do (store7=15.2) (atom "    "  191 HN) 
 vector do (store7=11.3) (atom "    "  192 HN) 
 vector do (store7=7.3) (atom "    "  194 HN) 
 vector do (store7=10.6) (atom "    "  195 HN) 
 vector do (store7=9.3) (atom "    "  196 HN) 
 vector do (store7=9.4) (atom "    "  198 HN) 
 vector do (store7=61.3) (atom "    "  199 HN) 
 vector do (store7=43.6) (atom "    "  200 HN) 
 vector do (store7=35.6) (atom "    "  205 HN) 
 vector do (store7=24.8) (atom "    "  206 HN) 
 vector do (store7=12.2) (atom "    "  207 HN) 
 vector do (store7=38.6) (atom "    "  213 HN) 
 vector do (store7=107.0) (atom "    "  214 HN) 
 vector do (store7=14.1) (atom "    "  220 HN) 
 vector do (store7=48.2) (atom "    "  223 HN) 
 vector do (store7=9.2) (atom "    "  228 HN) 
 vector do (store7=28.9) (atom "    "  230 HN) 
 vector do (store7=65.1) (atom "    "  234 HN) 
 vector do (store7=168.8) (atom "    "  235 HN) 
 vector do (store7=83.1) (atom "    "  239 HN) 
 vector do (store7=50.1) (atom "    "  240 HN) 
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 vector do (store7=43.0) (atom "    "  241 HN) 
  
 !lower Rpara to store 8 
 vector do (store8=0.001) (atom "    "  151 HN) 
 vector do (store8=1.8) (atom "    "  156 HN) 
 vector do (store8=3.0) (atom "    "  161 HN) 
 vector do (store8=3.0) (atom "    "  169 HN) 
 vector do (store8=0.8) (atom "    "  170 HN) 
 vector do (store8=8.0) (atom "    "  175 HN) 
 vector do (store8=21.8) (atom "    "  176 HN) 
 vector do (store8=2.6) (atom "    "  177 HN) 
 vector do (store8=5.0) (atom "    "  181 HN) 
 vector do (store8=1.9) (atom "    "  182 HN) 
 vector do (store8=4.5) (atom "    "  188 HN) 
 vector do (store8=3.4) (atom "    "  189 HN) 
 vector do (store8=2.0) (atom "    "  190 HN) 
 vector do (store8=8.3) (atom "    "  191 HN) 
 vector do (store8=3.5) (atom "    "  192 HN) 
 vector do (store8=3.8) (atom "    "  194 HN) 
 vector do (store8=4.6) (atom "    "  195 HN) 
 vector do (store8=2.9) (atom "    "  196 HN) 
 vector do (store8=3.7) (atom "    "  198 HN) 
 vector do (store8=43.1) (atom "    "  199 HN) 
 vector do (store8=24.5) (atom "    "  200 HN) 
 vector do (store8=11.7) (atom "    "  205 HN) 
 vector do (store8=14.6) (atom "    "  206 HN) 
 vector do (store8=2.8) (atom "    "  207 HN) 
 vector do (store8=18.8) (atom "    "  213 HN) 
 vector do (store8=27.5) (atom "    "  214 HN) 
 vector do (store8=4.0) (atom "    "  220 HN) 
 vector do (store8=17.9) (atom "    "  223 HN) 
 vector do (store8=6.0) (atom "    "  228 HN) 
 vector do (store8=12.1) (atom "    "  230 HN) 
 vector do (store8=34.3) (atom "    "  234 HN) 
 vector do (store8=61.2) (atom "    "  235 HN) 
 vector do (store8=42.3) (atom "    "  239 HN) 
 vector do (store8=29.5) (atom "    "  240 HN) 




   class CL3 
   averaging CL3 r-6 
   potential CL3 square 
   sqconstant CL3 $a9 
   sqoffset CL3 0.0 
   scale CL3 $a12 
   sqexponent CL3 2 
 end 
  
! calculate distance from R2(para), incl. %bound factors 
! store distances  
  




        vector show element (STORE5) (ID $ide) 
 eval ($dist01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
        vector show element (STORE7) (ID $ide) 
 eval ($r01= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
        vector show element (STORE8) (ID $ide) 
 eval ($r02= (1E8*((1.23E-
32*(4*$tau_c+(3*$tau_c/(1+(600.1328E6*2*3.14*$tau_c)^2)))*$frl*$frb/
$RESULT)^(1/6)) ) ) 
 eval ($dist03 = $dist01 - $r01) 
 eval ($dist02 = $r02 - $dist01) 
 NOE 
     assign (ID $ide) (name TC) $dist01 $dist03 $dist02 
 end 
  vector do (store6=$dist01) (ID $ide) 
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